FDA Briefing Document

Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee

November 14, 2018
DISCLAIMER STATEMENT

The attached package contains background information prepared by the Food and Drug Administration (FDA) for the panel members of the advisory committee. The FDA background package often contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We have brought pharmacokinetic data, and results of studies evaluating the abuse of MNK-812 (oxycodone immediate release) tablets to this Advisory Committee in order to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered and all reviews have been finalized. The final determination may be affected by issues not discussed at the advisory committee meeting.
# Table of Contents

<table>
<thead>
<tr>
<th>Background Materials</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Division of Anesthesia, Analgesia, and Addiction Products (DAAAP) Director Memorandum (Dr. Hertz)</td>
<td>2</td>
</tr>
<tr>
<td>Regulatory History of Abuse-Deterrent Opioid Analgesics</td>
<td>6</td>
</tr>
<tr>
<td>Guidance for Industry: Abuse-Deterrent Opioids-Evaluation and Labeling</td>
<td>11</td>
</tr>
<tr>
<td>Drug Utilization Review</td>
<td>40</td>
</tr>
<tr>
<td>Epidemiology of Oxycodone Misuse and Abuse</td>
<td>52</td>
</tr>
<tr>
<td>Summary of Clinical and Non-Clinical Data for MNK-812 (oxycodone immediate-release tablets)</td>
<td>88</td>
</tr>
<tr>
<td>Summary of Abuse-Deterrent Findings for MNK-812 (oxycodone immediate-release tablets)</td>
<td></td>
</tr>
<tr>
<td>a. In Vitro Studies</td>
<td>98</td>
</tr>
<tr>
<td>b. In Vivo Studies</td>
<td>100</td>
</tr>
<tr>
<td>Labeling for Approved Abuse-Deterrent Opioids</td>
<td>105</td>
</tr>
<tr>
<td>Risk Evaluation and Mitigation Strategy (REMS)</td>
<td>152</td>
</tr>
<tr>
<td>Post-marketing Requirements</td>
<td>167</td>
</tr>
</tbody>
</table>
At this joint meeting of AADPAC and DSaRM, we will be discussing an application from SpecGx, LLC (“SpecGx”), for a new immediate-release formulation of oxycodone (MNK-812) designed with properties intended to deter abuse by the nasal and intravenous routes utilizing both physical/chemical barriers to manipulation and incorporation of aversive agents into the formulation. The proposed indication is the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Prescription opioid products are an important component of modern pain management. However, abuse and misuse of these products have created a serious and growing public health problem. To address this public health epidemic, FDA has announced a comprehensive review of our approach to opioid medications. This multi-year action plan focuses on new and existing policies to help curb abuse, addiction, and overdose of these drugs, while continuing to make them available to patients in need of effective pain relief.

One potentially important step towards the goal of creating safer opioid analgesics has been the development of opioids that are formulated to deter abuse. In April 2015, the Agency issued a
final guidance to assist industry in the development of opioid drug products with potentially abuse-deterrent properties. The “Guidance for Industry: Abuse-Deterrent Opioids,” explains the Agency’s current thinking regarding studies that should be conducted to demonstrate that a given formulation has abuse-deterrent properties, makes recommendations about how those studies should be performed and evaluated, and discusses how to describe those studies and their implications in product labeling.

We have heard concerns that the approval of new opioid analgesics increases the prescribing and availability of these products and may contribute to an increase in misuse and abuse. A recent article published in the journal Anesthesiology reports the results of a study that examined dispensed prescription patterns for opioids and approval of new opioid analgesics in order to investigate whether the introduction of these new drugs increased overall opioid prescribing. In summary, although there has been a dramatic increase in prescriptions dispensed for opioid analgesics since 1997, as well as an increasing number of opioid analgesic approvals, the number of opioid prescriptions dispensed has declined since 2012 despite an increasing number of approvals. (http://anesthesiology.pubs.asahq.org/article.aspx?articleid=2675976)

There are currently ten opioid analgesics labeled with abuse-deterrent properties as described in the guidance, nine extended-release products and one immediate-release product. The extended-release products with labeling language describing studies conducted in support of abuse-deterrent properties are OxyContin (oxycodone extended-release tablets), Targiniq (oxycodone and naloxone extended-release tablets), Embeda (morphine sulfate and naltrexone hydrochloride extended-release capsules), Hysingla ER (hydrocodone extended-release tablets), Morphabond ER (morphine sulfate extended-release tablets), Xtampza ER (oxycodone extended-release capsules), Troxyca ER (oxycodone and naltrexone hydrochloride extended-release capsules), Arymo ER (morphine sulfate extended-release tablets), and Vantrela ER (hydrocodone extended-release tablets). The immediate-release product is Roxybond (oxycodone HCl immediate-release tablets).

Targiniq and Arymo ER are listed as discontinued in the Orange Book. The NDAs for Troxyca ER and Vantrela ER have been withdrawn. There are currently no generic opioids with FDA-approved abuse-deterrent labeling.

When a product intended to have abuse-deterrent properties fails to demonstrate those properties in pre-approval studies, it is important for prescribers to be aware so they can consider the lack of abuse-deterrent properties into in their decision about the role of the product in their practice of pain management. There is one product, Apadaz (benzhydrocodone/acetaminophen) immediate-release tablets that has labeling describing the negative results of studies that were conducted to assess properties of the formulation that were intended to deter abuse. The labeling includes negative study results from in vitro testing and human abuse potential studies that state the studies failed to demonstrate properties expected to deter abuse based on endpoints specified in the above-mentioned guidance. The label also includes language describing the results of
additional secondary endpoints that are not described in the guidance, and for which the clinical significance is unknown.

The results of the Applicant’s in vitro physical and chemical manipulation assessments and in vivo intranasal human abuse potential study will be presented during this meeting. You will hear presentations from the Applicant and the Agency regarding these findings. FDA will present an analysis of prescribing patterns for oxycodone products and other opioid analgesics, as well as misuse and abuse patterns for oxycodone.

Based on feedback from prior advisory committee meetings, the Agency is now requesting that applicants address the safety of excipients when administered by unintended routes, that is abused by the IV or nasal route.1 You will hear a presentation by FDA on this issue that discusses the safety of excipients and how this relates to unintended routes of abuse.

You will be asked to discuss whether the Applicant has provided adequate support for labeling abuse-deterrent properties for MNK-812, whether the benefits of the product at issue outweigh its risks, and whether it should be approved.

These are clearly difficult questions for which there are no easy answers. We are asking that you provide your expertise, your experience and your best insights in order to help us find a reasonable and responsible path forward. Your advice and recommendations will be essential in assisting us with addressing this complex and critical public health concern. We are grateful that you have agreed to join us for this important discussion and look forward to seeing you at the meeting.

---

1 SpecGx was notified of this requirement in the NDA Filing letter
Draft Points to Consider

1. Has the Applicant demonstrated that oxycodone immediate-release tablets (MNK-812) has properties that can be expected to deter abuse by the:
   a. Nasal route of administration?
   b. IV route of administration?

2. Are there sufficient data to support inclusion of language regarding abuse-deterrent properties in the product label for the:
   a. Nasal route of administration?
   b. IV route of administration?

3. Does the committee have concerns regarding the public health impact of oxycodone immediate-release tablets (MNK-812) on misuse and abuse of opioids among patients and others in the community?

4. Should oxycodone immediate-release tablets (MNK-812) be approved?
MEMORANDUM

DATE: October 15, 2018

FROM: Sharon Hertz, MD
Director
Division of Anesthesia, Analgesia, and Addiction Products
Office of Drug Evaluation II, CDER, FDA

TO: Chair, Members and Invited Guests
Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC)
Drug Safety and Risk Management Advisory Committee (DSaRM)

RE: Regulatory History of Abuse-Deterrent Opioid Analgesics

Regulatory History of Abuse-Deterrent Opioid Analgesics

The growing epidemic of opioid abuse, misuse, and overdose in the United States is deeply concerning. In light of this, the Agency has encouraged drug companies to develop products that can mitigate abuse, while recognizing the importance of maintaining the availability of opioid analgesics for the millions of patients in this country who suffer from pain. The Agency has supported the development of novel formulations through multiple interactions with both the pharmaceutical industry and the academic community.

In April 2015, the Agency issued a final guidance to assist industry in the development of opioid drug products with potentially abuse-deterrent properties. The “Guidance for Industry: Abuse-Deterrent Opioids” explains the Agency’s current thinking regarding studies that should be conducted to demonstrate that a given formulation has abuse-deterrent properties, makes recommendations about how those studies should be performed and evaluated, and discusses how to describe those studies and their implications in product labeling. It is important to keep in mind that the science of abuse deterrence is relatively new, and both the formulation technologies and the analytical, clinical, and statistical methods for evaluating those technologies are rapidly evolving. Based on this, the Agency intends to take a flexible, adaptive approach to the evaluation and labeling of potentially abuse-deterrent products.
An effort has been made to improve the product labels for all opioid analgesics to help ensure safe use of these drugs. In April 2014, the Agency finalized the class-wide safety labeling changes (SLC) for all extended-release and long-acting (ERLA) opioid analgesics in order to better describe their risks and benefits and to better ensure safe use. All ERLA opioid analgesics, those with and without abuse-deterrent properties, used for the management of chronic pain now have a harmonized indication, the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatments are inadequate, which is intended to emphasize the need to balance risk with benefit. The safety labeling changes included the indication stated above, a new warning for Neonatal Opioid Withdrawal Syndrome (NOWS), and updated language in the Warnings and Precautions section of the label regarding addiction, abuse, and misuse, life-threatening respiratory depression, accidental ingestion, and drug interactions. On March 22, 2016, a class-wide SLC for immediate-release opioid analgesics was issued, similar to the 2014 SLC for ERLA opioid analgesics. The labeling changes included a boxed warning with information about the risks of misuse, abuse, addiction, overdose and death, and the potential for neonatal opioid withdrawal syndrome (NOWS) with prolonged maternal use of opioids during pregnancy; an updated indication stating that IR opioids should be reserved to manage pain severe enough to require opioid treatment and for which alternative treatment options are inadequate or not tolerated; and clearer information regarding patient monitoring and drug administration. New warnings were also included for all opioids regarding serotonin syndrome and endocrine effects.

A total of ten opioid analgesics have been approved with labeling language describing studies that evaluated their abuse-deterrent properties; nine ERLA opioid analgesic products and one immediate-release opioid analgesic. Additionally, another immediate-release opioid analgesic that did not demonstrate abuse-deterrent properties has been approved with labeling language describing its negative study results.

Embeda, approved in 2009, is an extended-release formulation of morphine sulfate with a sequestered opioid antagonist, naltrexone. The naltrexone is intended to be released only if the product is manipulated. In vitro and in vivo data reviewed by the Agency indicate that Embeda has properties that are expected to reduce abuse by the oral (crushing/chewing) and intranasal routes. A human abuse potential study of IV morphine and naltrexone to simulate injection of crushed Embeda demonstrated evidence of abuse deterrence; however, it is unknown whether the results from simulated crushed Embeda can predict a reduction in abuse by the IV route until additional postmarketing data are available.

The first formulation of extended-release oxycodone was OxyContin approved in 1995. A reformulation of the original OxyContin, approved in 2010, was designed with physicochemical properties intended to deter abuse by being more difficult to prepare for intravenous abuse by syringe and to resist breaking or crushing for intranasal abuse. The original OxyContin is no longer manufactured or marketed in the US. In 2012, language was added to the label describing
OxyContin’s abuse-deterrent properties based on the Agency’s review of in vitro and in vivo studies.

**Targiniq**, the second extended-release oxycodone product with abuse-deterrent properties, was approved in 2014. It is a fixed-dose combination drug product consisting of oxycodone and naloxone, an opioid antagonist. Naloxone has low oral bioavailability due to high first pass metabolism and is not intended to reach adequate levels to have an effect in patients taking the medication as prescribed. However, if Targiniq is manipulated for abuse by injection or nasal insufflation, the naloxone levels are high enough to antagonize the reinforcing opioid effects. Language in the label includes findings of in vitro studies and human abuse potential studies that indicate that Targiniq has pharmacologic properties that are expected to reduce abuse via the intranasal and IV routes of administration.

**Hysingla ER**, approved in 2014, is the first extended-release formulation of hydrocodone with properties intended to deter abuse. In vitro data demonstrate that Hysingla ER’s physicochemical properties can be expected to deter intranasal and intravenous abuse. Data from human abuse potential studies also support that these properties can be expected to deter intranasal abuse and oral abuse when chewed.

**Morphabond ER**, an extended-release formulation of morphine sulfate, approved in 2015, is the second extended-release morphine product with abuse-deterrent labeling. Morphabond ER has physicochemical properties expected to make abuse via injection difficult. Data from human abuse potential studies as well as in vitro data also support that these properties are expected to reduce abuse by the intranasal route of administration.

**Xtampza ER**, the third extended-release oxycodone product with abuse-deterrent properties, was approved on April 26, 2016. In vitro data demonstrate that Xtampza ER has physicochemical properties expected to make abuse by injection difficult. The data from pharmacokinetic and human abuse potential studies, along with support from the in vitro data, also indicate that Xtampza ER has physicochemical properties that are expected to reduce abuse via the intranasal route.

**Troxyca ER**, an extended-release formulation of oxycodone hydrochloride with a sequestered opioid antagonist, naltrexone, was approved on August 19, 2016. The naltrexone is intended to be released only if the product is manipulated. In vitro and in vivo data reviewed by the Agency indicate that Troxyca ER has properties that are expected to reduce abuse via the oral (crushing/chewing) and intranasal routes. A human abuse potential study of IV oxycodone and naltrexone to simulate injection of crushed Troxyca ER demonstrated evidence of abuse deterrence; however, it is unknown whether the results from simulated crushed Troxyca ER can predict a reduction in abuse by the IV route until additional postmarketing data are available.
**Arymo ER**, an extended-release formulation of morphine sulfate, approved in January 2017, is the third extended-release morphine product with abuse-deterrent labeling. In vitro data demonstrate that Arymo ER’s physicochemical properties can be expected to make abuse by injection difficult. The data from the in vitro studies and the intranasal human abuse potential study also indicate that Arymo ER has physical and chemical properties that are expected to reduce abuse via the intranasal route. As discussed at the August 4, 2016, advisory committee meeting, the data supporting that the formulation could be expected to reduce abuse by the intranasal route were not included in the initially approved labeling, as those data were blocked by exclusivity awarded to Morphabond ER. However, now that that exclusivity has expired, the data regarding the intranasal route appear in the currently approved labeling for Arymo ER. Although the results of the oral human abuse potential study showed a difference in the Drug Liking endpoint, there was no statistically significant reduction in the response to Take Drug Again. Therefore, it cannot be concluded that Arymo ER has properties that are expected to reduce abuse via the oral route.

**Vantrela ER**, approved in January 2017, is the second extended-release formulation of hydrocodone with properties intended to deter abuse. In vitro data demonstrate that the physicochemical properties of Vantrela ER can be expected to deter intravenous abuse. In vitro and in vivo data demonstrate that Vantrela ER has properties that are expected to reduce abuse via the oral and intranasal routes.

**Roxybond**, approved in April 2017, is the first immediate-release opioid approved with labeling language describing properties intended to deter abuse. Roxybond is an immediate-release formulation of oxycodone HCl with physicochemical properties expected to make abuse via injection difficult, and reduce abuse by the intranasal route, based on results of in vitro and in vivo studies.

**Apadaz**, approved in February 2018, is an immediate-release opioid approved with labeling language describing the negative results of studies conducted to assess properties intended to deter abuse. Apadaz is a combination of benzhydrocodone, a prodrug of the opioid agonist hydrocodone, and acetaminophen. In vitro data demonstrate that Apadaz is not expected to reduce abuse by the intravenous route or by smoking. In vivo data demonstrate that Apadaz is not expected to deter abuse by the oral or nasal routes.

Targiniq and Arymo ER are listed as discontinued in the Orange Book. The NDAs for Troxyca ER and Vantrela ER have been withdrawn. There are currently no generic opioids with FDA-approved abuse-deterrent labeling.

All Sponsors of opioid analgesics with approved abuse-deterrent language in labeling are required to conduct postmarketing epidemiologic studies to determine whether the properties of their product results in meaningful reductions in abuse, misuse, and related adverse clinical outcomes, including addiction, overdose, and death in the post-approval setting.
It is important to recognize that abuse-deterrent opioid products are not abuse-proof nor are they less addictive. As stated in the “Guidance for Industry: Abuse-Deterrent Opioids, “Because opioid products are often manipulated for the purposes of abuse by different routes of administration or to defeat extended-release (ER) properties, most abuse-deterrent technologies developed to date are intended to make manipulation more difficult or to make abuse of the manipulated product less attractive or less rewarding. It should be noted that these technologies have not yet proven successful at deterring the most common form of abuse, that is, swallowing a number of intact capsules or tablets to achieve a feeling of euphoria. Moreover, the fact that a product has abuse-deterrent properties does not mean that there is no risk of abuse. It means, rather, that the risk of abuse is expected to be lower than it would be without such properties. Because opioid products must, in the end, be able to deliver the opioid to the patient, there may always be some abuse of these products.”
Abuse-Deterrent Opioids —
Evaluation and Labeling
Guidance for Industry

Additional copies are available from:
Office of Communications
Division of Drug Information, WO51, Room 2201
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Phone: 301-796-3400; Fax: 301-847-8714
druginfo@fda.hhs.gov

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
Clinical Medical
April 2015
# TABLE OF CONTENTS

I. INTRODUCTION ............................................................................................................. 1

II. BACKGROUND ........................................................................................................... 1

III. ABUSE-DETERRENT PRODUCTS ............................................................................ 3

IV. PREMARKET STUDIES ................................................................................................ 4
   A. Laboratory Manipulation and Extraction Studies (Category 1) ............................. 6
   B. Pharmacokinetic Studies (Category 2) ................................................................. 8
   C. Clinical Abuse Potential Studies (Category 3) ....................................................... 9
      1. Blinding .................................................................................................................. 10
      2. Pre-qualification Phase ...................................................................................... 10
      3. Assessment Phase ............................................................................................... 11
      4. Subjects ................................................................................................................ 11
      5. Route of Administration, Dose Selection, Manipulation Mode, and Sample Preparation .... 12
      6. Outcome Measures and Data Interpretation ...................................................... 12
      7. Data Interpretation ............................................................................................. 13
      8. Statistical Analysis ............................................................................................ 14
         a. Background ....................................................................................................... 14
         b. Primary analyses ............................................................................................... 15
         c. Secondary analyses ......................................................................................... 15
         d. Multiplicity ....................................................................................................... 17

V. POSTMARKET STUDIES (CATEGORY 4) .............................................................. 17
   A. Formal Studies ....................................................................................................... 18
      1. General Characteristics ...................................................................................... 18
      2. Study Design Features ....................................................................................... 19
   B. Supportive Information ....................................................................................... 21

VI. LABELING ............................................................................................................... 22

VII. ADDITIONAL RESEARCH NEEDS ..................................................................... 25
Abuse-Deterrent Opioids — Evaluation and Labeling Guidance for Industry

This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not create any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page.

I. INTRODUCTION

This guidance explains FDA’s current thinking about the studies that should be conducted to demonstrate that a given formulation has abuse-deterrent properties. The guidance makes recommendations about how those studies should be performed and evaluated and discusses how to describe those studies and their implications in product labeling.

This guidance is intended to assist sponsors who wish to develop opioid drug products with potentially abuse-deterrent properties and is not intended to apply to products that are not opioids or opioid products that do not have the potential for abuse.

This guidance also does not address issues associated with the development or testing of generic formulations of abuse-deterrent opioid products. FDA intends to address that topic in one or more future guidance documents.

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required.

II. BACKGROUND

Prescription opioid products are an important component of modern pain management. However, abuse and misuse of these products have created a serious and growing public health problem. One potentially important step towards the goal of creating safer opioid analgesics has

---

1 This guidance has been prepared by the Division of Anesthesia, Analgesia, and Addiction Products, the Office of Regulatory Policy, the Office of Surveillance and Epidemiology, the Office of Biostatistics, and the Controlled Substance Staff in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration.
been the development of opioids that are formulated to deter abuse. FDA considers the development of these products a high public health priority.

Because opioid products are often manipulated for purposes of abuse by different routes of administration or to defeat extended-release (ER) properties, most abuse-deterrent technologies developed to date are intended to make manipulation more difficult or to make abuse of the manipulated product less attractive or less rewarding. It should be noted that these technologies have not yet proven successful at deterring the most common form of abuse—swallowing a number of intact capsules or tablets to achieve a feeling of euphoria. Moreover, the fact that a product has abuse-deterrent properties does not mean that there is no risk of abuse. It means, rather, that the risk of abuse is lower than it would be without such properties. Because opioid products must in the end be able to deliver the opioid to the patient, there may always be some abuse of these products.

For purposes of this guidance, abuse-deterrent properties are defined as those properties shown to meaningfully deter abuse, even if they do not fully prevent abuse. The term abuse is defined as the intentional, non-therapeutic use of a drug product or substance, even once, to achieve a desirable psychological or physiological effect.2 Abuse is not the same as misuse, which refers to the intentional therapeutic use of a drug product in an inappropriate way and specifically excludes the definition of abuse.3 This guidance uses the term abuse-deterrent rather than tamper-resistant because the latter term refers to, or is used in connection with, packaging requirements applicable to certain classes of drugs, devices, and cosmetics.4

The science of abuse deterrence is relatively new, and both the formulation technologies and the analytical, clinical, and statistical methods for evaluating those technologies are rapidly evolving. Based on the evolving nature of the field, FDA intends to take a flexible, adaptive approach to the evaluation and labeling of potentially abuse-deterrent products. Methods for evaluating the abuse-deterrent properties of new molecular entities may have to be adapted based on the characteristics of those products and the anticipated routes of abuse. The development of an abuse-deterrent opioid product should be guided by the need to reduce the abuse known or expected to occur with similar products.

Because FDA expects that the market will foster iterative improvements in products with abuse-deterrent properties, no absolute magnitude of effect can be set for establishing abuse-deterrent characteristics. As a result, FDA intends to consider the totality of the evidence when reviewing the results of studies evaluating the abuse-deterrent properties of a product.

---

3 Ibid.
4 FDA’s current Good Manufacturing Practice regulations include tamper-evident packaging requirements. See 21 CFR 211.132. There are also requirements for child resistant “special packaging” under the Poison Prevention Packaging Act and regulations adopted by the Consumer Protect Safety Commissioner (CPSC) in 16 CFR 1700.
As with all NDA products, FDA intends to consider opioids with abuse-deterrent properties within the context of available therapy. The standard against which each product’s abuse-deterrent properties are evaluated will depend on the range of abuse-deterrent and non-abuse-deterrent products on the market at the time of that application.\(^5\)

Abuse-deterrent properties can generally be established only through comparison to another product.

FDA encourages additional scientific and clinical research that will advance the development and assessment of abuse-deterrent technologies.

FDA believes it is critical to address the problem of opioid abuse while seeking to ensure that patients in pain have appropriate access to opioid products. Moreover, it is important that opioids without abuse-deterrent properties remain available for use in some clinical settings. For example, patients in hospice care and with difficulty swallowing may need access to opioid products that are in solution or that can be crushed.

The following section describes the categories of abuse-deterrent products. The premarket and postmarket studies that should be performed to assess the impact of a potentially abuse-deterrent product are discussed in subsequent sections. Finally, information is provided about labeling for abuse-deterrent products.

**III. ABUSE-DETERRENT PRODUCTS**

Opioid products can be abused in a number of ways. For example, they can be swallowed whole, crushed and swallowed, crushed and snorted, crushed and smoked, or crushed, dissolved and injected. Abuse-deterrent technologies should target known or expected routes of abuse relevant to the proposed product. As a general framework, abuse-deterrent formulations can currently be categorized as follows:

1. **Physical/chemical barriers** – Physical barriers can prevent chewing, crushing, cutting, grating, or grinding of the dosage form. Chemical barriers, such as gelling agents, can resist extraction of the opioid using common solvents like water, simulated biological media, alcohol, or other organic solvents. Physical and chemical barriers can limit drug release following mechanical manipulation, or change the physical form of a drug, rendering it less amenable to abuse.

2. **Agonist/antagonist combinations** – An opioid antagonist can be added to interfere with, reduce, or defeat the euphoria associated with abuse. The antagonist can be sequestered and released only upon manipulation of the product. For example, a drug product can be

---

formulated such that the substance that acts as an antagonist is not clinically active when the product is swallowed, but becomes active if the product is crushed and injected or snorted.

3. *Aversion* – Substances can be added to the product to produce an unpleasant effect if the dosage form is manipulated or is used at a higher dosage than directed. For example, the formulation can include a substance irritating to the nasal mucosa if ground and snorted.

4. *Delivery System* (including use of depot injectable formulations and implants) – Certain drug release designs or the method of drug delivery can offer resistance to abuse. For example, sustained-release depot injectable formulation or a subcutaneous implant may be difficult to manipulate.

5. *New molecular entities and prodrugs* – The properties of a new molecular entity (NME) or prodrug could include the need for enzymatic activation, different receptor binding profiles, slower penetration into the central nervous system, or other novel effects. Prodrugs with abuse-deterrent properties could provide a chemical barrier to the in vitro conversion to the parent opioid, which may deter the abuse of the parent opioid. New molecular entities and prodrugs are subject to evaluation of abuse potential for purposes of the Controlled Substances Act (CSA).

6. *Combination* – Two or more of the above methods could be combined to deter abuse.

7. *Novel approaches* – This category encompasses novel approaches or technologies that are not captured in the previous categories.

**IV. PREMARKET STUDIES**

First and foremost, any studies designed to evaluate the abuse-deterrent characteristics of an opioid formulation should be scientifically rigorous. Important general considerations for the design of these studies include the appropriateness of positive controls and comparator drugs, outcome measures, data analyses to permit a meaningful statistical analysis, and selection of subjects for the study.

The evaluation of an abuse-deterrent formulation should take into consideration the known routes of abuse for the non-abuse-deterrent predecessor or similar products, as well as anticipate the effect that deterring abuse by one route may have on shifting abuse to other, possibly riskier route. For example, if a product is known to be abused using nasal and intravenous routes, developing deterrent properties for the nasal route in the absence of deterrent properties for the intravenous route risks shifting abusers from the nasal to the intravenous route, which is associated with a greater risk for the spread of infectious diseases.

Another concept that should be considered is whether the deterrent effects can be expected to have a meaningful impact on the overall abuse of the product. For example, immediate-release (IR) opioid and acetaminophen combination products are predominantly abused using the oral

---

6 For purposes of this guidance, a positive control is an opioid drug product or drug substance expected to result in a predictable opioid drug liking effect and has a known potential for, or history of, abuse.
route. Demonstrating a deterrent effect by the nasal route may not meaningfully reduce overall abuse of the product.

FDA is committed to retaining a flexible, adaptive approach to evaluating potentially abuse-deterrent opioid drug products. This flexibility is intended to permit a sponsor to tailor the development program to suit the abuse-deterrent characteristics of their product and the routes of abuse for that product. The adaptive aspect is intended to permit a sponsor to take into consideration the relevant products on the market at the time they are developing their product, so that appropriate non-abuse-deterrent and abuse-deterrent comparators can be used. For example, for some proposed products the appropriate comparator may be a conventional formulation. However, if there are similar approved products with abuse-deterrent properties described in labeling, the appropriate comparator should be one of those abuse-deterrent products.

The following sections describe three categories of premarket studies. Although, in general, any development program for studying abuse-deterrent technologies should include data from all three categories of studies, there may be exceptions. For example, a formulation with a sequestered antagonist may intentionally be formulated not to resist crushing, so testing the syringeability of the product may not be relevant. In most cases, however, to obtain a full and scientifically rigorous understanding of the impact of a technology or technologies on a product’s abuse potential, data from each of the following three categories of premarket studies are appropriate:

1. Laboratory-based in vitro manipulation and extraction studies (Category 1)
2. Pharmacokinetic studies (Category 2)
3. Clinical abuse potential studies (Category 3)

The results of Category 1 studies may influence the design of Category 2 pharmacokinetic studies and Category 3 clinical abuse potential studies by suggesting the methods of manipulation that would yield the greatest release of opioid. The results of Category 2 studies may influence the need for Category 3 studies of clinical abuse potential and the designs and goals of these studies. For example, if the extended-release characteristics of an abuse-deterrent opioid formulation cannot be defeated and the pharmacokinetic profile remains unchanged following oral or nasal administration of the manipulated product, oral and nasal studies of abuse potential may not be necessary.

Additional studies (i.e., Category 4 studies) analyze postmarket data to assess the impact of an abuse-deterrent formulation on actual abuse. Nonclinical drug discrimination studies are useful in the evaluation of the abuse potential of a drug, but their utility in predicting the impact of abuse-deterrent properties on human behavior has not been established.7

---

A. Laboratory Manipulation and Extraction Studies (Category 1)

The goal of laboratory-based Category 1 studies should be to evaluate the ease with which the potentially abuse-deterrent properties of a formulation can be defeated or compromised. This information should be used when designing Category 2 and Category 3 studies. These studies are critical to the understanding of product characteristics and performance.8

Methodologically, these studies should be designed with knowledge of the physicochemical properties of the product and the methods available to abusers to manipulate the product and should be conducted on the to-be-marketed formulation. Sponsors should consider both the mechanisms by which abusers can be expected to attempt to deliberately overcome the abuse-deterrent properties of the product as well as the ways that patients may alter the formulation (unintentionally or intentionally) that change the rate or amount of drug released (e.g., dose dumping may occur when taking the product with alcohol or when the product is cut, chewed, or crushed). Testing should provide information sufficient to fully characterize the product’s abuse-deterrent properties, including the degree of effort required to bypass or defeat those properties. In some cases, when designing in vitro studies, it may be useful to obtain information from prescription opioid abusers about how they would manipulate and abuse an abuse-deterrent product.

In vitro studies should assess various simple and sophisticated mechanical and chemical ways a drug could be manipulated, such as by (1) defeating or compromising the controlled release of an opioid from ER formulations for purposes of abuse by different routes of administration; (2) preparing an IR formulation for alternative routes of administration; or (3) separating the opioid antagonist, if present, from the opioid agonist, thus compromising the product’s abuse-deterrent properties. The goal of these studies is to manipulate the product to the point of defeating its abuse-deterrent properties. Once this goal is achieved, it is no longer necessary to continue experiments using more sophisticated methods. For example, if 90% of the opioid can be extracted under a set of conditions in 10 minutes, there is no need to test the same condition for 30 minutes.

The test product should be compared to appropriate comparator products for ease of mechanical manipulation. The ability to crush, cut, grate, or grind the product formulation using readily available items such as spoons, cutters, and coffee grinders should be assessed. Particular attention should be given to particle size distribution following each mode of physical manipulation because particle size may influence the rate of opioid extraction from manipulated product. The effect of heat and cold on mechanical manipulation should also be studied.

Extractability and solubility studies should be designed to determine whether any of the formulation components might be differentially solubilized and extracted, allowing an abuser to

---

8 This topic has been discussed at meetings of the Anesthetic & Life Support Drugs Advisory Committee and the Drug Safety & Risk Management Advisory Committee (NDA 022272, OxyContin, May 5, 2008, and September 24, 2009). Additional information on these meetings is available on FDA’s web site at the following location: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM187082.pdf.
bypass the drug’s abuse-deterrent properties. In addition to extraction and solubility studies, an assessment should be made to determine if free-base opioid can be precipitated from solution by pH adjustment. After establishing how a product could be manipulated, chemical extraction of the opioid from the intact and the manipulated product should be assessed and compared to opioid extraction from the selected intact and similarly manipulated comparator products.

The ease of extracting the opioid from the intact and manipulated product should be determined using a variety of solvents that are commonly available (e.g., water, vinegar, ethanol, isopropanol, acetone, mineral spirits) and those that have potentially relevant solvent characteristics (e.g., pH, polarity, protic vs. aprotic). The effects of time, temperature, pH, and agitation on solvent extraction should also be determined. For products containing more than one drug substance, extractability and solubility studies should be designed to determine whether any of the active ingredients might be differentially solubilized and extracted. Sampling times should start early (e.g., 30 seconds) and continue until at least 80% of the opioid has been released, or 12 hours has been reached. The in vitro drug-release characteristics of the intact and manipulated product should also be compared using a discriminatory and robust dissolution method.

In addition to the general evaluation of the effects of physical and chemical manipulation on the product, there are important route-specific data that should be generated, as follows:

- For a product with potential for abuse by the nasal route, the particle size distribution following attempted manipulation by various methods should be established, and the method that provides the smallest particle size should be used in subsequent studies.

- For a product with potential for abuse by smoking, the amount of drug produced by vaporization at temperatures encompassing the range from the melting point of the active ingredient to its degradation point should be determined. Appropriate controls, such as pure active ingredient, both in salt and free-base form should be included in these assessments.

- For a product with potential for abuse by injection, the amount of opioid that can be obtained in a syringe should be based on studies of intact and manipulated test product and comparator(s) using small volumes of water (5-10 mL) at room temperature and at 90° C – 95° C with and without agitation. Extraction times should range from 30 seconds to 30 minutes. The amount of opioid extracted, the volume of solution collected and the viscosity of the samples should be recorded. The ability to get the sample into a syringe and expel the sample using needles of various gauges should also be explored.

The following examples illustrate the kinds of outcomes that in vitro studies should evaluate.

1. Characteristics of the product by crushing, grinding or melting, or by changing the intact formulation using other methods that would limit nasal administration of the manipulated product, and/or that would limit dissolution of the manipulated product and incorporation into a solvent that could then be injected by intravenous or subcutaneous routes.
2. Quantity of the opioid extracted from the product following the various methods attempted that could be used for injection by intravenous or subcutaneous routes and a description of any barriers resulting from attempts at dissolution for drawing the drug into a syringe.

3. Quantity of opioid antagonist released from an agonist/antagonist combination when it is manipulated for administration by ingestion, nasal administration, or injection.

4. Quantity of opioid product following in vitro manipulation of the prodrug.

**B. Pharmacokinetic Studies (Category 2)**

The goal of the clinical pharmacokinetic studies, Category 2, should be to understand the in vivo properties of the formulation by comparing the pharmacokinetic profiles of the manipulated formulation with the intact formulation and with manipulated and intact formulations of the comparator drugs through one or more routes of administration. Even though the same routes of administration should be studied for the new product and comparators, if specific circumstances prevent this approach, the study design should be discussed with FDA. The method of manipulation used for the pharmacokinetic studies should be based on the methods explored during in vitro testing that can be expected to result in the greatest drug release. The routes of administration chosen should be relevant to the proposed product, and likely will be based on what is known about the abuse of similar products. Note that, for some development programs, it may be preferable to combine measures of pharmacokinetic parameters for Category 3 studies, in which case separate Category 2 studies may not be necessary.

In general, the pharmacokinetic profile for the oral route of administration should be studied. Appropriate study subjects for Category 2 studies include healthy volunteers as long as naltrexone is used to block the pharmacodynamic effects of the opioids.

Depending on the product, it may be important to evaluate the pharmacokinetic profile for the nasal route of administration as well. For nasal pharmacokinetic studies, it is important to weigh the risk to the subject based on the excipients in the formulation. Only subjects with a history of nasal abuse of opioids should be recruited for these studies. As with the oral route of administration, it may be possible to combine the pharmacokinetic assessment and the pharmacodynamic assessment in one clinical abuse potential study with sampling for the pharmacokinetic analysis.

Relevant pharmacokinetic parameters for the opioid drug and any psychoactive metabolites that should be measured in these studies include the following.

- Maximum concentration ($C_{\text{max}}$)
- Time to maximum concentration ($T_{\text{max}}$)
- Area under the curve ($\text{AUC}_{0-t}$ and $\text{AUC}_{0-\infty}$)
- Relevant partial AUC, including early time points such as $\text{AUC}_{0-30\,\text{min}}$ minutes or $\text{AUC}_{0-2\,\text{hrs}}$ hours, the period of time when $C_{\text{max}}$ is expected
- Terminal elimination half-life ($T_{1/2}$)
Traditional pharmacokinetic study designs should be employed (e.g., crossover designs), and the results should be analyzed using bioequivalence methods. The rate of rise of drug concentration should be assessed when possible because it is thought to contribute to differential abuse potential among drugs, formulations, and routes of administration. To support these analyses, it is important to have specimen collection and analysis time points sufficient to cover the onset, peak, and offset of the effects of both IR and ER formulations, in both the intact and manipulated conditions. In addition, these data are necessary to calculate the relevant partial area under the curve, which should capture the time to maximum concentration of the opioid.

If food and alcohol alter the pharmacokinetic parameters of the formulation, data should be provided to characterize those effects. If food significantly increases systemic exposure of the intact formulation, the underlying mechanism for the food effect should be established by assessing whether the effect is based on the drug substance or the formulation and whether the effect is present with intact product as well as with manipulated product. When food is expected to increase exposure, subsequent abuse potential studies of the oral route should be conducted in the fed state to maximize the potential systemic exposure.

In addition to the pharmacokinetic profile of the opioid, for agonist/antagonist combinations, the pharmacokinetic characteristics of the antagonist should be defined for the intact product as well as for the manipulated formulation.

As with all clinical studies, adverse events should be collected, and those that can provide additional insight about the abuse-deterrent effects are especially important. For example, if the manipulated formulation is abused by snorting, it would be important to assess adverse events related to intranasal tolerability.

**C. Clinical Abuse Potential Studies (Category 3)**

In addition to their use by FDA to formulate its scheduling recommendation under the CSA for drug products containing a controlled substance, clinical studies of abuse potential, Category 3, are important for assessing the impact of potentially abuse-deterrent properties. As discussed in

---

9 References suggesting that drugs associated with a rapid onset of action are associated with greater abuse potential include:


10 FDA has issued a draft guidance on this topic (*Assessment of Abuse Potential of Drugs*). Once finalized, it will represent FDA’s current thinking on this topic.
FDA’s guidance on that topic, the preferred design is a randomized, double-blind, placebo-controlled and positive controlled crossover study. These studies generally are conducted in a drug-experienced, recreational user population. The use of a pre-qualification phase (see section 2 below) to identify subjects who can reproducibly distinguish active drug from placebo is a common enrichment strategy used to improve the power of the study to establish a difference between treatments.

Additional considerations applicable to clinical abuse potential studies used to assess potentially abuse-deterrent properties are discussed below. For products that are not susceptible to manipulation based on Category 1 and 2 testing, study designs for Category 3 testing should be discussed with FDA.

1. Blinding

Clinical studies of abuse potential should use a randomized, double-blind, placebo-controlled and positive controlled crossover design. Because study subjects are recreational drug users and familiar with the effects of the drug substances being studied, the double-dummy technique or other techniques should be used to ensure the blinding of all tests when possible. However, alternative designs may be suitable when the blinding of the study drug and the positive control cannot be maintained and treatment by period interactions may lead to sequence effects in a crossover design. For example, a parallel design may be useful when studying the intranasal route of administration, where subjects may be able to see the differences in volume or color between test drug and placebo or positive control, or when it is not possible to create similar results from manipulation, such as particle size from crushing. In these circumstances, early discussion with FDA is recommended.

For clinical abuse potential studies in which the subjects will snort test samples, administration of the samples in a narrow neck, opaque container with a pre-inserted straw may help facilitate blinding. However, even though subjects might not be able to see the sample, un-blinding may still occur due to the physical properties of samples with similar particle size distribution. In some formulations, higher crushed tablet/capsule volume or larger particle size may inhibit complete intranasal administration thereby contributing to the deterrence effects. To be able to evaluate these effects, it may be necessary to maintain differences in tablet/capsule volume between the potentially abuse-deterrent formulation and the comparator. To facilitate blinding and maintain the crossover design, placebos matched to each of the differing weights or particle sizes may be useful. The details of the preparation of the samples should be provided in the study protocol.

2. Pre-qualification Phase

The purpose of the pre-qualification phase is to increase the power of a study to detect differences in the abuse potential of the various formulations of drug and placebo. In general,

11 Ibid.

12 An additional advantage of a pre-qualification phase is that it helps familiarize subjects with and train them in the use of various scales and questionnaires that measure subjective effects.
the pre-qualification phase should ensure that subjects can distinguish between placebo and a conventional IR formulation of the same opioid being developed in an abuse-deterrent formulation, using the same route of administration as planned for the assessment phase. There is little value in having subjects unable to distinguish placebo from active drug continue in the study. The positive control should include a strength that is at least equal to the lowest strength selected for the assessment during the clinical phase. An important aspect of the pre-qualification phase is assessing the ability of subjects to tolerate the study dose. If the dose used in the pre-qualification phase is lower than the lowest strength planned for the assessment phase, some subjects may not be able to tolerate the higher dose that will be administered in the assessment phase. Thus, when tolerability may be an issue, particularly if more than one dose is planned for the assessment phase, a pre-qualification dose that is no lower than the lowest dose planned may be the most efficient choice to establish that the subject can distinguish active drug from placebo and can tolerate the study drug in the range to be tested. For example, a 30 mg or 45 mg dose of opioid could be used in the pre-qualification phase when a 30 mg and 60 mg doses will be assessed in the clinical phase.

Qualifying criteria that help identify subjects with an acceptable placebo response and an acceptable response for the positive control should be pre-specified in the study protocol. After a range for an acceptable placebo response is set, a minimum value for the maximum effect (E_max) for the positive control should be defined. The minimum E_max for the positive control may vary from measure to measure, and from study to study. However, an acceptable response for the positive control should not overlap with the acceptable range for placebo response.

### 3. Assessment Phase

The potentially abuse-deterrent product should be compared to a positive control, and the positive control should be compared to placebo to validate the study. For an IR product with potentially abuse-deterrent properties, the positive control should be an IR formulation of the same opioid. For an ER formulation with potentially abuse-deterrent properties, the positive control could be an IR formulation of the same opioid or an ER formulation of the same opioid. In general, these studies should include one strength of the positive control which is associated with high levels of drug liking. However, when assessing drug liking through the intranasal route, the use of two strengths of the positive control may be helpful to both identify a strength of the positive control associated with high drug liking scores and to validate the study.

If there are no approved products with the same drug substance, the positive control should be a drug that, based on pharmacological profile or nonclinical data, can be expected to have similar pharmacodynamic effects. Selection of the positive control in this setting should be discussed with FDA.

### 4. Subjects

Studies should be conducted in opioid-experienced, recreational drug users who have experience with the particular route of abuse being studied. Subjects should generally not be physically dependent and should not be currently seeking or participating in treatment for drug abuse such that participating in the study could make them vulnerable to relapse. Depending on the
formulation being studied, however, clinical abuse potential studies can be conducted in physically dependent subjects. For example, if the deterrent product contains an opioid antagonist, clinical abuse potential studies in a physically dependent population may provide information not only on the drug liking of the product, but on the ability of the antagonist to precipitate withdrawal in this population.

Detailed characteristics of the study population with respect to past and current drug use and abuse should be captured (e.g., drugs abused, drug of choice, duration of abuse or abstinence).

5. Route of Administration, Dose Selection, Manipulation Mode, and Sample Preparation

The selection of the route(s) of administration should be based on epidemiological data showing that a selected route is a relevant route of abuse. For NMEs, the sponsor should review the relevant routes of abuse for products similar to the test product and discuss the selected routes with FDA. For each relevant route of administration, the potentially abuse-deterrent product and comparator should be manipulated based on the results of Category 1 studies to cause the highest release of the opioid and the highest plasma levels. The dose of the opioid selected for the study should be known to produce high levels of liking in non-tolerant opioid-experienced recreational users.

For studies using the intranasal route of administration, the preparation of the samples is extremely important. The potentially abuse-deterrent product and comparator study drug should be produced with similar particle size distribution based on a detailed protocol for the preparation of the samples, even if different methods are necessary to do so. With some formulations, a high volume of the crushed tablet/capsule or larger particle size may inhibit complete intranasal administration and, thereby, contribute to deterrence effects. To evaluate these effects, it may be necessary to maintain differences in tablet/capsule volume between the potentially abuse-deterrent product and the comparator.

For studies using the intravenous route of administration, the oral formulations may not be safe for intravenous use depending on the excipients used in the formulation. In place of the manipulated oral formulation, a solution for injection should be prepared using approved, commercially available parenteral products when available, or products suitably formulated for the study. The amount of the opioid and that of the antagonist, when relevant, should be based on extrapolation from in vitro extraction studies of manipulated solid formulations.

6. Outcome Measures and Data Interpretation

In abuse potential studies, the primary method for evaluating the subjective effects of drugs should be through the use of standardized instruments.

---

13 Available safety-related information on the use of the various excipients through the intranasal route should be provided. Additionally, some sponsors have conducted intranasal tolerability studies before the abuse potential studies to evaluate irritation of the nasal cavity, nasal congestion, and discharge, among other measures.
In typical abuse potential studies, several instruments have been used to measure subjective responses predictive of the likelihood of abuse. These instruments include:

- Visual Analogue Scales (VAS) – used for drug liking, good effects, bad effects, and other drug abuse-related effects
- Profile of Mood States

The VAS should be the primary measure for drug liking because it appears to correlate most directly with potential for abuse. Other measures of particular interest include assessment of likelihood to take the drug again and assessment of overall drug liking. These measures can be assessed using either a unipolar or bipolar scale, and a rationale should be provided for the choice for a particular scale. In general, FDA recommends using a bipolar scale for the primary measure of drug liking. Unipolar scales have been used to measure other drug effects, such as good and bad effects. Regardless of whether a unipolar or bipolar scale is selected, FDA recommends that for purposes of training subjects, the same scale be used in the pre-qualification and assessment phases.

7. Data Interpretation

For clinical studies of abuse potential conducted on potentially abuse-deterrent opioid drug products, the primary analysis should be the difference in means of the E\text{max} for the primary measure(s) based on the population of study completers. A statistical analysis plan (SAP) should be included in the study protocol or submitted as a separate document before un-blinding the study. The sponsor should provide data and dropout information for non-completers. To ensure adequate power, the sponsor should take into account that there will be subjects who drop out of the study early and plan the sample size calculation accordingly. Proper planning should avoid any need to replace subjects who discontinue without completing the study.

Additional pharmacodynamic measures, including positive subjective effects other than drug liking (e.g., take drug again, high, overall drug liking) and other subject-rated assessments, are generally considered secondary endpoints. Other subject-rated assessments of interest include: alertness; drowsiness; nausea; and, when the intranasal route is used, intranasal irritation, burning, need to blow nose, runny nose/nasal discharge, facial pain/pressure, and nasal congestion.

Some sponsors provide descriptive statistics including mean, standard error, median, and interquartile range, calculated for all pharmacodynamic endpoints by time and treatment. What

---

14 Overall drug liking measures the user’s retrospective assessment of a drug, whereas VAS for drug liking measures the user’s immediate assessment.

15 In general, the primary endpoint of interest is drug liking, and the E\text{max} is captured within 8 hours after dosing. However, the timeframe of measuring the maximum response will be determined by the pharmacokinetic and pharmacodynamic parameters of the formulations studied.

16 See Statistical Analysis Section for further guidance.
constitutes a clinically significant difference in drug liking, between the manipulated and intact versions of the potentially abuse-deterrent product and positive control, is an area requiring further research and will be evaluated on a case-by-case basis. Analysis of postmarket data on abuse levels associated with the potentially abuse-deterrent product being studied may help to support the findings from abuse potential studies.

In addition, when interpreting results from clinical abuse potential studies, attention should be given to the profile of subjective effects produced by the manipulated and intact formulation in terms of onset, peak duration of activity, and offset. The rate of rise of drug onset for the intact and manipulated potentially abuse-deterrent product should be given appropriate weight in the overall analysis of the abuse-deterrent properties. A more rapid onset of action or a shorter time-to-peak effect is generally associated with greater abuse potential. Regarding the duration of effect, it may be difficult to interpret the abuse potential of a formulation that produces a sustained liking effect when taken intact or after manipulation, though lower than that produced by the positive control formulation.

The overall assessment of abuse potential should be based on the pattern of findings across all of the measures. In addition, qualitative aspects of the findings, such as the steepness of the drug liking response and duration of the liking effects associated with manipulated formulations, should be taken into consideration, along with other positive effects and negative effects.

8. **Statistical Analysis**

a. **Background**

The overall goal of a clinical study of abuse potential is to assess a number of abuse potential outcome measures (e.g., drug liking VAS) in the potentially abuse-deterrent product \((T)\) relative to a formulation of the drug without abuse-deterrent properties \((C)\), or a newly formulated opioid product (positive control). Substantial decreases in the responses for the potentially abuse-deterrent formulation compared to the positive control are evidence of deterrence.

A clinical study of abuse potential should be validated by comparing the responses to \(C\) with those of placebo \((P)\). Thereafter, the assessment of the abuse-deterrence properties of \(T\) is of primary interest. This can be achieved by comparing the difference in means between \(C\) and \(T\) with a margin for abuse potential measures and comparing the difference between \(C\) and \(T\) relative to \(C\) in drug liking on a bipolar VAS.

The statistical analysis of the data in a clinical study should begin with descriptive statistics making up tabulations and graphs that include tables of the mean, standard error, and other summary statistics: minimum, Q1, median, Q3, and maximum of the responses of interest for each treatment and for each paired difference among treatments.
Useful graphs include mean time course profiles, heat-maps, and continuous responder profiles.

The next subsection describes the statistical test that sponsors should use for the primary analysis of $E_{\text{max}}$ on the VAS for drug liking. An analysis of the percent reduction in drug liking for $T$ relative to $C$ on the individual level in subsection c is recommended as a secondary analysis.

b. Primary analyses

The primary analysis of abuse-deterrent effects should be based on the comparison of means between crushed, chewed, or otherwise modified $T$ and $C$ with an abuse deterrence margin on drug liking VAS. That is, test

$$H_0 : \mu_C - \mu_T \leq \delta_1 \text{ versus } H_a : \mu_C - \mu_T > \delta_1$$

where $\delta_1 = \delta^*(\mu_C - 50)$, and $0 < \delta^* < 1$. Because $C$ is an opioid drug, the validation test also needs a margin, say $\delta_2$. That is,

$$H_0 : \mu_C - \mu_P \leq \delta_2 \text{ versus } H_a : \mu_C - \mu_P > \delta_2$$

where $\delta_2 \geq 15$.

The significant level for both tests is 2.5%.

The actual value of $\delta_1$ is related to $\mu_C$, hence, it may vary according to abuse potential measures and the route of drug administration. The $\delta^*$ should be pre-specified in the protocol. We also suggest the use of 95% confidence intervals to assess both the differences $\mu_C - \mu_T$ and $\mu_C - \mu_P$.

c. Secondary analyses

In addition to the primary analysis, an analysis should be performed of the percent reduction for the potentially abuse-deterrent product $T$ relative to $C$ from each individual study subject for drug liking VAS on a bipolar scale from 0 to 100. One definition for percent reduction for individual subjects is as follows:

$$\%\text{reduction} = \left(\frac{c_i - t_i}{c_i - p_i}\right) \times 100\%, \ i = 1, 2, ..., n,$$

where $c_i$, $t_i$, and $p_i$ are the $E_{\text{max}}$ values for $C$, $T$, and $P$ from the $i$th subject, respectively; $n$ is the sample size.

---


18 If a nonparametric method is necessary, analysis of the median difference in $E_{\text{max}}$ may be appropriate.
However, this definition is problematic because for two subjects having the same \( E_{\text{max}} \) values for \( T \) and \( C \) (\( t_1 = t_2 \) and \( c_1 = c_2 \)), the larger the placebo response, the greater the percent reduction. A more appropriate definition of percent reduction can be derived by replacing \( p_i \) by the neutral score 50 on a bipolar scale; that is,

\[
\% \text{ reduction} = \frac{c_i - t_i}{c_i - 50} \times 100\%, \quad i = 1, 2, \ldots, n
\]

where we assume that \( c_i > 50 \). In case some subjects have \( c_i \leq 50 \), define \( \% \text{ reduction} = 0 \).

Note that even though most abuse potential studies have a pre-qualification phase, approximately 10% of subjects still have placebo responses \( p_i \) over 65, with 5% over 75 in the assessment phase. Consequently, it may be necessary to penalize subjects with large values of \( p_i \) in computing percent reduction. For example, the percent reduction could be multiplied by an adjustment factor that equals 1 when \( p_i \) is around 50 or less and decreases from 1 when \( p_i \) is large. Sponsors should discuss with FDA the need for an adjustment factor in computing percent reduction and an appropriate formula for defining the penalty to be applied before finalizing the study protocol.

Two approaches for assessing the deterrent effects using percent reduction for crossover design studies are provided below. Note that when a parallel design is used, the percent reduction for individual subjects is not applicable, and the primary analysis may also serve the purpose for assessing the percent reduction based on \( \mu_c - \mu_T \) related to \( \mu_c - 50 \).

- **Responder Analysis**

A responder is defined as a subject who had at least \( \delta \times 100\% \) of reduction, in \( E_{\text{max}} \) for \( T \) relative to \( C \). To ensure that a majority of subjects are responders, a proportion test can be used to test the null hypothesis that 50% or fewer subjects are responders. That is, test

\[
H_0 : p^* \leq 50\% \quad \text{versus} \quad H_a : p^* > 50\%
\]

at the 2.5% significance level where \( p^* \) denotes the percentage of responders. The 95% confidence interval of \( p^* \) can also be calculated.

- **Analysis of the Median Percent Reduction**

The median of the percent reduction \( (\text{ptr}) \) is a descriptive measure of central tendency of \( \text{ptr} \). At most 50% of subjects have \( \text{ptr} \) less than the median, and at most 50% of subjects have \( \text{ptr} \) greater than the median. If the median of \( \text{ptr} \) is equal to 30%, for example, it means that approximately 50% of subjects have greater than or equal to a 30% reduction.
For assessing deterrent effects, we can test

\[ H_0: \text{median}(\text{ptr}) \leq \text{DR}\% \text{ versus } H_a: \text{median}(\text{ptr}) > \text{DR}\% \]

at the 2.5% significance level, where DR denotes deterrent reduction. To be consistent with the responder analysis, we recommend \( \text{DR}\% = \delta \times 100\% \). If the distribution of \( \text{ptr} \) is symmetric, the Wilcoxon-signed rank test can be used to test the null hypothesis that the median of \( \text{ptr} \) is less than or equal to \( \text{DR}\% \), and a 95% confidence interval for the median based on this test can be readily calculated using standard methods. Otherwise, the sign test should be used or an alternate method of this test can be pre-specified in the SAP.

Sponsors should pre-specify one of the two analysis methods for the percent reduction in their SAP in addition to the primary analysis in their clinical studies and discuss with FDA the definition of a responder in the responder analysis or the value of \( \text{DR}\% \) used in the analysis of the median percent reduction before finalizing the study protocol.

d. Multiplicity

Whether or not an adjustment for multiplicity is needed for claiming significant results on the primary or key secondary endpoints varies from study to study. Sponsors should refer to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidance \textit{E9 Statistical Principles for Clinical Trials} for statistical principles regarding the multiplicity adjustment.

V. POSTMARKET STUDIES (CATEGORY 4)

Premarket studies focus on assessing the potentially abuse-deterrent properties of a product under controlled conditions. The goal of postmarket studies, Category 4, is to determine whether the marketing of a product with abuse-deterrent properties results in meaningful reductions in abuse, misuse, and related adverse clinical outcomes, including addiction, overdose, and death in the post-approval setting. As more abuse-deterrent products are approved, it is possible that the amount of reduction observed in an epidemiologic study may also change. Consequently, a reduction that is deemed meaningful at one time may not be meaningful at another. Given the changing landscape, a numerical threshold cannot define what would be considered a meaningful reduction.

Currently, data on the impact of an abuse-deterrent product on drug abuse in the U.S. population are limited, and thus the optimal data sources, study variables, design features, analytical

\[ \text{ICH guidelines are available on FDA’s guidance webpage at } \text{http://www.fda.gov/RegulatoryInformation/Guidances/default.htm.} \]

\[ \text{FDA requires postmarket studies for all opioids with abuse-deterrent labeling claims. For more information on postmarket requirements, see } \text{http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Post-marketingPhaseIVCommitments/ucm070766.htm.} \]
techniques, and outcomes of interest of postmarket epidemiologic studies are not fully established.

Postmarket evaluations of abuse deterrence fall into two categories—formal studies and supportive information. Sponsors should submit protocols to FDA for all formal studies of abuse deterrence. Supportive information can also be submitted to FDA, but cannot substitute for formal studies.

A wide range of interrelated behavioral, clinical, and societal factors contribute to drug abuse; therefore, the effects of an abuse-deterrent formulation can manifest in a variety of ways. Understanding the actual impact of a particular abuse-deterrent formulation may require using a variety of study designs to examine different abuse-related outcomes in given populations of interest. Generally, multiple formal studies using a variety of data sources should be conducted to provide insights into product-specific abuse and the effect of an abuse-deterrent product on the outcomes of interest for other opioid drug products. The use of multiple study designs will also generally help with assessment of the impact of abuse-deterrent products on the full spectrum of abuse-related outcomes (i.e., addiction, overdose, and death) and to characterize and quantify the relevant clinical events that are associated with these outcomes.

Recognizing that the current thinking in this area may change, the following subsections provide recommendations for designing postmarket epidemiologic studies that are capable of detecting a change in the occurrence of abuse as a result of a drug product’s abuse-deterrent properties.

A. Formal Studies

1. General Characteristics

Formal studies have the following characteristics:

1. They are hypothesis-driven, population-based, observational evaluations that follow good epidemiological practices\(^ {21,22}\) and use outcomes that provide meaningful measures of abuse deterrence.
2. They capture one or more outcomes that can be used to assess meaningful reductions in misuse, abuse, addiction, overdose, and death.
3. They produce estimates of abuse and related clinical outcomes that are nationally representative, or are based on data from multiple large geographic regions that can reasonably be generalized to the national level. In the absence of nationally generalizable

---


Contains Nonbinding Recommendations

data, smaller or regional studies may be informative, but must be accompanied by a clear
explanation of their representativeness and generalizability for appropriate interpretation.

4. They assess overall and route-specific (i.e., injected, snorted, smoked) changes in abuse
levels that are associated with an abuse-deterrent product.

5. They are sufficiently powered statistically to assess meaningful changes in drug abuse
and are of sufficient duration to examine trends in abuse following the marketing of the
abuse-deterrent product. The necessary duration of the studies will depend on a variety
of factors, including drug utilization and market share, early postmarket abuse deterrence
data, and changes in the prescription opioid or illicit drug market.

2. Study Design Features

The epidemiologic methods and data sources that underlie formal postmarket studies to evaluate
the effect of abuse-deterrent formulations are evolving, and best practices have not been
established. In addition, characterizing the relevant clinical events that are most useful for
understanding the actual impact of a product on abuse-related adverse events is also an evolving
science. Based on the current state of this field, we provide below some basic guidelines on
recommended study design features that will enable FDA to evaluate the results of formal
studies.

1. The study hypothesis and its relationship to assessing abuse deterrence should be clearly
stated. The study hypothesis should also include the route(s) of abuse that will be
studied.

2. An understanding of each data source is important to the design and interpretation of the
study. A description of each data source should be provided in the protocol and should
include if and how the data source captures drugs, study outcomes, drug formulation, and
route of abuse. The sampling methods, study population, or catchment area for the data
source should be clearly described.23

3. The choice of population(s) in each study should be carefully considered. The
populations included in the study should be described in the protocol. At least one study
should include a high-risk population, such as a population of known drug abusers, but
formal studies should not be limited to only high-risk populations.

4. The protocol and study reports should thoroughly define the study outcomes. The choice
of the outcome measure(s) should be justified. Formal studies should, as a group, capture
all relevant outcomes: misuse, abuse, addiction, overdose, and death, as well as misuse
and abuse clinical outcomes. Overall and route-specific misuse and abuse estimates
should include prevalence and frequency of abuse. Clinical outcomes should include,
when possible, an assessment of severity of abuse outcomes (e.g., addiction or overdose).

23 See FDA guidance Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using
Electronic Healthcare Data.
Contains Nonbinding Recommendations

5. Both population- and drug utilization-based estimates should be included in the study protocol. Drug utilization-based estimates should use multiple denominators. The denominators are generally the number of prescriptions and the number of extended units (e.g., tablets or capsules). The catchment area for drug utilization data should be specified, particularly for sub-national or regional populations.

6. Sponsors should list all proposed opioid comparators and describe the rationale behind their inclusion. When branded and generic versions of a comparator are marketed, all should be included in the study when possible because many data sources used in abuse studies can identify only active ingredients and do not distinguish between branded and generic products or among multiple generic products. Information should be provided on the ability of data sources and study participants to accurately discriminate among different opioid products and formulations. The choice of comparator is critical for determining if a reduction in drug abuse is the result of a product’s abuse-deterrent properties or the result of other factors (e.g., educational programs, prescription drug monitoring programs, changes in law enforcement policies, and the availability of other drugs) or secular trends. The choice of comparators will depend on the particular abuse-deterrent product studied and the opioid market environment at the time the study is initiated. Multiple comparators should be used to achieve the most complete picture of the impact of a product’s abuse-deterrent properties. For the purposes of hypotheses, some comparators should be selected and justified as primary comparators in the study protocol before data collection, with additional comparators providing context. The following are examples of several potential abuse-deterrent study comparator scenarios.

If an abuse-deterrent formulation of a previously marketed product is introduced to the market, the primary comparators should include historical and currently available non-abuse-deterrent formulations of the products (including branded and generic whenever possible). Additional individual opioid products should be included as well and should be agreed upon with FDA and identified before the start of the study.

If a new abuse-deterrent product does not have an historical or currently available non-abuse-deterrent version of the same opioid, an appropriate group of comparators should be identified before the start of the study through mutual agreement with FDA. Examples of appropriate primary comparators include immediate release non-abuse-deterrent products with the same active moiety and/or a non-abuse-deterrent product with a relatively stable market share and abuse estimates captured at baseline during the postmarket period. Larger groupings of products can also serve as comparators and can help determine secular trends.

When available, a product that has the same active moiety, but has a different abuse-deterrent property, can serve as a comparator.

---

7. Understanding the background rates of drug abuse is important for protocol design and interpretation of study results. A baseline assessment of the prevalence of drug abuse for formulations of the same opioid that lack abuse-deterrent properties should be conducted and the baseline time period should be justified.

8. Submissions should include the SAP. The plan should include parameter definitions, unit of analysis, model specification, power and sample size calculations, and any additional variables or predictors. Assessment of the abuse outcome measures should consider both average levels of abuse comparing pre- and post-periods to currently available product (means analysis) and trend analysis.

9. Statistical models should include variables that may affect how the product is used and also other related confounders (e.g., geographic variability and demographic characteristics).

10. Exposure and outcome measures that include self-reported assessments should be validated before the start of the study.

11. The precision of outcome measures will also influence the observational period. Outcome measures with large uncertainty (due to bias or variability) in the exposure or study variable measures, for example, may warrant longer observational periods.

12. Interim analyses are encouraged, but results should be considered tentative in light of their preliminary nature.

B. Supportive Information

Information is considered supportive if it can be used to provide additional context on societal, behavioral, and clinical aspects of abuse and abuse-deterrence. Supportive information may be qualitative or descriptive, and it may rely on sources that capture drug utilization or prescribing patterns, diversion events, attitudes and practices (e.g., tampering) of abusers and other information that may not directly be considered abuse (e.g., data concerning the street value of prescription drugs, information about drug use and misuse from social websites). Investigations that provide supportive information may also include investigations that are conducted in smaller populations or subgroups, and that while perhaps not broadly generalizable, may contribute to the totality of the evidence relating to abuse deterrence.

As is the case for formal studies, best practices for collecting and submitting supportive information are still evolving. However, below are some basic recommendations relating to supportive information.

1. Supportive information should be clearly stated, and the rationale for how the supportive information contributes to a sponsor’s portfolio of abuse-related studies should be clearly identified.

2. How supportive information is representative of the population from which it is derived or sampled should be clearly described.
3. How the exposure and outcome are measured should be clearly described along with the relationship between the outcomes measured and the primary outcomes of interest: misuse, abuse, addiction, overdose, and death.

4. Collections of supportive information that include populations of particular interest or geographically diverse settings is strongly encouraged. Overlapping geographic areas between formal and supportive information should be considered.

VI. LABELING

Including information about a product’s abuse-deterrent properties in labeling is important to inform health care professionals, the patient community, and the public about a product’s abuse potential. Accordingly, FDA encourages sponsors to propose labeling that sets forth the results of in vitro, pharmacokinetic, clinical abuse potential and formal postmarket studies and appropriately characterizes the abuse-deterrent properties of a product.

There are several important concepts about the state of the science of pre- and postmarket studies of abuse deterrence that should be considered as these are reflected in labeling. First, as stated earlier in the guidance, abuse-deterrent does not mean abuse-proof. Therefore, labeling should reflect a product’s abuse-deterrent properties, as supported by the data, but should include a caveat that abuse is still possible. Next, premarket studies are intended to demonstrate properties that are predictive of a meaningful abuse-deterrent effect for a particular route of administration. FDA has limited data correlating the abuse-deterrent properties of certain opioid drug products, as demonstrated by premarket studies, with the impact of those properties on abuse or adverse events associated with abuse in the post-approval setting. Even though postmarket studies have the potential to demonstrate such effects, the findings of postmarket studies are not available at the time of initial product approval. Labeling should reflect the predictive quality of premarket studies and include results of relevant completed postmarket studies.

When premarket data show that a product’s abuse-deterrent properties can be expected to result in a meaningful reduction in that product’s abuse, these data, together with an accurate characterization of what the data mean, should be included in product labeling. \(^{25}\) When postmarket data become available that demonstrate a meaningful reduction in abuse by one or more routes of administration, these data should be added to the product labeling. However, if these postmarket data fail to confirm that the abuse-deterrent properties result in a reduction in abuse, or demonstrate a shift in routes of abuse that represent a greater risk (e.g., a shift from oral and nasal abuse to intravenous abuse), FDA may determine that labeling revisions are needed.

Labeling language regarding abuse deterrence should describe the product’s specific abuse-deterrent properties as well as the specific routes of abuse that the product has been developed to deter. For example, a formulation that limits an abuser’s ability to crush a tablet and to extract the opioid can be described as limiting manipulation for the purpose of snorting or injection if

\(^{25}\) Abuse-deterrence information in labeling should be presented in the DRUG ABUSE AND DEPENDENCE section under 9.2 Abuse.
the data support such a statement. For this characterization to be accurate and not misleading, however, appropriate caveats are likely to be necessary as described above. For example, a product’s labeling should explain that the product’s abuse-deterrent properties only make abuse more difficult, not impossible, and that these properties provide no deterrence against other potential forms of abuse.

As noted at the outset of this guidance, FDA will take a flexible, adaptive approach to the evaluation and labeling of abuse-deterrent opioid products. FDA expects sponsors to update their formulations to take advantage of technological improvements and further expects to allow labeling statements related to abuse deterrence commensurate with those advances.

Furthermore, FDA expects sponsors to compare their formulations against approved abuse-deterrent versions of the same opioid. The comparisons should be based on the relevant categories of testing. For instance, if a proposed product is less resistant to manipulation than an approved product, the proposed product may not be eligible for labeling regarding abuse-deterrent properties.

FDA is concerned that, with time, abusers may adapt to abuse-deterrent technologies and discover methods to defeat them. If and when abusers can overcome a technology such that it no longer has a meaningful effect in deterring abuse, FDA may require labeling revisions.

As discussed below, the nature of information in labeling on abuse deterrence for a particular product will depend on the types of studies performed and the result of those studies. Because it cannot provide specific guidance on the magnitude of effect that would be sufficient to support each type of claim, FDA will assess the appropriateness of all proposed labeling statements about abuse deterrence based on the data provided.

Information describing the results of the evaluation of abuse-deterrent properties can be used to support labeling statements based on the three premarket categories (i.e., in vitro data, pharmacokinetic data, and clinical abuse potential studies) and the fourth category (postmarket data) once it is available.

The data necessary to support abuse-deterrent labeling will depend on the characteristics of the product that impart the abuse deterrence and the route of abuse. In general, most abuse-deterrent information included in product labeling will be based on data from more than one category.

Key elements of the study design and conduct should be summarized in the product labeling. Category 1 studies can be described in general terms to avoid creating a *road map* for defeating the product’s abuse-deterrent properties. However, the design, conduct, and results of Category 2 and 3 studies should be described in sufficient detail, including the primary outcome measure data from Category 3 studies, to support clear labeling regarding a product’s abuse-deterrent properties.

The following are examples of information for inclusion in labeling for different types of abuse-deterrent effects based on various types of premarket studies performed.
Contains Nonbinding Recommendations

• Category 1

For this product, in vitro data demonstrated that an abuse-deterrent product cannot be crushed and dissolved or extracted in a small volume of solution suitable for injection. In this case, Category 1 in vitro data may be sufficient to support a statement in labeling about abuse deterrence for the intravenous route of abuse (See Section IV Premarket Studies). Possible labeling text:

In vitro physical and chemical tablet manipulation studies were performed to evaluate the ability of different extraction methods to defeat the formulation. Results support that Tradename resists crushing, breaking, and dissolution using a variety of tools and solvents and retains some extended-release properties despite manipulation.

These in vitro data demonstrate that Tradename has physical and chemical properties that are expected to deter intravenous abuse. However, abuse of this product is still possible by the oral and nasal routes.

• Category 1 and Category 2

For this product, in vitro and pharmacokinetic data from study of the oral and nasal routes of administration demonstrated that no changes occurred in the extended-release properties of the opioid after crushing or dissolution in a variety of solvents. These data may be sufficient to support statements in labeling about abuse deterrence for the nasal and intravenous routes of abuse. Possible labeling text:

In vitro physical and chemical tablet manipulation studies were performed to evaluate the ability of different extraction methods to defeat the formulation, and pharmacokinetic studies of the oral and intranasal routes were performed to determine the effect of manipulation on drug release. Results support that Tradename resists crushing, breaking, and dissolution using a variety of tools and solvents and retains its extended-release properties despite manipulation.

The in vitro data demonstrate that Tradename has physical and chemical properties that are expected to deter oral, nasal and intravenous abuse. However, abuse of intact product is still possible by the oral route.

• Category 2 and Category 3

For this product, pharmacokinetic and clinical abuse potential studies demonstrated the release of an antagonist from an opioid and antagonist combination product following crushing and that the presence of the antagonist resulted in less drug liking compared to a similar amount of opioid alone when administered by the oral and intranasal routes. In
addition, an additional clinical abuse potential study simulating intravenous abuse using the amounts of opioid and antagonist found to be released from the crushed product also demonstrated reduced drug liking.

The pharmacokinetic data demonstrate that crushing Tradename results in the simultaneous release and rapid absorption of opioid and antagonist. These data along with the results from oral and intranasal clinical abuse potential studies and a clinical abuse potential study of intravenous opioid and antagonist to simulate crushed Tradename indicate that Tradename has properties that are expected to deter abuse via the oral, intranasal, and intravenous routes. However, abuse of Tradename by these routes is still possible.

All of these statements based on Categories 1, 2, or 3 testing should be followed by a statement that data from laboratory and clinical studies may not fully predict abuse potential in the post-approval setting.

As discussed in Section V, postmarket data from a variety of sources can demonstrate that a product’s abuse-deterrent properties result in persistent and relevant abuse deterrence. These data can result from appropriately designed, conducted, and analyzed formal postmarket studies and from supportive information on the abuse of the product.

FDA is currently considering formal studies plus a variety of supportive information (e.g., data concerning the street value of prescription drugs) as sources that may be acceptable to provide evidence that a product’s formulation has had an actual impact on reducing its abuse. FDA anticipates that data from some or all three of the premarket categories along with data from postmarket studies (including both formal studies and supportive information) would be needed to support a statement in labeling that the product has been shown to reduce abuse. The combined results from all of these studies would be described in the product labeling, including specific study designs, conduct, analyses, and study data.

An example of labeling for a product with evidence of a reduction in abuse is:

These data demonstrated a reduction in the abuse of Tradename in the community setting compared to the levels of abuse, overdose, and death that occurred when only formulations of the same opioid without abuse-deterrent properties were available. This reduction in abuse appears to be attributable to the product’s formulation, which deters abuse by injection or snorting of the manipulated product. However, such abuse of this product is still possible, and the product’s abuse deterrence properties do not deter abuse associated with swallowing the intact formulation.

VII. ADDITIONAL RESEARCH NEEDS

As discussed above, the science of abuse deterrence is relatively new. Both the technologies involved and the analytical, clinical, and statistical methods for evaluating those technologies are
rapidly evolving. For these reasons, FDA will take a flexible, adaptive approach to the evaluation and labeling of potentially abuse-deterrent opioid products. Additionally, there is considerable room for additional scientific work that could advance the development and assessment of abuse-deterrent products. In particular, FDA encourages additional research on the following topics:

- The quantitative link between changes in the pharmacokinetics of opioids in different formulations and results of a clinical abuse potential study with those same formulations.
- The best assessment methods to employ when analyzing a clinical study of abuse potential.
- The quantitative link between the outcomes from a clinical study of abuse potential comparing formulations and the effect on those same formulations on abuse in the community.
- Further understanding of the best study methods to employ to assess the effect of a product with abuse-deterrent properties on the rates of abuse in the community.
- Development of a communication tool (e.g., a simple graph or chart) to inform prescribers of the relative impact the product has on the different routes of abuse.

Progress on these topics could facilitate the ability of sponsors to propose and FDA to approve labeling that would give a more complete picture of the anticipated effect of products with abuse-deterrent properties. Ultimately, progress in these areas could facilitate product development by reducing the amount of information that is needed to accurately assess a product with abuse-deterrent properties and predict its impact on abuse in the community.
Drug Utilization Review

Date: October 1, 2018

Drug Utilization Analyst(s): Daniel Bak, PharmD
Drug Utilization Data Analyst
Division of Epidemiology II

Team Leader(s): LCDR Travis Ready, PharmD
Drug Utilization Data Analyst Team Leader
Division of Epidemiology II

Deputy Director for Drug Utilization: LCDR Grace Chai, PharmD
Deputy Director for Drug Utilization
Division of Epidemiology II

Associate Director: Judy Staffa, Ph.D., R.Ph.
Associate Director for Public Health Initiatives
Office of Surveillance and Epidemiology

Product Name(s): Oxycodone IR (MNK-812)

Application Type/Number: NDA 209774

Applicant/Sponsor: SpecGx LLC (Mallinckrodt)

OSE RCM #: 2018-1363
TABLE OF CONTENTS

Executive Summary ........................................................................................................................................... 1

1 Introduction .................................................................................................................................................. 2
  1.1 Background ........................................................................................................................................... 2

2 Methods and Materials ............................................................................................................................... 2
  2.1 Data Sources ......................................................................................................................................... 2
  2.2 Molecules Included ............................................................................................................................. 3

3 Results ........................................................................................................................................................ 3
  3.1 Determining Settings of Care ............................................................................................................... 3
  3.2 Prescription Data ................................................................................................................................. 3
    3.2.1 Oxycodone Products ....................................................................................................................... 3
    3.2.2 Opioid Analgesics with Labeling for Abuse Deterrent Properties .............................................. 4

4 Discussion .................................................................................................................................................. 5

5 Conclusion .................................................................................................................................................. 6

6 Appendices ................................................................................................................................................ 7
  6.1 Appendix A. Tables ............................................................................................................................... 7
  6.2 Appendix B. Drug Utilization Database Descriptions/Limitations .................................................... 9
  6.3 References ............................................................................................................................................ 10
EXECUTIVE SUMMARY

On November 14, 2018, the Anesthetics and Analgesic Drug Products Advisory Committee (AADPAC) and the Drug Safety and Risk Management Advisory Committee (DsARM) will meet to discuss and evaluate data for a New Drug Application (NDA) of MNK-812, an oxycodone immediate-release (IR) product, formulated with properties intended to deter abuse. In support of this upcoming meeting, this review intends to provide context for the committee to better understand recent utilization of oxycodone IR products and other opioid analgesics with and without labeling for abuse-deterrent properties/formulations (ADF).

In the outpatient retail pharmacy setting, an estimated 50-56 million prescriptions were dispensed for oxycodone-containing products annually from 2013 through 2017. Single-ingredient oxycodone IR and oxycodone IR combination products accounted for the two most frequently dispensed products among oxycodone-containing products throughout the time examined. Overall, prescriptions dispensed for single-ingredient oxycodone IR products appeared to increase from approximately 14.5 million dispensed prescriptions in 2013 to a range of 17.3 million to 17.8 million prescriptions dispensed annually for years 2015 through 2017.

The number of prescriptions dispensed for ADF opioid analgesic products decreased 22% from approximately 4.9 million prescriptions in 2013 to 3.8 million prescriptions in 2017. Of the 3.8 million prescriptions dispensed for ADF opioid analgesics in 2017, reformulated OxyContin (oxycodone ER) accounted for the majority of total prescriptions at nearly 88% (3.4 million prescriptions).

Our findings show use of single-ingredient oxycodone IR products appeared to increase from about 14.5 million dispensed prescriptions in 2013 to about 17.3 million prescriptions in 2017. Among abuse-deterrent opioid analgesics, reformulated OxyContin accounted for the highest proportion of total prescriptions dispensed in 2017.
1 INTRODUCTION

On November 14, 2018, the Anesthetics and Analgesic Drug Products Advisory Committee (AADPAC) and the Drug Safety and Risk Management Advisory Committee (DsARM) is scheduled to meet to discuss whether the data submitted for a New Drug Application (NDA) for an immediate-release (IR) formulation of oxycodone with properties intended to deter abuse (ADF) is sufficient for approval and for labeling as abuse-deterrent. To create context for the upcoming meeting, this review examines the extent of use of marketed immediate-release oxycodone and other opioid analgesic products with and without formulations designed to deter abuse.

1.1 BACKGROUND

On January 16, 2018, SpecGx LLC (Mallinckrodt) submitted a New Drug Application (NDA) 209774 for an immediate-release formulation of oxycodone with abuse-deterrent properties (ADF). The proposed formulation was designed to prevent tampering when subjected to various physical and chemical manipulations by abusers. The proposed indication for single-ingredient oxycodone IR is for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.¹

2 METHODS AND MATERIALS

Proprietary drug utilization databases available to the Agency were used to conduct these analyses. Detailed descriptions of the databases are included in Appendix B.

2.1 DATA SOURCES

The IQVIA, National Sales Perspectives (NSP) database was used to obtain the nationally estimated number of bottles and packages sold for immediate-release oxycodone from the manufacturer to all U.S. channels of distribution, from 2013 through 2017. The sales distribution data represent the amount of product sold from manufacturers to pharmacies and other settings of care; it does not reflect what is being sold to or administered to patients directly.

The IQVIA National Prescription Audit (NPA) database was used to obtain the nationally estimated number of prescriptions dispensed for oxycodone-containing products and other opioid analgesics with abuse-deterrent formulations from U.S. outpatient retail pharmacies, from 2013 through 2017, annually.
2.2 **Molecules Included**

**Table 1** provides the list of molecules included in this review:

<table>
<thead>
<tr>
<th>Oral Oxycodone Immediate-Release (IR) Analgesic</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Active Ingredient</td>
<td>Brand Name</td>
</tr>
<tr>
<td>Oxycodone IR</td>
<td>Roxicodone</td>
</tr>
<tr>
<td></td>
<td>Oxaydo</td>
</tr>
<tr>
<td>(Roxybond)</td>
<td></td>
</tr>
<tr>
<td>Oxycodone-Acetaminophen IR</td>
<td>Percocet</td>
</tr>
<tr>
<td></td>
<td>Roxicet</td>
</tr>
<tr>
<td></td>
<td>Tylox</td>
</tr>
<tr>
<td>Oxycodone-Aspirin IR</td>
<td>Percodan</td>
</tr>
<tr>
<td>Oxycodone-Ibuprofen IR</td>
<td>Combunox</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Oral Opioid Analgesic Products with Labeling for Abuse Deterrent Properties</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Active Ingredient</td>
<td>Brand Name</td>
</tr>
<tr>
<td>Hydrocodone ER</td>
<td>(Hysingla)</td>
</tr>
<tr>
<td></td>
<td>(Vantrela)</td>
</tr>
<tr>
<td>Morphine ER</td>
<td>(Morphabond)</td>
</tr>
<tr>
<td></td>
<td>(Arymo)</td>
</tr>
<tr>
<td>Morphine-Naltrexone ER</td>
<td>(Embeda)</td>
</tr>
<tr>
<td>Oxycodone ER</td>
<td>(OxyContin)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Xtampza)</td>
</tr>
<tr>
<td>Oxycodone-Acetaminophen ER</td>
<td>Xartemis</td>
</tr>
<tr>
<td>Oxycodone-Naloxone ER</td>
<td>(Targiniq)</td>
</tr>
<tr>
<td>Oxycodone-Naltrexone ER</td>
<td>(Trasyca)</td>
</tr>
</tbody>
</table>

Brand name products in parenthesis indicate opioid medications with FDA-approved labeling describing abuse-deterrent properties.

3 **RESULTS**

3.1 **Determining Settings of Care**

In 2017, approximately 68% of all oxycodone IR products were distributed to U.S. outpatient retail pharmacies, followed by 31% to non-retail pharmacies, and 0.4% to mail-order/specialty pharmacies. According to the data, we focused our efforts on the outpatient retail pharmacies. Data from other settings of care were not included.

3.2 **Prescription Data**

3.2.1 **Oxycodone Products**

**Figure 1 below and Table 1 in Appendix A** shows the nationally estimated number of dispensed prescriptions for oxycodone-containing products from U.S. outpatient retail

---

pharmacies from 2013 through 2017, annually. Approximately 50-56 million prescriptions of oxycodone-containing products were dispensed annually from 2013 through 2017. Of the total number of prescriptions dispensed for oxycodone-containing products in 2017, prescriptions dispensed for oxycodone IR combination products accounted for the majority at approximately 59% (29.4 million prescriptions), followed by single-ingredient oxycodone IR at 35% (17.3 million prescriptions), single-ingredient oxycodone ER at 7% (3.4 million prescriptions), and combination oxycodone ER at <0.5% (2700 prescriptions). Overall, prescriptions dispensed for single-ingredient oxycodone IR products appeared to increase slightly from about 14.5 million dispensed prescriptions in 2013 to a range of 17.3 million to 17.8 million prescriptions dispensed annually for years 2015 through 2017.

**Figure 1. Nationally Estimated Number of Prescriptions for Oxycodone-Containing Products from U.S. Outpatient Retail Pharmacies, from January 2013 Through December 2017, Annually.**

![Figure 1](image)


*Immediate-Release (IR) formulations include oral solid tablets/capsules and oral liquids

**Extended-Release (ER)**

### 3.2.2 Opioid Analgesics with Labeling for Abuse Deterrent Properties

**Figure 2 below and Table 2 in Appendix A** shows the nationally estimated number of prescriptions dispensed for abuse-deterrent formulation (ADF) opioid analgesic products from U.S. outpatient retail pharmacies from 2013 through 2017, annually. The number
of prescriptions dispensed for ADF opioid analgesic products decreased 22% from approximately 4.9 million prescriptions in 2013 to 3.4 million prescriptions in 2017. In 2017, of the total number of prescriptions dispensed for ADF prescriptions, prescriptions for reformulated oxycodone ER accounted for the majority at nearly 88% (3.4 million prescriptions).

Figure 2. Nationally Estimated Number of Prescriptions Dispensed for Opioid Analgesic Products with Labeling for Abuse Deterrent Properties (ADF) from U.S. Outpatient Retail Pharmacies, 2013-2017, Annually


Hysingla (hydrocodone ER) - Approved 11/2014
Embeda (morphine/naltrexone ER) - was first approved on August 13, 2009 but was voluntarily withdrawn from the market in March 2011 due to testing that found stability concerns in the manufacturing process. The FDA confirmed that these issues were resolved with its approval of a manufacturing supplement in November 2013.
 Xtampza ER (oxycodone ER) - Approved 04/2016
Arymo ER (morphine ER) - Approved 01/2017
Morphabond ER (morphine ER) - Approved 10/2015
OxyContin (oxycodone ER) - Reformulated Version Approved 04/2010

* Products not marketed during study period: RoxyBond (oxycodone IR) - Approved 04/2017, Targiniq (oxycodone/naloxone) - Approved 07/2014, Troxyca (oxycodone/naltrexone ER) - Approved 08/2016, Vantrrela (hydrocodone ER) - Approved 01/2017

4 DISCUSSION

An analysis of oxycodone IR and other opioid analgesics with and without abuse-deterrent properties for recent years was performed to provide context for the advisory committees to evaluate the NDA for an immediate-release oxycodone with abuse-deterrent properties.
Of the oxycodone products reviewed, single-ingredient oxycodone IR and oxycodone IR combination products have accounted for the two most frequently dispensed oxycodone prescriptions each year throughout the time examined.

Findings from this review should be interpreted in the context of the known limitations of the databases used. The nationally estimated numbers of dispensed prescriptions provided in this review represent the U.S. outpatient retail pharmacy setting only and may not apply to other important settings of care.

5 CONCLUSION

Our findings suggest use for single-ingredient oxycodone IR products appeared to increase slightly from 2013 through 2014, but leveled off from 2015 through 2017. Among opioid analgesics with labeling for abuse deterrent properties, reformulated OxyContin (oxycodone ER) accounted for the highest proportion of total prescriptions dispensed from 2013 through 2017.
### 6.1 Appendix A. Tables

Table 1. Nationally Estimated Number of Prescriptions for Oxycodone Products from U.S. Outpatient Retail Pharmacies, from January 2013 Through December 2017, Annually.

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TRx</td>
<td>%</td>
<td>TRx</td>
<td>%</td>
<td>TRx</td>
</tr>
<tr>
<td>Grand Total Oxycodone</td>
<td>53,101,127</td>
<td>100.0%</td>
<td>54,043,581</td>
<td>100.0%</td>
<td>56,335,360</td>
</tr>
<tr>
<td>Oxycodone IR Combination*</td>
<td>33,722,400</td>
<td>63.5%</td>
<td>33,340,684</td>
<td>61.7%</td>
<td>34,575,502</td>
</tr>
<tr>
<td>Oxycodone IR Single-Ingredient*</td>
<td>14,513,238</td>
<td>27.3%</td>
<td>15,972,555</td>
<td>29.6%</td>
<td>17,317,048</td>
</tr>
<tr>
<td>Oxycodone ER Single-Ingredient**</td>
<td>4,865,489</td>
<td>9.2%</td>
<td>4,699,154</td>
<td>8.7%</td>
<td>4,423,455</td>
</tr>
<tr>
<td>Oxycodone ER Combination**</td>
<td>…</td>
<td>…</td>
<td>31,188</td>
<td>&lt;0.5%</td>
<td>19,355</td>
</tr>
</tbody>
</table>

*Immediate-Release (IR) formulations include oral solid tablets/capsules and oral liquids
**Extended-Release (ER) formulations include oral solid tablets/capsules designed to dissolve for an extended period of time.
<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total ADF</strong></td>
<td>4,850,154</td>
<td>4,686,484</td>
<td>4,519,991</td>
<td>4,264,525</td>
<td>3,806,205</td>
</tr>
<tr>
<td>Hysingla(^1)</td>
<td>...</td>
<td>...</td>
<td>85,934</td>
<td>166,208</td>
<td>214,954</td>
</tr>
<tr>
<td>Embeda(^2)</td>
<td>...</td>
<td>...</td>
<td>27,775</td>
<td>110,865</td>
<td>139,334</td>
</tr>
<tr>
<td>Xtampza ER(^3)</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>7,880</td>
<td>88,360</td>
</tr>
<tr>
<td>Arymo ER(^4)</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>7,080</td>
</tr>
<tr>
<td>Morphabond ER(^5)</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>...</td>
<td>2,540</td>
</tr>
<tr>
<td>OxyContin Reformulated (brand and generic)(^6)</td>
<td>4,850,153</td>
<td>4,686,484</td>
<td>4,406,282</td>
<td>3,979,572</td>
<td>3,353,937</td>
</tr>
</tbody>
</table>


Hysingla (hydrocodone ER)\(^1\) - Approved 11/2014
Embeda (morphine/naltrexone ER)\(^2\) - was first approved on August 13, 2009 but was voluntarily withdrawn from the market in March 2011 due to testing that found stability concerns in the manufacturing process. The FDA confirmed that these issues were resolved with its approval of a manufacturing supplement in November 2013\(^{iv}\).
Xtampza ER (oxycodone ER)\(^3\) – Approved 04/2016
Arymo ER (morphine ER)\(^4\) – Approved 01/2017
Morphabond ER (morphine ER)\(^5\) – Approved 10/2015
OxyContin (oxycodone ER)\(^6\) – Reformulated Version Approved 04/2010
* Products not marketed during study period: RoxyBond (oxycodone IR) – Approved 04/2017, Targiniq (oxycodone/naloxone) – Approved 07/2014, Troxyca (oxycodone/naltrexone ER) – Approved 08/2016, Vantrela (hydrocodone ER) – Approved 01/2017
6.2 **APPENDIX B. DRUG UTILIZATION DATABASE DESCRIPTIONS/LIMITATIONS**

**IQVIA, National Sales Perspectives™: Retail and Non-Retail**

The IQVIA National Sales Perspectives (NSP) measures the volume of drug products, both prescription and over-the-counter, and selected diagnostic products moving from manufacturers into various outlets within the retail and non-retail markets. Volume is expressed in terms of sales dollars, eaches, extended units, and share of market. These data are based on national projections. Outlets within the retail market include the following pharmacy settings: chain drug stores, independent drug stores, mass merchandisers, food stores, and mail service. Outlets within the non-retail market include clinics, non-federal hospitals, federal facilities, HMOs, long-term care facilities, home health care, and other miscellaneous settings.

**IQVIA National Prescription Audit™**

The IQVIA National Prescription Audit (NPA) measures the “retail outflow” of prescriptions, or the rate at which drugs move out of retail pharmacies, mail service houses, or long-term care facilities into the hands of consumers via formal prescriptions in the U.S. The NPA audit measures what is dispensed by the pharmacist. Data for the NPA audit is a national level estimate of the drug activity from retail pharmacies. NPA receives over 3.7 billion prescription claims per year, captured from a sample of the universe of approximately 59,900 pharmacies throughout the U.S. The pharmacies in the database account for most retail pharmacies and represent nearly 93% of retail prescriptions dispensed nationwide. The type of pharmacies in the sample are a mix of independent, retail, chain, mass merchandisers, and food stores with pharmacies, and include prescriptions from cash, Medicaid, commercial third-party and Medicare Part-D prescriptions. Data is also collected from approximately 45 – 75% (varies by class and geography) of mail service pharmacies and approximately 71 – 83% of long-term care pharmacies. Data are available on-line for 72-rolling months with a lag of 1 month.
6.3 REFERENCES

i DARRTS: NDA 209774, User Fee/Coversheet; New/NDA; Form 3674, Supporting Document 1/eCTD0001, dated 1/5/2018.


Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Surveillance and Epidemiology (OSE)
Office of Pharmacovigilance and Epidemiology (OPE)

Epidemiology Review

Date: October 15, 2018

Reviewer(s): Mallika Mundkur, MD, MPH
Division of Pharmacovigilance II

Sara Karami, PhD, MPH
Division of Epidemiology I
Data Management and Analysis Team

Tertiary Reviewer: Tamra Meyer, PhD, MPH
Division of Epidemiology II
Prescription Drug Abuse Team

Subject: Review of recent epidemiologic data on misuse and abuse of oxycodone

Drug Name(s): MNK-812

Application Type/Number: NDA #209774
Applicant/sponsor: SpecGX
OSE RCM #: 2018-1362
# TABLE OF CONTENTS

ABBREVIATIONS ............................................................................................................ 2  
EXECUTIVE SUMMARY .............................................................................................. 4  
1 INTRODUCTION ....................................................................................................... 5  
  1.1 Regulatory History ............................................................................................... 6  
  1.2 Product Labeling .................................................................................................. 6  
2 REVIEW METHODS AND MATERIALS ................................................................ 6  
  2.1 Overview and Framework .................................................................................... 6  
  2.2 National Survey of Drug Use and Health (NSDUH) ........................................... 8  
  2.3 American Association of Poison Control Centers (AAPCC), National Poison Data System (NPDS) .............................................................. 9  
  2.4 Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS®) System Treatment Center Program (TCP) ............................................ 10  
  2.5 Published Literature: National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO™) ................................................................. 11  
  2.6 National Electronic Injury Surveillance System -- Cooperative Adverse Drug Event Surveillance (NEISS-CADES) ............................................................. 11  
  2.7 National Vital Statistics System – Mortality (NVSS-M) and Drug-Involved Mortality (DIM) Linked Data ............................................................................... 12  
3 RESULTS .................................................................................................................. 12  
4 DISCUSSION ............................................................................................................ 26  
  4.1 Summary of the Data .......................................................................................... 26  
  4.2 Limitations of Data and Reviewed Studies ........................................................ 28  
5 CONCLUSIONS ....................................................................................................... 30  
6 APPENDICES ........................................................................................................... 31  
  6.1 Appendix A. NPDS—Definitions of Exposure Reasons .................................... 31  
  6.2 Appendix B: Description of the Drug-Induced Mortality Data Source ............ 31  
7 REFERENCES .......................................................................................................... 32
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAPCC</td>
<td>American Association of Poison Control Centers</td>
</tr>
<tr>
<td>AC</td>
<td>Advisory Committee</td>
</tr>
<tr>
<td>AD</td>
<td>Abuse-Deterrent</td>
</tr>
<tr>
<td>ASI-MV</td>
<td>Addiction Severity Index Multimedia Version</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control and Prevention</td>
</tr>
<tr>
<td>CNS</td>
<td>Central Nervous System</td>
</tr>
<tr>
<td>CRT</td>
<td>Crush Resistant Tablets</td>
</tr>
<tr>
<td>CSA</td>
<td>Controlled Substances Act</td>
</tr>
<tr>
<td>DIM</td>
<td>Drug-Involved Mortality</td>
</tr>
<tr>
<td>DSM-IV</td>
<td>Diagnostic and Statistical Manual of Mental Disorders, 4th Edition</td>
</tr>
<tr>
<td>ED</td>
<td>Emergency Department</td>
</tr>
<tr>
<td>ER</td>
<td>Extended-release</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FDC</td>
<td>Fixed Dose Combination</td>
</tr>
<tr>
<td>ICD-10</td>
<td>International Statistical Classification of Diseases and Related Health Problems, 10th Revision</td>
</tr>
<tr>
<td>IR</td>
<td>Immediate-release</td>
</tr>
<tr>
<td>MOA</td>
<td>Mode of Administration</td>
</tr>
<tr>
<td>NAVIPPRO</td>
<td>National Addictions Vigilance Intervention and Prevention Program</td>
</tr>
<tr>
<td>NDA</td>
<td>New Drug Application</td>
</tr>
<tr>
<td>NPDS</td>
<td>National Poison Data System</td>
</tr>
<tr>
<td>NEISS-CADES</td>
<td>National Electronic Injury Surveillance System -- Cooperative Adverse Drug Event Surveillance</td>
</tr>
<tr>
<td>NSDUH</td>
<td>National Survey on Drug Use and Health</td>
</tr>
<tr>
<td>NVSS</td>
<td>National Vital Statistics System</td>
</tr>
<tr>
<td>OTP</td>
<td>Opioid Treatment Program</td>
</tr>
<tr>
<td>PCC</td>
<td>Poison Control Center</td>
</tr>
<tr>
<td>PMR</td>
<td>Postmarket Requirement</td>
</tr>
<tr>
<td>RADARS</td>
<td>Researched Abuse, Diversion, and Addiction-Related Surveillance</td>
</tr>
<tr>
<td>RMPDC</td>
<td>Rocky Mountain Poison and Drug Center</td>
</tr>
</tbody>
</table>
**SKIP**: Survey of Key Informants’ Patients

**US**: United States
EXECUTIVE SUMMARY

MNK-812 is an immediate-release (IR) formulation of oxycodone designed to deter abuse via non-oral routes through modified physical and chemical properties. MNK-812 will be discussed at an Advisory Committee (AC) meeting on November 14, 2018. This review is intended to provide the committee members with an informed perspective regarding potential patterns of misuse and abuse for new oxycodone-containing products, based upon recent patterns of misuse and abuse for marketed products with similar characteristics. Given the nature of the product under consideration, we attempt to provide more detailed information, where possible, on abuse patterns for approved, IR formulations of oxycodone. Below, we outline key points from this review regarding the abuse profile of oxycodone and other opioid products in recent years. These points synthesize data drawn from distinct data sources, and relate to misuse/abuse in both the general US population, as well as in the subset of patients with more advanced opioid use disorder who are entering treatment.

- **Scale of misuse and abuse of prescription opioid analgesics:**
  In 2016, prescription opioids were the largest category of approved pharmaceutical products to be misused or abused by Americans, with 11.5 million individuals reporting misuse and 1.8 million individuals meeting DSM IV criteria for a substance use disorder involving a prescription opioid analgesic in a general population survey of non-institutionalized individuals ages 12 years and older. In comparison, an estimated 600,000 individuals in the US abused heroin the same year while 15 million individuals abused alcohol.

- **Relative frequency of misuse and abuse of oxycodone and other selected opioids:**
  During 2016, the most frequently misused opioid analgesics reported in a general population survey of non-institutionalized individuals ages 12 years and older were hydrocodone, oxycodone and codeine, estimated to have occurred in 6.9, 3.9 and 2.8 million individuals respectively. Among patients entering treatment for opioid use disorder, heroin abuse was most commonly reported (57%), followed by oxycodone (35%) and hydrocodone (28%). Such individuals endorsed abuse of both immediate-release (IR) (22%) and extended release/long-acting (ER/LA) (15%) formulations of oxycodone. Product availability appears to be an important factor driving abuse patterns, and adjustment for dispensed dosage units appears to increase the relative frequency of abuse of less widely prescribed opioids such as oxymorphone and hydromorphone compared with oxycodone and hydrocodone.

- **Routes of abuse for oxycodone-containing products:**
  In recent years, calls to poison control centers relating to single-substance exposures suggest that oxycodone-containing products are abused predominantly through the oral route (80% of intentional abuse exposures). Data from one surveillance system suggests distinct routes of exposure for combination-ingredient versus single-entity products. For combination-ingredient oxycodone IR, over 70% of respondents reported oral routes of exposure, with nearly 40% also reporting snorting, and just over 10% reporting injection. In contrast, for single-entity oxycodone IR, only 40% of respondents reported oral routes, with nearly 60% endorsing snorting and 40% reporting injection. Paradoxically, crush-resistant tablets (CRT) appear to be abused significantly more frequently by alternative oral modes of administration (i.e., chewing, dissolving in mouth) than non-CRT.

- **Morbidity and mortality for oxycodone and other specific opioid products:**
  During 2016, an estimated 51,204 Emergency Department (ED) visits involved non-medical use of oxycodone, alone or in conjunction with other agents, leading to
unresponsiveness, cardiac arrest or respiratory failure/distress in approximately 40% of such visits. Over the period 2010-2015, deaths involving oxycodone, as reported in the literal text on US death certificates, remained high, with between five and six thousand deaths per year, and a total of 32,128 deaths occurring over this time frame. In comparison, deaths involving heroin have been rising in frequency, with a total of 46,603 deaths over the same time-period.

In evaluating any new oxycodone-containing product for approval, it is essential to consider the public health risks as well as potential benefits. Misuse, abuse, and deaths involving oxycodone products continue to occur, and while most abuse of oxycodone occurs via the oral route, intranasal and IV abuse of oxycodone is common in individuals entering treatment for substance use disorder. Public health benefits of abuse-deterrent opioid analgesics have been proposed, though no data demonstrating such benefit have been submitted and reviewed by FDA, and published studies evaluating such benefits have limitations. FDA is requiring sponsors of abuse-deterrent opioid products to conduct rigorous studies under a postmarket requirement (PMR) to assess potential benefits of AD products in the community.

1 INTRODUCTION

During 2016, opioids were associated with 42,000 deaths in the US, nearly half of which involved a prescription opioid.\(^1\) Given the persistent contribution of prescription opioid analgesics to the burden of opioid-related morbidity and mortality in the United States, FDA aims to evaluate the impact of new opioid drug approval on public health at the time of approval.\(^2\) The Division of Anesthesia, Analgesia, and Addiction Products in the Office of New Drugs (OND) will present information on the risk-benefit profile of the intended use of this product in the target patient population, while this review aims to provide a basis for considerations about risks and benefits to the population at-large.

Opioid analgesic formulations with abuse-deterrent (AD) properties have been proposed to promote several positive public health outcomes: reduction in product-specific abuse, transition to riskier routes of abuse, diversion of AD products, and deaths from overdose involving the AD product. Although these questions have been explored in a number of published epidemiologic studies, these studies are subject to significant limitations with regard to data quality, methods, and the ability to make clear causal inferences regarding the effect of the AD properties.\(^3-8,\)\(^9\) FDA is requiring sponsors of approved AD opioid analgesic products to conduct epidemiologic studies under a postmarket requirement (PMR) to more directly assess the effects of abuse-deterrent products in the community. According to the 2015 guidance issued by FDA, sponsors of approved products with AD labeling claims based on premarketing studies must conduct studies to “determine whether a product with abuse-deterrent properties results in meaningful reductions in abuse, misuse and related adverse clinical outcomes, including addition, overdose, and death” in the community.\(^9\)

For the purposes of this review, we focus on the landscape of abuse and related morbidity and mortality for oxycodone and comparator opioid analgesic products to give the committees an idea of the potential abuse-related harms and potential for prevention of route-specific abuse of the product under discussion.

1.1 REGULATORY HISTORY

MNK-812 is an immediate-release (IR) formulation of oxycodone with physical/chemical barriers to manipulation and incorporation of aversive agents, intended to impede tampering via intranasal and intravenous routes.

1.2 APPROVED ABUSE-DETERRENT LABELING FOR RELATED PRODUCTS

In the United States, there is currently only one approved IR opioid analgesic product with abuse-deterrent labeling based on premarket testing. RoxyBond (oxycodone HCl tablets) was approved on 4/20/2017. RoxyBond is a single-ingredient oxycodone tablet with physiochemical properties intended to deter intranasal and intravenous abuse. RoxyBond has not yet been marketed in the US. Two extended-release (ER), single-ingredient, formulations of oxycodone, OxyContin and Xtampza, are marketed with abuse-deterrent labeling based on premarket studies. Of note, FDA approved a reformulated version of OxyContin in April 2010. The reformulated version has properties intended to deter abuse. On August 5, 2010, the sponsor stopped shipping original OxyContin tablets to pharmacies and began shipping only reformulated OxyContin. AD labeling was approved in April 2013, and at that time, FDA determined that original OxyContin was withdrawn for “reasons of safety or effectiveness.” Other AD ER formulations of oxycodone-products have been approved as multi-ingredient formulations such as Targiniq (oxycodone-naloxone ER), and Troxyca (oxycodone-naltrexone ER). However, the NDAs for these products were withdrawn without being marketed.

There are four categories of studies that contribute to the final approved labeling in the section on Drug Abuse and Dependence (9.2). The first three categories are conducted in the premarket setting and the fourth is conducted in the postmarket setting. Briefly, pre-market studies assess:

1. Laboratory-based in vitro manipulation and extraction studies (Category 1),
2. Pharmacokinetic studies (Category 2), and
3. Clinical abuse potential studies (Category 3).

Postmarket studies (Category 4) assess whether introduction of the abuse-deterrent formulation reduces actual abuse, misuse, and related adverse clinical outcomes including addiction, overdose, and death in the postmarket setting. While there are opioid analgesic products with section 9.2 labeling that describes expected abuse-deterrent properties based on premarket testing (Category 1-3 studies), no products have category 4 labeling, to date. Each AD opioid product with labeling based on category 1-3 studies was assigned the postmarket Category 4 studies under postmarket requirements (PMRs), upon approval; such studies are currently ongoing. Details regarding precise labeling language for currently approved ADF products are available on the FDA website.

2 REVIEW METHODS AND MATERIALS

2.1 OVERVIEW AND FRAMEWORK
We reviewed several data sources to describe the misuse/abuse of oxycodone and related morbidity and mortality in recent years. We selected data sources that could provide insight into patterns of misuse/abuse and overdose death in the general population, as well as the subset of individuals with more advanced substance use disorder (SUD). The framework used to summarize findings from these data sources is outlined in Table 1, with a more detailed description of our use of each data source in the sections below. Standard regulatory definitions of misuse/abuse were applied throughout this review, unless otherwise indicated.13,14

**Misuse:** the intentional therapeutic use of a drug product in an inappropriate way and specifically excludes the definition of abuse

**Abuse:** the intentional, non-therapeutic use of a drug product or substance, even once, to achieve a desirable psychological or physiological effect

<table>
<thead>
<tr>
<th>Characteristic assessed</th>
<th>Data sources used</th>
<th>Use of data source(s)</th>
<th>Major limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scale of misuse/abuse</td>
<td>General population National Survey on Drug Use and Health (NSDUH), 2015-2016; National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance (NEISS-CADES, 2016)</td>
<td>• Estimate number of individuals in the general US population reporting misuse/abuse of prescription opioid analgesics (NSDUH) • Estimate number of Emergency Department (ED) visits resulting from non-medical use of prescription opioid analgesics (NEISS-CADES)</td>
<td>• 2016 data from NSDUH, NEISS-CADES</td>
</tr>
<tr>
<td>Specific products, relative frequency of misuse/abuse</td>
<td>General population NSDUH, 2015-2016; National Poison Data System (NPDS) exposure calls to Poison Control Centers (PCCs), 2012-2016 Population with opioid or substance use disorders RADARS® Treatment Center Program, 2016 (TCP); Literature (Cassidy, et al) /National Addictions Vigilance Intervention</td>
<td>• Misuse of specific opioid analgesic products in general population (NSDUH) • Calls to PCCs, by product (NPDS) • Proportion of patients with opioid or substance use disorder (OUD/SUD) reporting past thirty-day abuse of specific products (RADARS® TCP, NAVIPRO™)</td>
<td>• Earliest NSDUH data on opioid analgesic subtype in 2015, inability to assess long-term trends • Product information may not be available in all exposure calls to PCCs (NPDS) • Findings from people entering treatment for OUD/SUD may not be broadly generalizable</td>
</tr>
</tbody>
</table>
and Prevention Program, 2016 (NAVIPPRO™)

<table>
<thead>
<tr>
<th>Characteristic assessed</th>
<th>Data sources used</th>
<th>Use of data source(s)</th>
<th>Major limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routes of abuse</td>
<td>General population NPDS</td>
<td>• Assess routes of abuse for single-substance exposure calls (NPDS)</td>
<td>• Findings regarding route from NPDS exposure calls may not generalize to the entire US population</td>
</tr>
<tr>
<td></td>
<td>Population with OUD or SUD</td>
<td>• Assess product-specific routes of abuse among people entering or being assessed for SUD (Literature/NAVIPPRO™)</td>
<td>• Findings from patients entering treatment for SUD may not be broadly generalizable</td>
</tr>
<tr>
<td></td>
<td>Literature (Cassidy, et al/NAVIPPRO™)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morbidity and mortality</td>
<td>General population Drug-involved Mortality (DIM) data for overdose deaths, 2010-2015</td>
<td>• Assess outcomes such as need for healthcare intervention, or death occurring in association with specific opioid analgesic active ingredients</td>
<td>• Under-capture of serious outcomes</td>
</tr>
<tr>
<td></td>
<td>NEISS-CADES, 2016</td>
<td></td>
<td>• Limited ability in attributing events to specific products</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• NEISS-CADES did not begin capture of ED visits for non-medical pharmaceutical use until 2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• The most current data available for DIM is for 2015</td>
</tr>
</tbody>
</table>

## 2.2 **NATIONAL SURVEY OF DRUG USE AND HEALTH (NSDUH)**

*Data Source*

NSDUH is an annual, federally-funded survey sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA) designed to provide nationally representative estimates of illicit as well as prescription drug misuse/abuse in the general US population. Strengths of this data source include an in-person survey, and predominantly stable survey design with the ability to assess temporal changes in drug misuse/abuse in the general US population.¹⁷,¹⁸

NSDUH uses a multistage probability sample design to provide representative state and county-level estimates for non-institutionalized residents of the United States who are aged 12 years and above. Population subgroups not covered by the survey include individuals residing within institutional facilities (e.g., jails, nursing homes), as well as those without a permanent address (e.g., homeless individuals). The survey is conducted in a face-to-face manner, and during the year 2016, the interview response rate of 53% included 67,942 completed interviews. For the years 2015 and 2016, NSDUH began to include more detailed data on use and misuse of specific prescription opioid analgesic subtypes. NSDUH defines misuse of a drug as the following: “use in any way not directed by a doctor, including use without a prescription of one’s own; use in..."
greater amounts, more often, or longer than told.” NSDUH defines dependence and abuse using DSM IV criteria, combining both for the purpose of reporting into the broad category of “substance use disorder.”

**Search Strategy and Analysis**

We extracted data from the 2016 survey that related to misuse or abuse/dependence of prescription opioid analgesics overall, as well as by subtype. We also extracted analogous data for heroin, as this is currently the only illicit opioid for which SAMHSA is collecting responses. Weighted estimates of abuse and/or misuse were compared to estimates from 2015, where possible. We reported past-year weighted estimates of abuse/dependence of heroin and prescription opioids, relative to other commonly used substances in the United States in 2016. We also reported estimates of past-year misuse of opioids, by subtype. All values were reported in numbers of individuals in thousands, percent of the total population, and percent of any past-year users. Statistically significant changes in percentages were demarcated.

### 2.3 American Association of Poison Control Centers (AAPCC), National Poison Data System (NPDS)

**Data Source**

NPDS is a database managed by the American Association of Poison Control Centers (AAPCC), and derived from a nationwide network of Poison Control Centers (PCCs) that receives calls from individuals, healthcare professionals, and other interested persons regarding exposures to prescription drugs, over-the-counter medications as well as unapproved products. NPDS provides more detailed product-specific information compared with other data sources, such as information on reported routes of exposure and associated medical outcomes in the general US population.

Within NPDS, calls for exposures may result in documentation of an event, provision of information, or advice regarding medical management, and AAPCC staff managing these calls undergo training in the efforts to standardize documentation across centers. Documentation of calls includes detail on the drug(s), patient characteristics, route of exposure, reported reasons for exposure, level of care received (e.g., admitted to critical care unit vs. treated and released), medical outcomes (e.g., death, no effect) and other more curated variables, such as “relatedness” requiring manual chart review to determine the relatedness of the reported exposure to the outcomes of interest. Reasons for exposure are categorized into groups by AAPCC, and include such categories as “intentional”, “unintentional”, the former encompassing the subgroups of intentional misuse, abuse, suspected suicide or unknown intent. Additional details regarding the definition of these variables are provided in Appendix A.

**Search Strategy and Analysis**

In our review of NPDS, we assessed calls for oxycodone and comparators of interest (i.e., hydrocodone, morphine, and heroin). We limited our search to “closed” intentional exposure calls reported for humans (i.e., exposures and outcomes validated by NPDS) and restricted our analysis to individuals 12 years of age and older. Drug codes (i.e., “generic” and/or “product” codes) used to search NPDS for exposures involving oxycodone and comparators, including both single-ingredient and combination products, were obtained from Micromedex™ as well as the online lookup tool available through NPDS. We restricted our date range to capture a recent five year period, 2012 through 2016, for which all cases had been closed (i.e., no unverified or “open” cases).
Search parameters used for oxycodone and the comparator drugs of interest are summarized below in Table 2.

### Table 2. NPDS Search Parameters- Oxycodone and comparators

<table>
<thead>
<tr>
<th>Report name</th>
<th>Case Log (Generic Code/Product Code)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Month/year of query</td>
<td>4/2018</td>
</tr>
<tr>
<td>Date range for query</td>
<td>1/1/2012-12/31/2016</td>
</tr>
<tr>
<td>Call type</td>
<td>Exposure</td>
</tr>
<tr>
<td>Case status</td>
<td>Closed</td>
</tr>
<tr>
<td>Species</td>
<td>Human</td>
</tr>
<tr>
<td>Exposure Reason</td>
<td>Intentional</td>
</tr>
<tr>
<td>Minimum Age</td>
<td>12 (years)</td>
</tr>
</tbody>
</table>

Our analysis of NPDS consisted of two components: evaluation of trends and characteristics in exposure calls. Analyses were performed independently by two analysts to optimize accuracy of results, with any discrepancy resolved by detailed review of processes.

For exposure trends, we stratified intentional exposure calls by year and exposure reasons (i.e., all intentional, misuse and/or abuse) to portray national patterns in trends of calls for misuse/abuse for oxycodone vs. comparators through this data source. Trends were adjusted for population changes using Census Bureau estimates of population size, and annual rates of exposure calls were reported as calls per million population. In describing exposure characteristics, we aggregated data for the 5-year period, and evaluated reasons for exposure, for both oxycodone and comparators, stratifying the former by formulation (i.e., IR versus ER/LA). In addition, we evaluated routes of abuse for oxycodone and comparators. Of note, for drugs involved in multi-substance exposures, NPDS does not currently provide reliable information on route of exposure information for individual drugs, therefore analyses of route were restricted to single-substance exposures (personal communication, Elisa Aguenza, AAPCC).

### 2.4 RESEARCHED ABUSE, DIVERSION, AND ADDICTION-RELATED SURVEILLANCE (RADARS®) SYSTEM TREATMENT CENTER PROGRAM (TCP)

**Data Source**

The RADARS® System Substance Abuse Treatment Program surveys individuals entering treatment in private and public opioid dependence treatment programs with a total of 194 participating sites from 48 states during the year 2016. This data source provides information on specific products and routes of abuse in a specialized segment of the population with presumably more advanced disease severity with respect to opioid dependence or addiction.

RADARS® TCP includes data from two distinct programs: the RADARS® System Opioid Treatment Program, and the RADARS® System Survey of Key Informants’ Patients Program (SKIP). The Opioid Treatment Program surveys a convenience voluntarily recruited sample of patients enrolling in public medication-assisted treatment programs from 65 sites in 31 states, while SKIP surveys patients seeking treatment at a private treatment facility and covers 129 sites in 45 states. Surveys in both settings are self-administered, and include questions about
prescription or illicit drugs used in the past month for the purpose of “getting high” (i.e., abuse). Surveys also include questions relating to the primary source of the drug and route of abuse.

**Search Strategy and Analysis**

FDA obtains analytic reports from RADARS® TCP every six months through an ongoing contract with the Rocky Mountain Poison and Drug Center (RMPDC). This report contains both quarterly and cumulative (i.e., annual) rates of abuse for specific opioid products, in which numerators represent the total number of endorsements and denominators represent the total number of respondents for that time-period. The analytic report also includes rates that adjust for the total estimated number of dosage units dispensed in a given coverage area, using zip-code-based projections from IQVIA (previously QuintilesIMSTM). For the purpose of this review, we first assessed cumulative and dosage unit-adjusted rates of abuse at the level of active pharmaceutical ingredient. Subsequently, we assessed analogous data for IR and ER/LA formulations, allowing for more robust comparison of abuse at the level of specific products. Future reports will include information on route of abuse, though this information is not currently available from the bi-annual report provided to FDA from RADARS® TCP.

### 2.5 Published Literature: National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO™)

**Data Source**

The National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO™) is a surveillance system that includes a number of data streams relating to drug abuse. One of these streams is derived from administration of a computerized survey instrument, the Addiction Severity Index-Multimedia Version® (ASI-MV®), which measures addiction severity and includes questions relating to use or abuse of specific products. ASI-MV® is administered to a convenience sample of adults seeking treatment at a participating facility, with variable adoption by state and locality— during the year 2016, NAVIPPRO included a total of 445 treatment sites in 38 states.22

**Search Strategy and Analysis**

For this review, we cite data from this system using recently published data containing descriptive information of interest. We selected only recently published articles that utilized the NAVIPPRO™ system to assess relative frequency and routes of abuse of various prescription opioids, including but not limited to oxycodone. These articles were identified searching PubMed for the following search terms: (route[tiab] OR routes[tiab]) AND opioid[tiab] AND abuse[tiab] AND NAVIPPRO[tiab], restricting to publications within the past two years, and human studies only. The date of the search was May 12, 2018.

### 2.6 National Electronic Injury Surveillance System -- Cooperative Adverse Drug Event Surveillance (NEISS-CADES)

Cases and national estimates of the number of emergency department (ED) visits for drug-related adverse events were based on data from the NEISS-CADES project, a national stratified probability sample of approximately 60 hospitals with a minimum of six beds and a 24-hour ED in the United States and its territories. The NEISS-CADES project, which has been described in detail elsewhere, is a joint effort of the Centers for Disease Control and Prevention (CDC), the US Consumer Product Safety Commission, and the US Food and Drug Administration.23-26 In brief, trained coders located at each participating hospital review clinical records of every ED visit to identify clinician-diagnosed drug related adverse events, to report up to four medications
implicated in each adverse event, and to record narrative descriptions of the incident (including clinical diagnoses and manifestations). Each NEISS-CADES case is assigned a sample weight derived from the inverse probability of selection, adjusted for nonresponse and post-stratified to adjust for the number of annual hospital ED visits.

NEISS-CADES has historically focused exclusively on ED visits due to use of medications for a therapeutic indication, or unintended medication exposures by young children. However, in 2016 NEISS-CADES surveillance activities were expanded to represent the full spectrum of pharmaceutical-related harm, encompassing ED visits resulting from abuse, self-harm, drugs used for unknown intent, and assault, in addition to therapeutic adverse drug events.

Analyses of 2016 NEISS-CADES data were conducted and provided to FDA by the CDC Division of Healthcare Quality Promotion. Cases included ED visits in 2016 for harms from single-ingredient or combination oxycodone-containing analgesic products and were compared to ED visits in 2016 for harms from other prescription opioid products. ED visits in 2016 for harms from single-ingredient or combination hydrocodone-containing or morphine-containing analgesic products were used as a comparison group. Cases involving opioid-containing cough medications were excluded.

2.7 NATIONAL VITAL STATISTICS SYSTEM – MORTALITY (NVSS-M) AND DRUG-INVOLVED MORTALITY (DIM) LINKED DATA

National data on drug-involved mortality were made available to the Agency by the National Center for Health Statistics. Drug-involved mortality (DIM) data combine the cause-of-death, demographic, and geographic information from the National Vital Statistics System (NVSS) – Mortality files, with information extracted from the death certificate literal text, which allow for a more granular analysis of specific drugs involved in deaths. The method used to extract information on DIM has been described previously and is briefly described here. The information written on the death certificate by the medical certifier on the cause, manner, circumstances, and other factors contributing to the death is referred to as the literal text fields. The literal text information has been processed to allow for the identification of cases of drug-involved mortality, i.e., mortality cases having at least one literal text mention of a drug, drug class, or exposure not otherwise specified, excluding mentions where information in the literal text suggests that the drug was not involved in the death. Additional information on these variables is provided in Appendix B.

In NVSS-M, cause of death is captured by ICD-10 codes, where no information on specific drug involvement is available. Our review of DIM data was performed on January 29, 2018 and included all overdose deaths, defined using ICD-10 underlying cause-of-death codes X40–X44 (accidental self-poisoning), X60–X64 (intentional self-poisoning), X85 (homicide), and Y10–Y14 (undetermined poisonings), of U.S. residents, ages 12 years and older, from January 1, 2010 through December 31, 2015 (the most recent data year available) where oxycodone, hydrocodone, morphine and heroin were mentioned in the literal text as contributing to the death. For overdose deaths involving these substances, we evaluated trends and patterns of overdose deaths by year.

3 RESULTS

NSDUH
During 2016, over 90 million individuals in the general US population were estimated to have used prescription opioid analgesics during the previous year. Nearly 12 million, or 4.3% of the total US population, were estimated to have misused them—“misuse” being defined in NSDUH as “use in any way not directed by a doctor, including use without a prescription of one’s own; use in greater amounts, more often, or longer than told.” In the subgroup of individuals reporting any past-year use of a prescription opioid analgesic, the most frequently misused products were buprenorphine, oxymorphone and methadone, respectively misused in 31.6%, 27.6% and 25.5% of individuals who reported past-year use of each opioid (Table 3).

The top three most frequently misused opioid analgesic products in the general population were hydrocodone, oxycodone and codeine, with estimated misuse in 6.9 million, 3.9 million and 2.8 million individuals, respectively (Figure 1).

Within the subgroup of individuals misusing prescription opioid analgesics, an estimated 2 million or 0.7% of the total population appeared to meet criteria for abuse or dependence (i.e., substance use disorder), second only to marijuana and alcohol in terms of frequency of abuse/dependence for the substances assessed by NSDUH. No significant changes in the relative frequency of abuse/dependence for these substances were observed from 2015 to 2016 (Figure 2).
Figure 1. NSDUH 2015-2016*: Past-year misuse of prescription opioid analgesics, individuals ≥12 years

NSDUH, National Survey of Drug Use and Health
*Asterisks denote changes that are statistically significant

Source: SAMHSA detailed tables, Tables 1.97 A-B, 1.97D. Available from: https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.htm#tab1-97A. Accessed on 4/20/2018. Note: NSDUH defines misuse of a drug as the following: “use in any way not directed by a doctor, including use without a prescription of one’s own; use in greater amounts, more often, or longer than told.”

Figure 2. NSDUH 2015-2016*: Past-year abuse/dependence (substance use disorder), illicit drugs or alcohol, individuals ≥12 years

NSDUH, National Survey of Drug Use and Health
*No values in 2016 were statistically different from those in 2015

Source: SAMHSA detailed tables, Tables 5.2 A-B, 5.2 D. Available from: https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.htm#tab1-
AAPCC/NPDS

Over the period 2012-2016, a total of 51,836 calls reporting intentional exposure to any oxycodone product among individuals ≥12 years of age were received by U.S Poison Control Centers (PCCs) (Table 4). Over the same time frame, a total of 75,939 hydrocodone, 9,466 morphine, and 24,275 heroin exposure calls were received by U.S. PCCs. Population-adjusted rates of calls for drug products varied depending upon the type of exposure. Across all intentional exposure calls, hydrocodone and oxycodone-involved exposure call rates were highest (56.3 and 38.4 calls per million, respectively). Among intentional abuse exposure calls, exposure call rates were highest for heroin and oxycodone (12.7 and 6.8 calls per million, respectively). For misuse/abuse exposure calls combined, adjusted rates of exposure calls involving heroin, hydrocodone and oxycodone appeared similar (14.2, 14.1 and 12.0 calls per million, respectively). Across exposure types, rates of exposure calls involving IR oxycodone products were several-fold higher than rates of exposure calls involving ER oxycodone (Table 4).

Table 4. AAPCC/NPDS 2012-2016: Number of intentional exposure calls by exposure type, individuals 12 years and older
(Population-adjusted rate*)

<table>
<thead>
<tr>
<th>Exposure Type</th>
<th>Specific Oxycodone Products</th>
<th>Active Pharmaceutical Ingredient</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ER</td>
<td>IR, SE</td>
</tr>
<tr>
<td>All**</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4,564 (3.4)</td>
<td>17,082 (12.7)</td>
</tr>
<tr>
<td>Abuse</td>
<td>1,115 (0.8)</td>
<td>3,909 (2.9)</td>
</tr>
<tr>
<td>Misuse</td>
<td>605 (0.4)</td>
<td>2,119 (1.6)</td>
</tr>
<tr>
<td>Misuse/Abuse</td>
<td>1,720 (1.3)</td>
<td>6,028 (4.5)</td>
</tr>
</tbody>
</table>

AAPCC, American Association of Poison Control Centers; ER, extended-release; IR, immediate-release; NPDS, National Poison Data System; SE, single-entity
*Average call rate per 1 million census population for those 12 years and older
**Includes suicide attempt, other, misuse/abuse
Trends in PCC misuse/abuse exposure calls are depicted in Figure 3, showing stable levels of exposure calls involving oxycodone (both ER and IR formulations) and morphine, a decline in exposure calls for hydrocodone, and a rise in heroin exposure calls, with a pronounced rise in exposure calls for the latter since 2015.

As noted earlier, due to current limitations in NPDS, routes of exposure for individual drugs could be assessed only for patients with single-substance exposures. For patients with single-substance abuse exposures, the majority of abuse exposures for oxycodone products overall occurred via ingestion (74-88%) (Table 5). A nontrivial percentage of single-substance abuse exposures indicated injection of single-entity oxycodone IR products (12.6%), though this was substantially lower than the percentage of such exposures indicating injection of morphine products (23%) or heroin (58%).

<table>
<thead>
<tr>
<th>Route</th>
<th>Specific Oxycodone Products</th>
<th>IR. Combination Ingredient</th>
<th>Active Pharmaceutical Ingredient</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ER (N=497)</td>
<td>(N=1,358)</td>
<td>Oxycodone Any (N=3,444)</td>
</tr>
<tr>
<td>Aspiration (with ingestion)</td>
<td>0.4</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Ingestion</td>
<td>74.3</td>
<td>74.3</td>
<td>80.6</td>
</tr>
<tr>
<td>Inhalation/</td>
<td>12.7</td>
<td>13.6</td>
<td>10.6</td>
</tr>
</tbody>
</table>

AAPCC, American Association of Poison Control Centers; IR, Immediate Release; ER, Extended Release; NPDS, National Poison Data System; SE, single-entity

Table 5. AAPCC/NPDS, 2012-2016: Percentage (%) of single-substance abuse exposure calls reporting specific exposure routes, oxycodone and selected other opioids, among individuals 12 years and older.
Table 5. AAPCC/NPDS, 2012-2016: Percentage (%) of single-substance abuse exposure calls reporting specific exposure routes, oxycodone and selected other opioids^, among individuals 12 years and older

<table>
<thead>
<tr>
<th>Route</th>
<th>nasal</th>
<th>Other*</th>
<th>Parenteral (injection)</th>
<th>Rectal</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.6</td>
<td>0.5</td>
<td>0.4</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td>Parenteral (injection)</td>
<td>12.3</td>
<td>12.6</td>
<td>5.4</td>
<td>9.4</td>
<td>1.0</td>
</tr>
<tr>
<td>Rectal</td>
<td>0.2</td>
<td>0.1</td>
<td>0.2</td>
<td>0.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Unknown</td>
<td>1.4</td>
<td>1.0</td>
<td>0.4</td>
<td>0.8</td>
<td>0.3</td>
</tr>
</tbody>
</table>

AAPCC, American Association of Poison Control Centers; ER, extended-release; IR, immediate-release; NPDS, National Poison Data System; SE, single-entity

^Routes are represented as percentage of exposure calls reporting a specific route. A single-substance exposure call may be associated with more than one exposure route, thus the sum for total route of exposure may be greater than the sum for total number of single-substance exposure calls

* “Other” includes exposure routes categorized as dermal, vaginal, and/or other

RADARS® TCP

In 2016, assessment of individuals with opioid use disorder (OUD) entering private and public treatment programs participating in the RADARS® surveillance program indicated that, at the level of active pharmaceutical ingredient (API) or drug substance, past-month abuse of heroin was most prevalent, followed by oxycodone, and hydrocodone—with 57%, 35% and 28% of respondents reporting past-month abuse of these products, respectively. For both IR and ER products, past-month abuse of oxycodone was significantly more common than abuse of hydrocodone (Table 6, Figure 4A-C).

Adjusting for the number of dispensed dosage-units, the estimated relative frequency of abuse by product differed from unadjusted frequencies (Table 6, Figure 4D-F).

Table 6. RADARS® Substance Abuse Treatment Program, 2016: Past-Month Abuse (% of respondents), or Rate of Past-Month Abuse per 100,000 Dispensed Dosage-Units

<table>
<thead>
<tr>
<th>API</th>
<th>IR</th>
<th>ER</th>
<th>API</th>
<th>IR</th>
<th>ER</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>17.8</td>
<td>(17.0-18.6)</td>
<td>NR</td>
<td>NR</td>
<td>0.64</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>11.2</td>
<td>(10.6-11.9)</td>
<td>NR</td>
<td>NR</td>
<td>3.19</td>
</tr>
<tr>
<td>Heroin</td>
<td>36.7</td>
<td>(35.6-35.7)</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Hydrocodone</td>
<td>27.9</td>
<td>(27.0-28.8)</td>
<td>15.5</td>
<td>(14.8-16.3)</td>
<td>3.7</td>
</tr>
<tr>
<td>Hydromorphone</td>
<td>14.4</td>
<td>(13.7-15.1)</td>
<td>7.7</td>
<td>(7.2-8.3)</td>
<td>2.2</td>
</tr>
<tr>
<td>Methadone</td>
<td>15.5</td>
<td>(14.8-16.2)</td>
<td>NR</td>
<td>NR</td>
<td>0.66</td>
</tr>
<tr>
<td>Morphine</td>
<td>16.6</td>
<td>6.1</td>
<td>6.6</td>
<td>0.47</td>
<td>0.97</td>
</tr>
<tr>
<td>API, Active Pharmaceutical Ingredient</td>
<td>IR, Immediate-Release Formulation</td>
<td>ER, Extended-Release Formulation</td>
<td>API, Past-Month Abuse, Unadjusted (% Respondents, 95% CI)</td>
<td>IR, Rate of Past-Month Abuse per 100,000 Dispensed Dosage-Units (95% CI)</td>
<td>ER, Rate of Past-Month Abuse per 100,000 Dosage-Units (95% CI)</td>
</tr>
<tr>
<td>-------------------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------------------------</td>
<td>------------------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Oxycodone</td>
<td></td>
<td></td>
<td>35.2 (34.2-36.2)</td>
<td>22.3 (21.4-23.2)</td>
<td>14.6 (13.9-15.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(15.8-17.4)</td>
<td>(5.6-6.6)</td>
<td>(6.0-7.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(0.44-0.49)</td>
<td>(0.89-1.05)</td>
<td>(0.22-0.26)</td>
</tr>
<tr>
<td>Oxymorphone</td>
<td></td>
<td></td>
<td>9.7 (9.1-10.3)</td>
<td>6.2 (5.7-6.7)</td>
<td>3.9 (3.5-4.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(1.66-1.90)</td>
<td>(4.14-4.89)</td>
<td>(0.86-1.06)</td>
</tr>
<tr>
<td>Tapentadol</td>
<td></td>
<td></td>
<td>1.1 (0.9-1.3)</td>
<td>0.6 (0.4-0.8)</td>
<td>0.4 (0.3-0.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(0.23-0.34)</td>
<td>(0.18-0.31)</td>
<td>(0.23-0.44)</td>
</tr>
<tr>
<td>Tramadol</td>
<td></td>
<td></td>
<td>4.9 (4.4-5.3)</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(0.03-0.04)</td>
<td>NR</td>
<td>NR</td>
</tr>
</tbody>
</table>

API, Active Pharmaceutical Ingredient; IR, Immediate-Release Formulation; ER, Extended-Release Formulation; NR, Not Reported
Figure 4. RADARS® Substance Abuse Treatment Program, 2016: Past-Month Abuse (% of Respondents) or Rate of Past-Month Abuse (per 100,000 Dispensed Dosage-Units)*

<table>
<thead>
<tr>
<th>% of Respondents Reporting Past-Month Abuse</th>
<th>Rate of Past-Month Abuse per 100,000 Dispensed Dosage-Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>API</td>
<td></td>
</tr>
<tr>
<td><img src="image1.png" alt="Graph A" /></td>
<td><img src="image2.png" alt="Graph D" /></td>
</tr>
<tr>
<td>IR</td>
<td></td>
</tr>
<tr>
<td><img src="image3.png" alt="Graph B" /></td>
<td><img src="image4.png" alt="Graph E" /></td>
</tr>
<tr>
<td>ER</td>
<td></td>
</tr>
<tr>
<td><img src="image5.png" alt="Graph C" /></td>
<td><img src="image6.png" alt="Graph F" /></td>
</tr>
</tbody>
</table>

* Scales on y-axes may differ
API, Active Pharmaceutical Ingredient; IR, Immediate-Release opioid analgesic Formulation; ER, Extended-Release opioid analgesic Formulation
IR/ER data do not include data on buprenorphine, fentanyl, heroin, tramadol, methadone
PUBLISHED LITERATURE: NAVIPPRO™

Using the search strategy described in Section 3 to identify studies reporting data from NAVIPPRO™, one article was identified.28

Cassidy, 2017

This study examined patterns of abuse and routes of administration for various opioid products, with a focus on hydrocodone IR, though also examining patterns of abuse for other prescription opioid analgesics such as oxycodone.

This study included NAVIPPRO™ ASM IV® assessments of adults 18 years and older and also incorporated assessments from adolescents (primarily aged 13-18), derived from the Comprehensive Health Assessment for Teens (CHAT®). The time-period covered by this study was January 1, 2012 through June 30, 2015. In this study, the primary measure of abuse prevalence was measured by number of past 30-day abuse endorsements per 100 assessments. Additional measures of abuse prevalence were number of endorsements adjusted for number of prescriptions dispensed (per 100,000 prescriptions). Routes of administration were assessed based on the number and proportion of individuals reporting specific routes of abuse for specific products of interest.

Results from this study included 226,357 adult assessments from 831 sites in the US, and 12,906 adolescent assessments from 180 sites in 26 states in the US. The study reported that past thirty-day abuse prevalence for IR hydrocodone and IR oxycodone products was significantly higher than for other prescription opioid products. The primary findings from this study were that among both adults and adolescents past thirty-day abuse-prevalence of hydrocodone and oxycodone IR products were significantly greater than for other products, although when adjusting for number of prescriptions dispensed, the relative frequency of abuse appeared to be significantly higher for ER/LA products, including both AD and non-AD formulations (Figure 5).

The study also reported routes of administration by product, reporting that oral routes of administration were generally more common for most products including oxycodone IR combination products. Intranasal abuse was more common for oxycodone IR single-entity products, and injection was more common for IR opioid products excluding oxycodone and hydrocodone (Figure 6).

| Figure 5. NAVIPPRO™/ASM IV®, January 1, 2012- June 30, 2015: Past thirty-day abuse-prevalence of prescription opioid analgesics |
|---|---|
| Abuse prevalence (Number of endorsements per 100 assessments) | Adjusted abuse prevalence (per 100,000 prescriptions) |

Figure Source: Cassidy, et al.; PDS, 2017
In summary, the study we identified that utilized the NAVIPPRO™ surveillance system highlights that while oral abuse remains the most common route of administration for the majority of prescription opioid products, even for AD formulations, alternative routes of administration such as snorting and injection are reported among 20-30% of individuals endorsing abuse of such products.

**NEISS-CADES**

During 2016, there were an estimated 274,940 ED visits for harms attributed to use of a prescription opioid product, of which nearly half (105,771) involved oxycodone-containing products specifically. Among ED visits associated with non-medical use of an opioid product, 40% (N=51,204) involved an oxycodone product (Table 7).
oxycodone, an estimated 43% led to an admission, transfer or observation in the emergency room. An oxycodone product was the only implicated pharmaceutical in over half of ED visits involving nonmedical use of oxycodone (53%); a benzodiazepine was also implicated in 32% of these visits. Approximately one-fifth of ED visits for nonmedical use of oxycodone products involved concurrent use of alcohol (21%) or marijuana (18%) (Table 8).

In 38% of nonmedical use visits involving oxycodone products, the patient experienced cardiac arrest, was unresponsive, or had respiratory failure/distress, and in an additional 33% of visits, the patient experienced altered mental status (Table 9).

<table>
<thead>
<tr>
<th>Table 7. National Estimates of ED Visits for Harms from Use of Oxycodone-containing and Comparator Products, by Intent of Drug Use, 2016a</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Opioid Analgesic Product</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Non-medical Use</strong>b (Total Estimate = 129,862 ED Visits)</td>
</tr>
<tr>
<td>Oxycodone-containing Product</td>
</tr>
<tr>
<td>Hydrocodone-containing Product</td>
</tr>
<tr>
<td>Morphine-containing Product</td>
</tr>
<tr>
<td><strong>Therapeutic Use</strong>c (Total Estimate = 106,066 ED Visits)</td>
</tr>
<tr>
<td>Oxycodone-containing Product</td>
</tr>
<tr>
<td>Hydrocodone-containing Product</td>
</tr>
<tr>
<td>Morphine-containing Product</td>
</tr>
<tr>
<td><strong>Self-harm Attempt</strong> (Total Estimate = 39,012 ED Visits)</td>
</tr>
<tr>
<td>Oxycodone-containing Product</td>
</tr>
<tr>
<td>Hydrocodone-containing Product</td>
</tr>
<tr>
<td>Morphine-containing Product</td>
</tr>
</tbody>
</table>

CI, Confidence Interval; ED, Emergency Department
bData are from the National Electronic Injury Surveillance System–Cooperative Adverse Drug Event Surveillance project, CDC.
cIncludes pharmaceutical abuse, therapeutic misuse, and undetermined intent of use.
dIncludes adverse events from therapeutic use (e.g., adverse effects, allergic reactions, medication errors, and unsupervised ingestions by children aged <11 years).

Source: Data provided by the CDC Division of Healthcare Quality Promotion

<table>
<thead>
<tr>
<th>Table 8. National Estimates of ED Visits for Nonmedical Use of Oxycodone-containing Products, by Case Characteristics, 2016a</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient and Case Characteristics</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Patient Age (Years)</strong></td>
</tr>
<tr>
<td>&lt;10</td>
</tr>
<tr>
<td>10-24</td>
</tr>
<tr>
<td>25-34</td>
</tr>
</tbody>
</table>
Table 8. National Estimates of ED Visits for Nonmedical Use of Oxycodone-containing Products, by Case Characteristics, 2016*

<table>
<thead>
<tr>
<th>Patient and Case Characteristics</th>
<th>Cases</th>
<th>Annual Estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>No.</td>
</tr>
<tr>
<td></td>
<td>%</td>
<td>95% CI</td>
</tr>
<tr>
<td>35-44</td>
<td>123</td>
<td>8,830</td>
</tr>
<tr>
<td></td>
<td>17.2</td>
<td>(13.8 - 20.7)</td>
</tr>
<tr>
<td>45-54</td>
<td>132</td>
<td>9,706</td>
</tr>
<tr>
<td></td>
<td>19.0</td>
<td>(15.6 - 22.4)</td>
</tr>
<tr>
<td>55-64</td>
<td>130</td>
<td>8,630</td>
</tr>
<tr>
<td></td>
<td>16.9</td>
<td>(13.5 - 20.2)</td>
</tr>
<tr>
<td>65-74</td>
<td>43</td>
<td>2,950</td>
</tr>
<tr>
<td></td>
<td>5.8</td>
<td>(3.5 - 8.0)</td>
</tr>
<tr>
<td>&gt;74</td>
<td>4</td>
<td>--</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>%</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>273</td>
<td>20,680</td>
</tr>
<tr>
<td></td>
<td>40.4</td>
<td>(34.6 - 46.1)</td>
</tr>
<tr>
<td>Male</td>
<td>478</td>
<td>30,525</td>
</tr>
<tr>
<td></td>
<td>59.6</td>
<td>(53.9 - 65.4)</td>
</tr>
</tbody>
</table>

| Disposition                    |       |                 |
| Admitted, Transferred, or Held | 304   | 22,208          |
|                                | 43.4  | (32.6 - 54.2)   |
| Treated/Released or Left       | 447   | 28,997          |
|                                | 56.6  | (45.8 - 67.4)   |

| Number of Implicated           |       |                 |
| Pharmaceuticals                 |       |                 |
| 1                               | 387   | 26,876          |
|                                | 52.5  | (45.4 - 59.6)   |
| 2                               | 247   | 16,194          |
|                                | 31.6  | (26.8 - 36.5)   |
| 3                               | 86    | 6,055           |
|                                | 11.8  | (8.2 - 15.4)    |
| 4                               | 31    | 2,079           |
|                                | 4.1   | (2.1 - 6.0)     |

| Implicated Oxycodone Product   |       |                 |
| Single-ingredient Oxycodone    | 425   | 28,529          |
|                                | 55.7  | (46.8 - 64.6)   |
| Oxycodone in Combination with  | 334   | 22,970          |
| Acetaminophen                  |        | 44.9            |
|                                |        | (35.7 - 54.0)   |
| Oxycodone in Combination with Aspirin | 1 | --              |
|                                |        | --              |

| Co-implicated Pharmaceuticals  |       |                 |
| >1 Rx Opioid                   | 116   | 7,538           |
|                                | 14.7  | (9.9 - 19.6)    |
| Benzodiazepine                | 248   | 16,241          |
|                                | 31.7  | (26.3 - 37.2)   |

| Illicit Drugs/Alcohol          |       |                 |
| ≥1 Illicit Drug               | 287   | 18,198          |
|                                | 35.5  | (30.4 - 40.7)   |
| Alcohol                       | 167   | 10,859          |
|                                | 21.2  | (16.8 - 25.6)   |
| Illicit Drug(s) or Alcohol    | 388   | 24,725          |
|                                | 48.3  | (44.1 - 52.5)   |
| Cocaine                       | 101   | 5,656           |
|                                | 11.0  | (7.1 - 15.0)    |
| Fentanyl                      | 8     | --              |
|                                | --    | --              |
| Heroin                        | 68    | 4,021           |
|                                | 7.9   | (4.7 - 11.0)    |
| Marijuana                     | 141   | 9,591           |
|                                | 18.7  | (14.3 - 23.1)   |
| Methamphetamine              | 36    | 2,246*          |
|                                | 4.4*  | (0.9 - 7.8)     |
| Other/Unknown Illicit Drug    | 24    | --              |
|                                | --    | --              |

| Total                          | 751   | 51,204          |
|                                | 100.0 |                 |

CI, Confidence Interval; ED, Emergency Department
*Data are from the National Electronic Injury Surveillance System–Cooperative Adverse Drug Event Surveillance project, CDC. Nonmedical use includes pharmaceutical abuse, therapeutic misuse, and undetermined intent of use. Estimates based on <20 cases or total estimates <1,200 are considered statistically unreliable and are not shown (--).
Table 8. National Estimates of ED Visits for Nonmedical Use of Oxycodone-containing Products, by Case Characteristics, 2016a

<table>
<thead>
<tr>
<th>Patient and Case Characteristics</th>
<th>Cases</th>
<th>Annual Estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>No.</td>
</tr>
<tr>
<td>Adverse event manifestations were categorized in a mutually exclusive and hierarchical manner based on severity (e.g., a case involving a patient who had depressed consciousness and had a fall would be classified as altered mental status based on the depressed consciousness).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Coefficient of variation &gt;30%.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Data provided by the CDC Division of Healthcare Quality Promotion

Table 9. National Estimates of ED Visits for Nonmedical Use of Oxycodone-containing Products, by Adverse Event Manifestation, 2016a

<table>
<thead>
<tr>
<th>Adverse Event Manifestationb</th>
<th>Oxycodone-containing Product</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cases</td>
</tr>
<tr>
<td></td>
<td>No.</td>
</tr>
<tr>
<td>Cardiac Arrest/Unresponsive/Respiratory Failure/Distress</td>
<td>253</td>
</tr>
<tr>
<td>Severe Allergic Reaction</td>
<td>0</td>
</tr>
<tr>
<td>Altered Mental Status</td>
<td>271</td>
</tr>
<tr>
<td>Injection-related Infection/Reaction</td>
<td>15</td>
</tr>
<tr>
<td>Fall/Injury</td>
<td>21</td>
</tr>
<tr>
<td>Presyncope/Syncope/Dyspnea</td>
<td>15</td>
</tr>
<tr>
<td>Psychiatric or Other Central Nervous System Effect</td>
<td>27</td>
</tr>
<tr>
<td>Cardiovascular Effect</td>
<td>17</td>
</tr>
<tr>
<td>Mild-to-Moderate Allergic Reaction</td>
<td>0</td>
</tr>
<tr>
<td>Gastrointestinal Effect</td>
<td>15</td>
</tr>
<tr>
<td>Other/Unspecified Effect</td>
<td>117</td>
</tr>
<tr>
<td>Total</td>
<td>751</td>
</tr>
</tbody>
</table>

CI, Confidence interval; ED, Emergency Department

aData are from the National Electronic Injury Surveillance System–Cooperative Adverse Drug Event Surveillance project, CDC. Nonmedical use includes pharmaceutical abuse, therapeutic misuse, and undetermined intent of use. Estimates based on <20 cases or total estimates <1,200 are considered statistically unreliable and are not shown (--).

bAdverse event manifestations were categorized in a mutually exclusive and hierarchical manner based on severity (e.g., a case involving a patient who had depressed consciousness and had a fall would be classified as altered mental status based on the depressed consciousness).

*Coefficient of variation >30%.

Source: Data provided by the CDC Division of Healthcare Quality Promotion

NSVSS-M and DIM

Analysis of the NVSS-M and DIM linked databases found that in the six-year period from 2010-2015, there were a total of 32,128 oxycodone, 18,551 hydrocodone, 19,149 morphine, and 46,303
heroin-involved overdose deaths in the U.S. in individuals aged 12 years and older (Table 10). Oxycodone-involved overdose deaths rose slightly from 5,257 in 2010 to 5,566 in 2011, then decreased gradually to 4,956 deaths in 2013, and subsequently increased to 5,711 deaths in 2015 (Figure 7). A gradual increase in the number of overdose deaths involving morphine (from 2,655 to 3,651) was observed from 2010-2015. In general, a similar pattern was observed for hydrocodone-involved overdose deaths, though with small decreases from 2011-2012 and 2014-2015. A sharp increasing trend was observed for heroin-involved overdose deaths from 2010 to 2015, where the number of deaths rose from 3,020 to 13,296.

Table 10. Select Opioid Involved Drug Overdose Deaths among Individuals 12+ Years of Age by Year, 2010-2015

<table>
<thead>
<tr>
<th>Drug</th>
<th>2010</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>5257</td>
<td>5566</td>
<td>5165</td>
<td>4956</td>
<td>5413</td>
<td>5771</td>
<td>32128</td>
</tr>
<tr>
<td>Hydrocodone</td>
<td>2854</td>
<td>3204</td>
<td>3033</td>
<td>3112</td>
<td>3298</td>
<td>3050</td>
<td>18551</td>
</tr>
<tr>
<td>Morphine</td>
<td>2655</td>
<td>2909</td>
<td>3144</td>
<td>3283</td>
<td>3507</td>
<td>3651</td>
<td>19149</td>
</tr>
<tr>
<td>Heroin</td>
<td>3020</td>
<td>4562</td>
<td>6149</td>
<td>8410</td>
<td>10866</td>
<td>13296</td>
<td>46303</td>
</tr>
</tbody>
</table>

Underlying cause of death ICD-10: X40-X44, X60-X64, X85 or Y10-Y14
4 DISCUSSION

4.1 SUMMARY OF THE DATA AND DISCUSSION

Scale of misuse/abuse

Although national discourse on the opioid epidemic is now dominated by discussion of deaths arising from ultra-potent illicit opioids such as fentanyl, our analysis indicates that prescription opioids continue to contribute substantially to opioid-related adverse outcomes, such as abuse, misuse, ED visits, and overdose deaths. During 2016, an estimated 90 million individuals in the general US population had used prescription opioid analgesics the previous year, 12 million had misused them, and 2 million individuals met the criteria for abuse or dependence involving prescription opioid analgesics. The same year, approximately 275,000 estimated ED visits in the United States were for harms from use of a prescription opioid analgesic, of which, nearly 130,000 visits were for non-medical opioid use, and over 50,000 involved non-medical use of oxycodone products specifically.

Specific products, relative frequency of misuse/abuse

Data from NSDUH suggest that the most frequently misused opioid analgesics in the general population during 2016 were hydrocodone, oxycodone and codeine, with misuse occurring among 6.9 million, 3.9 million and 2.8 million individuals respectively. Over the period 2012-2016, calls to poison control centers in NPDS reporting intentional abuse were highest for heroin and oxycodone, respectively at 12.7 and 6.8 calls per million individuals; trends in exposure calls over this time demonstrate a plateau in calls for oxycodone, with a sharp rise in calls for heroin since 2015.
While national estimates for the number of individuals abusing specific opioid analgesic products in the general population could not be identified through NSDUH due to current survey design, data on the relative frequency of abuse of such products in patients entering treatment for substance use disorder was inferred from the RADARS® and NAVIPPRO™ surveillance systems. In RADARS®, we found that heroin was the most frequently abused opioid followed by oxycodone, with past-month abuse endorsed among 57% and 35% of respondents, respectively; 22% of respondents endorsed abuse of IR oxycodone, specifically. Estimates of abuse in RADARS® for substances with a smaller marketshare may be less accurate due to a category of respondents referred to by RADARS® as “Careless Responders” and should be interpreted with caution (see Limitations). The Cassidy study based upon data from NAVIPPRO™ revealed a slightly different though not entirely inconsistent pattern, with the highest abuse prevalence reported for hydrocodone followed by oxycodone.

In both RADARS® data as well as the Cassidy study, differences between the utilization-adjusted and unadjusted rates of abuse were observed. However, in the Cassidy paper, adjustment for number of prescriptions led to an apparent increase in the relative frequency of abuse of oxycodone ER/LA ADs, a shift not observed in the RADARS® data. Differences between utilization-adjusted and unadjusted rates of abuse occurred because the unadjusted rates can be driven largely by product availability while differences in utilization-adjusted rates may be more attributable to properties of the active moiety or characteristics of the formulation like the dosage strength, the bio-availability of the drugs via different routes, the relative likability of the active moiety, and other factors.

Differences in the patterns of abuse-prevalence of opioid products in the RADARS® and NAVIPPRO™ surveillance systems may be explained by several factors, including differences in the underlying populations as well as in survey format and methods. For example, RADARS® TCP represents a population of patients specifically entering treatment for OUD, while the NAVIPPRO™ treatment centers include patients entering or being assessed for treatment for any SUD. As such, the represented populations are distinct, and care should be taken to acknowledge these population differences prior to generalizing results or comparing results between populations. Differences in format and order of survey questions relating to specific opioid products, as well as the inherent potential for product misclassification, may also contribute to discrepancies between the two surveillance systems in relative abuse rates.

**Route of misuse/abuse**

AAPCC/NPDS and the NAVIPPRO™ study, depicted somewhat different pictures regarding routes of abuse, underscoring differences in population characteristics, the former being a population of patients with single-substance abuse exposures resulting in a call to a PCC; the latter, a population of patients with presumably more advanced substance use disorders. Although oral abuse was generally the most common route of abuse for prescription opioids in both populations, specific products were abused by alternate routes in each population to a differing extent.

The NAVIPPRO™ study revealed that patterns of exposure for single-entity and combination ingredient oxycodone differed. For combination-ingredient oxycodone IR, over 70% of respondents reported oral routes of exposure, with nearly 40% also reporting snorting, and just over 10% reporting injection. In contrast, for single-entity oxycodone IR, only 40% of respondents reported oral routes, with nearly 60% endorsing snorting and 40% reporting injection.
Morbidity and mortality
A high frequency of adverse outcomes continues to be reported in association with misuse/abuse of prescription opioid analgesics. Data from NEISS-CADES indicated that an estimated 51,204 ED visits in 2016 involved non-medical use of oxycodone products, either alone or in conjunction with other agents such as a benzodiazepine or marijuana; concurrent use of alcohol or illicit drugs was also frequently documented. Over 40% of such visits required observation, admission or transfer to another hospital; and an estimated 19,600 visits involved patients with cardiac arrest, respiratory failure/distress or non-responsiveness. Mortality data from NVSS-M/DIM for the period 2010-2015 identified a total of 32,128 deaths involving oxycodone, 18,551 deaths from hydrocodone and 19,149 deaths involving morphine. Although deaths involving heroin increased dramatically over time, with a total of 46,303 deaths over the period 2010-2015, the trends in deaths involving prescription opioids have not declined. For instance, with oxycodone, deaths have fluctuated from between five to six thousand deaths per year during the six-year period assessed.

4.2 LIMITATIONS OF DATA AND REVIEWED STUDIES

NSDUH
Although NSDUH is one of the few resources capable of producing national estimates of prescription drug misuse and abuse, it is subject to the inherent limitations of self-reported data, such as non-response bias, misclassification, and recall bias, and in general it is not sufficiently detailed to examine specific branded products and formulations. Information on route of administration is very limited. Individuals with advanced substance use disorders may be underrepresented, particularly if they become homeless, incarcerated, or enter a residential treatment facility.

NPDS
PCC call data should not be interpreted as representing the complete incidence of national exposures or cases of misuse/abuse related to any substance. These data only capture abuse events if the exposure resulted in a call to a PCC. PCC data rely on information electively shared by patients and healthcare personnel, and most substance classification is based on history alone and does not involve any biologic confirmation. Drug exposures resulting in unattended or out-of-hospital death are unlikely to generate a call to a PCC, and therefore, fatal poisonings are expected to be substantially under-reported in PCC call data. Follow-up and medical outcomes are not available for all calls. It is possible that changes in PCC rates in part reflect changes in public and professional awareness of the risks associated with specific drugs, and awareness of the abuse potential of a drug among call center personnel could also increase the likelihood of an exposure being coded as intentional abuse. Call rates may also be influenced by general changes in use of PCCs over time.

RADARS® TCP and NAVIPPRO™/ASI-MV® data
An important limitation of data collected from people entering or being assessed for substance use disorder treatment is the potential for misclassification, including in the identification of the specific product(s) being abused. Another limitation is that these are convenience samples, and because they are enriched with individuals with advanced substance use disorders who have sought or been referred for treatment or assessment, patterns observed in these study populations may not reflect those that exist in a broader population of individuals who abuse drugs. Numerous factors—for example, judicial referral policies and availability and funding of substance use disorder treatment—can affect the probability that an individual who is abusing or addicted to
prescription opioids is assessed for treatment and included in the sample. Further, these data are not geographically representative of all individuals being assessed for substance use disorder treatment in the U.S.

Finally, a category of responders that the RADARS refers to as “Careless Responders,” may inappropriately endorse abuse of multiple products that they may not have abused, leading to inaccurate estimates of use. We believe these careless response patterns may impact certain drugs with lower market share (i.e., fentanyl, tapentadol, and oxymorphone) more than others (i.e., oxycodone, hydrocodone). In other words, for products with large market shares that are commonly abused, such as oxycodone and hydrocodone products, careless responses will make up a smaller proportion of the total endorsements of abuse of the product than for products that have lower market share and are less commonly encountered for abuse. Our understanding of the impact of misclassification together with “Careless Responders” upon data quality is evolving.\textsuperscript{b}

\textbf{NEISS-CADES}

NEISS-CADES data can be used to calculate national estimates of ED visits for harms from pharmaceutical use, but NEISS-CADES does not include cases that do not result in an ED visit or that result in death before or during ED evaluation. NEISS-CADES also does not include inadequate therapy, drug withdrawal, detoxification treatment, medical clearance, occupational exposures, or adverse events from ED treatment. The quality of these surveillance data depend on the completeness and accuracy of medical record documentation by the healthcare provider and, to be included in the database, cases require documentation by the healthcare provider that a drug or drug class (e.g., “opioid”) was implicated in the ED visit. Up to four medications may be recorded as being implicated in a case, but it is possible that additional drugs were involved and not recorded. It is also possible that some medications recorded as “oxycodone” may have been oxycodone-combination products.

\textbf{NVSS-M and DIM linked data}

\begin{itemize}
\item[b] For further discussion of potential misclassification issues in RADARS\textsuperscript{®} treatment center data, and details regarding “Careless Responders” please refer to the following resources:
\end{itemize}

FDA briefing document [Internet]. “Joint Meeting of the Drug Safety and Risk Management (DSaRM) Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) Meeting: Postmarketing safety issues related to reformulated Opana ER\textsuperscript{®}, Addendum” [cited 2018 May 25.] Available from:
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM545761.pdf

Joint Meeting of the Drug Safety and risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee: Transmucosal Immediate-Release Fentanyl (TIRF) REMS [cited 2018 Sept 28]. Available from:
The DIM dataset relies on drug mentions in the death certificate literal text to identify cases. Opioid-involved deaths can only be identified when these substances are specifically mentioned on death certificates. Therefore, findings may describe the minimum number of opioid-involved deaths. Moreover, there may have been changes in the probability of reporting or testing for specific drug-involvement in the literal text over the course of the study period.

5 CONCLUSIONS

As new opioid analgesic products with proposed AD properties are considered for approval, risks to both patients and the broader community must be weighed against potential benefits. This review focuses on considerations relevant to public health. Misuse and abuse of prescription opioid analgesics is a persistent problem in the US, and commonly observed for individuals in both the general population and those more specifically with SUD. Both IR and ER formulations of oxycodone are abused, including products with AD labeling based on premarket testing. For currently marketed ER/LA opioid analgesic products with AD labeling based on premarket studies, successful manipulation of such products has been reported in a sizeable fraction of individuals, with chewing, insufflation, and intravenous injection all being reported routes of abuse. It is unclear whether the frequency of circumventing AD mechanisms for an IR oxycodone product will be similar to ER products since the ER products generally contain more opioid, and there may be an added desire by the user to circumvent the ER mechanism to convert it to an IR product. Prescription opioid analgesics such as oxycodone continue to contribute to a large burden of morbidity and mortality in the United States, and approval of new products should be considered with respect to both the patient and public health risk/benefit balance.
6 APPENDICES

6.1 APPENDIX A. NPDS—DEFINITIONS OF EXPOSURE REASONS

<table>
<thead>
<tr>
<th>Intentional Exposure Reasons</th>
<th>NPDS Definition&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suspected Suicides</td>
<td>“An exposure resulting in the inappropriate use of a substance for self-harm or self-destruction or manipulative reasons.”</td>
</tr>
<tr>
<td>Abuse</td>
<td>“An exposure resulting from the intentional improper or incorrect use of a substance where the victim was likely attempting to gain a high, euphoric effect or some other psychotropic effect”, including recreational use of a substance for any effect.</td>
</tr>
<tr>
<td>Misuse</td>
<td>“An exposure resulting from the intentional improper or incorrect use of a substance for reasons other than the pursuit of a psychotropic effect.”</td>
</tr>
<tr>
<td>Unknown</td>
<td>Exposures that are deemed to be intentional although the specific motive is undetermined.</td>
</tr>
</tbody>
</table>

6.2 APPENDIX B: DESCRIPTION OF THE DRUG-INVOLVED MORTALITY DATA SOURCE

The drug-involved mortality data combine the cause-of-death, demographic, and geographic information from the National Vital Statistics System – Mortality files, with drug-involved mortality information extracted from the death certificate.

literal text. The analytical dataset was constructed for analysis on October 6, 2016. The method used to extract information on drug-involved mortality has been described previously\textsuperscript{27} and is briefly described here. The information written on the death certificate by the medical certifier on the cause, manner, circumstances, and other factors contributing to the death is referred to as the literal text fields. The literal text information had been processed to allow for the identification of cases of drug-involved mortality, i.e., mortality cases having at least one literal text mention of a drug, drug class, or exposure not otherwise specified, excluding mentions where information in the literal text suggests that the drug was not involved in the death. For example, the drug “METHICILLIN” in the phrase “METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION” does not suggest drug involvement in mortality, but rather a type of bacterial infection. Similarly, the phrase “NOT DRUG RELATED” clearly indicates that a death did not involve drugs.

Although the drug-involved mortality data overcome a major limitation of the current coding system for mortality data by enabling the identification of specific drugs, the drug-involved mortality data have other limitations and considerations. These limitations and considerations are described in more detail elsewhere.\textsuperscript{27} Most importantly, the quality of data extracted from death certificates depends on the amount and level of detail provided by medical certifiers, and such information can vary by certifier, jurisdiction, and over time. For example, the percent of drug overdose deaths with at least one mention of a specific drug has improved from 67\% in 2010 to 78\% in 2014.\textsuperscript{31} Undercounting of deaths with involvement of specific drugs is likely with the drug-involved mortality data.

7 REFERENCES


DATE: October 5, 2018

FROM: Suresh Naraharisetti, PhD
Clinical Pharmacology Reviewer
Division of Clinical Pharmacology 2
Office of Clinical Pharmacology, OTS, CDER, FDA

Jennifer Nadel, MD
Medical Officer
Division of Anesthesia, Analgesia, and Addiction Products
Office of Drug Evaluation II, CDER, FDA

THROUGH: Yun Xu, PhD
Clinical Pharmacology Team Leader
Division of Clinical Pharmacology 2
Office of Clinical Pharmacology, OTS, CDER, FDA

Chandrahas Sahajwalla,
Director, Division of Clinical Pharmacology 2
Office of Clinical Pharmacology, OTS, CDER, FDA

Dan Mellon, PhD
Pharmacology Toxicology Supervisor
Office of Drug Evaluation II, CDER, FDA

Erika Torjusen, MD, MHS
Clinical Team Leader, Division of Anesthesia, Analgesia, and Addiction Products
Office of Drug Evaluation II, CDER, FDA

TO: Chair, Members and Invited Guests
Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC)
Drug Safety and Risk Management Advisory Committee (DSaRM)

RE: Summary of Clinical and Non-Clinical Data for MNK-812, Oxycodone Immediate-Release (IR) Tablets
Clinical Summary

MNK-812 is an immediate-release (IR) oxycodone hydrochloride tablet that was designed with properties intended to deter abuse by the nasal and intravenous routes through both physical/chemical barriers to manipulation and incorporation of aversive agents. Specifically, the formulation was designed to make it more difficult to crush and is designed to form a viscous hydrogel not suitable for injection. Additionally, two aversive agents were included in the formulation to cause potentially irritating effervescence when the tablet comes into contact with water.

MNK-812 is presented in 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg dosage strengths with a proposed indication of management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The safety and efficacy of MNK-812 is based on demonstration of bioequivalence to the approved drug Roxicodone (oxycodone hydrochloride immediate-release tablets; NDA 021011), for this 505(b) (2) New Drug Application (NDA). The Applicant conducted two Phase 1 pharmacokinetic (PK) studies (in the fasted and fed state) to demonstrate bioequivalence. Efficacy and safety studies were not conducted with or required for MNK-812, as the safety and effectiveness of MNK-812 are supported by the PK data (studies MNK48121004 and MNK48121005) to cross-reference the data in the Applicant’s Roxicodone NDA. Safety information was collected from the two PK studies and one human abuse potential study.

As described in Table 1, study results for the intranasal human abuse potential (HAP) study, MNK48121013, demonstrated a higher frequency of treatment emergent adverse events (TEAEs) occurring in the intact oral MNK-812 and intranasal MNK-812 treatment groups, as compared to the intranasal oxycodone IR and placebo groups. Notably, there was an increased frequency of adverse events occurring in the respiratory, thoracic and mediastinal system organ class (SOC) and gastrointestinal SOC for both the intact oral MNK-812 and intranasal MNK-812 treatment groups, which may be expected for an abuse-deterrent formulation that includes an aversive agent. The most common events reported by preferred term (PT) within these SOCs consisted of cough, nasal discomfort, nausea, vomiting, constipation and retching. While most TEAEs were classified as mild in severity, there were two episodes each of moderate severity cough and moderate severity nasal burning sensation, which occurred in the intranasal MNK-812 treatment group. Other adverse events were generally similar between the treatment groups.
<table>
<thead>
<tr>
<th>System Organ Class Preferred Term, N (%)</th>
<th>Intact Oral MNK-812 N=41</th>
<th>Intranasal MNK-812 N=40</th>
<th>Intranasal Oxycodone (IR) N=42</th>
<th>Placebo N=42</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects at least 1 AE</td>
<td>32 (78)</td>
<td>29 (72.5)</td>
<td>24 (57.1)</td>
<td>12 (28.6)</td>
</tr>
<tr>
<td>Respiratory, Thoracic, Mediastinal Disorders</td>
<td>6 (14.6)</td>
<td>21 (52.5)</td>
<td>4 (9.5)</td>
<td>6 (14.3)</td>
</tr>
<tr>
<td>Cough</td>
<td>3 (7.3)</td>
<td>11 (27.5)</td>
<td>4 (9.5)</td>
<td>6 (14.3)</td>
</tr>
<tr>
<td>Nasal Discomfort</td>
<td>0</td>
<td>10 (25.0)</td>
<td>0</td>
<td>1 (2.4)</td>
</tr>
<tr>
<td>Nasal Congestion</td>
<td>1 (2.4)</td>
<td>2 (5.0)</td>
<td>1 (2.4)</td>
<td>0</td>
</tr>
<tr>
<td>Hiccups</td>
<td>2 (4.9)</td>
<td>1 (2.5)</td>
<td>1 (2.4)</td>
<td>0</td>
</tr>
<tr>
<td>Oropharyngeal Pain</td>
<td>1 (2.4)</td>
<td>1 (2.5)</td>
<td>0</td>
<td>1 (2.4)</td>
</tr>
<tr>
<td>Paranasal Sinus Discomfort</td>
<td>0</td>
<td>1 (2.5)</td>
<td>1 (2.4)</td>
<td>0</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (2.4)</td>
</tr>
<tr>
<td>Hypoxia</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (2.4)</td>
</tr>
<tr>
<td>Nasal Pruritus</td>
<td>0</td>
<td>1 (2.5)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Pulmonary Congestion</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (2.4)</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td>11 (26.8)</td>
<td>10 (25)</td>
<td>6 (14.3)</td>
<td>2 (4.8)</td>
</tr>
<tr>
<td>Nausea</td>
<td>7 (17.1)</td>
<td>2 (5)</td>
<td>3 (7.1)</td>
<td>0</td>
</tr>
<tr>
<td>Vomiting</td>
<td>4 (9.8)</td>
<td>3 (7.5)</td>
<td>3 (7.1)</td>
<td>0</td>
</tr>
<tr>
<td>Constipation</td>
<td>0</td>
<td>3 (7.5)</td>
<td>1 (2.4)</td>
<td>1 (2.4)</td>
</tr>
<tr>
<td>Retching</td>
<td>0</td>
<td>4 (10)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>2 (4.9)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Abdominal distension</td>
<td>0</td>
<td>0</td>
<td>1 (2.4)</td>
<td>0</td>
</tr>
<tr>
<td>Abdominal pain upper</td>
<td>1 (2.4)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1 (2.4)</td>
</tr>
</tbody>
</table>

Source: Sponsor Clinical Study Report MNK48121013, Table 12-3, Page 118
A dose of 30 mg was used for MNK-812 and oxycodone-IR treatments.
The safety population represented in this table includes all subjects who received any amount of any study drug in the treatment phase.
Clinical Pharmacology Summary

The clinical pharmacology summary focuses on two Phase 1 PK studies (MNK48121004 and MNK48121005) using the 15 mg strength of the to-be-marketed commercial formulation compared to Roxicodone. A waiver of in vivo bioavailability and bioequivalence studies (i.e., biowaiver) is appropriate for the other proposed strengths (5 mg, 10 mg, 20 mg and 30 mg). Both Phase 1 PK studies were randomized, open-label, crossover studies conducted in healthy volunteers under naltrexone blockade. Study MNK48121004 assessed the comparative bioavailability of MNK-812 (15-mg strength) to Roxicodone 15-mg tablets under the fasted state and Study MNK48121005 assessed the comparative bioavailability between the two drugs under the fed state. The PK findings in an intranasal (IN) human abuse liability study (MNK 48121013) were also described.

In Study MNK48121004, 40 healthy subjects were enrolled, and 37 subjects completed MNK-812 treatment and 33 subjects completed Roxicodone treatment. The mean ± SD plasma concentration time profiles of oxycodone from MNK-812 versus Roxicodone under fasted conditions are shown in Figure 1 and the PK parameters are shown in Table 2. The results show that MNK-812 (15-mg strength) met the criteria for bioequivalence (BE) to Roxicodone 15-mg under fasted conditions (n=37, MNK-812; n=33, Roxicodone). The point estimates of the geometric mean ratios (MNK-812 / Roxicodone) for AUClast, AUCinf, and Cmax were 94%, 94% and 87%, respectively and the corresponding 90% CIs were within the 80-125% BE limits (lower bound- upper bound; 92-97%, 92-97% and 81-93%, respectively). The median Tmax (min, max) for MNK-812 was 1.5h (0.75, 2.15 h) and was similar to Roxicodone 1.01 h (0.5, 2.0 h). There was no difference in mean half-life between MNK-812 and Roxicodone (4.3 h and 4.5 h, respectively) under fasted conditions.
Figure 1: The mean ± SD plasma concentration time profiles of oxycodone from MNK-812 (n=37) versus Roxicodone (n=33) under fasted conditions in study MNK48121004. The dosing-interval (0-4 h) PK profile is represented as the smaller graph within the figure.

![Figure 1: Mean plasma concentration time profiles of oxycodone from MNK-812 (n=37) versus Roxicodone (n=33) under fasted conditions in study MNK48121004.](image)

Table 2: The PK parameters of oxycodone from MNK-812 (n=37) versus Roxicodone (n=33) under fasted conditions in study MNK48121004.

<table>
<thead>
<tr>
<th>PK Parameter *</th>
<th>MNK-812, 15 mg Tablet</th>
<th>Roxicodone, 15 mg Tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Single dose, fasted (n=37)</td>
<td>Single dose, fasted (n=33)</td>
</tr>
<tr>
<td>Mean</td>
<td>Mean</td>
<td>Mean</td>
</tr>
<tr>
<td>SD</td>
<td>38</td>
<td>38</td>
</tr>
<tr>
<td>Mean</td>
<td>146</td>
<td>152</td>
</tr>
<tr>
<td>SD</td>
<td>38</td>
<td>38</td>
</tr>
<tr>
<td>AUCt (ng.hr/mL)</td>
<td>147</td>
<td>153</td>
</tr>
<tr>
<td>AUCinf (ng.hr/mL)</td>
<td>27</td>
<td>31</td>
</tr>
<tr>
<td>Cmax (ng/mL)</td>
<td>4.3</td>
<td>4.5</td>
</tr>
<tr>
<td>Halflife (h)</td>
<td>0.9</td>
<td>1.1</td>
</tr>
<tr>
<td>Tmax</td>
<td>1.50 (0.75, 2.15)</td>
<td>1.01 (0.50, 2.0)</td>
</tr>
</tbody>
</table>

*Arithmetic mean ± standard deviation (N) except Tmax for which the median is represented (minimum, maximum)

In Study MNK48121005, 55 healthy subjects were enrolled, and 50 subjects completed the MNK-812 and Roxicodone treatment arms. The mean ± SD plasma concentration time profiles of oxycodone from MNK-812 versus Roxicodone under fed conditions are shown in Figure 2 and the PK parameters are shown in Table 3. When bioequivalence was assessed, MNK-812 (15-mg strength) met bioequivalence criteria to Roxicodone 15-mg under fed conditions (n=50). The point estimates of the geometric mean ratios (MNK-812 / Roxicodone) for AUClast, AUCinf,
and Cmax were 98%, 98% and 90%, respectively and the corresponding 90% CIs were within the 80-125% BE limits (lower bound- upper bound; 94-101%, 94-101% and 81-99%, respectively). There was no difference in mean half-life between MNK-812 or Roxicodone, 4.2 h for both drugs under fed conditions.

**Figure 2**: The mean ± SD plasma concentration time profiles of oxycodone from MNK-812 (n=50) versus Roxicodone (n=50) under fed conditions in study MNK48121005. The dosing-interval (0-4 h) PK profile is represented as the smaller graph within the figure.
Table 3: The PK parameters of oxycodone from MNK-812 (n=50) versus Roxicodone (n=50) under fed conditions in study MNK48121005.

<table>
<thead>
<tr>
<th>PK Parameter</th>
<th>MNK812, 15 mg Tablet Single dose, fed (n=50)</th>
<th>Roxicodone, 15 mg Tablet Single dose, fed (n=50)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>AUCₐ₀₋₀.₅h (ng.hr/mL)</td>
<td>3.2</td>
<td>5.3</td>
</tr>
<tr>
<td>AUCₐ₀₋₁h (ng.hr/mL)</td>
<td>10.8</td>
<td>13.8</td>
</tr>
<tr>
<td>AUCₐ₀₋₂h (ng.hr/mL)</td>
<td>28</td>
<td>25</td>
</tr>
<tr>
<td>AUCₐ₀₋₃h (ng.hr/mL)</td>
<td>48</td>
<td>30</td>
</tr>
<tr>
<td>AUCₐ₀₋₄h (ng.hr/mL)</td>
<td>68</td>
<td>32</td>
</tr>
<tr>
<td>AUCₐ₀₋₅h (ng.hr/mL)</td>
<td>86</td>
<td>33</td>
</tr>
<tr>
<td>AUCₐ₀₋₆h (ng.hr/mL)</td>
<td>100</td>
<td>33</td>
</tr>
<tr>
<td>AUCt (ng.hr/mL)</td>
<td>170</td>
<td>39</td>
</tr>
<tr>
<td>AUCinf (ng.hr/mL)</td>
<td>171</td>
<td>39</td>
</tr>
<tr>
<td>Cmax (ng/mL)</td>
<td>29</td>
<td>15</td>
</tr>
<tr>
<td>Halflife (h)</td>
<td>4.2</td>
<td>0.8</td>
</tr>
<tr>
<td>Tmax*</td>
<td>3 (0.25, 8)</td>
<td>2 (0.5, 4.0)</td>
</tr>
</tbody>
</table>

*Arithmetic mean ± standard deviation (N) except Tmax for which the median is represented (minimum, maximum)

The partial area ratio % (MNK-812 fed / Roxicodone fed) is shown in Figure 3. Under fed conditions, based on the partial areas ratio %, MNK-812 has a higher exposure compared to Roxicodone tablets during the first 1.5 hours after dosing. After the 1.5-hour time point, the exposure is reasonably comparable to Roxicodone (Figure 3). The Tmax frequency distribution of MNK-812 (n=50) versus Roxicodone (n=50) under fed conditions in Study MNK48121005 is shown in Figure 4. Under the fed state, the median Tmax for MNK-812 was 3 h with a range of 0.25 h to 8 h, while Roxicodone had a median Tmax of 2 h with a range of 0.5 to 4 h. For MNK-812, out of 50 subjects, 3 subjects had Tmax values greater than 4 h; two subjects with 6 h and one subject with 8 h. Although the maximum Tmax is 8 h in 1 subject out of 50 subjects, MNK-812 appears to have no absorption issues and shows reasonably comparable concentrations to Roxicodone based on the concentration profile within the dosing interval (Figure 2) and partial areas ratio % (Figure 3).
**Figure 3**: The partial AUC ratio % of oxycodone from MNK-812 or Roxicodone under fed conditions [MNK-812-fed / Roxicodone-fed], from 0.5 to 6 h after drug administration; N=50

![Partial AUC Ratio % (MNK-812 fed / Roxicodone fed)](image)

**Figure 4**: The Tmax frequency distribution of oxycodone from MNK-812 (n=50) versus Roxicodone (n=50) under fed conditions in study MNK48121005.

![Oxycodone Tmax Frequency Distribution Single dose, fed](image)

Roxicodone is labeled to be taken without regard to food. In Study MNK48121005, MNK-812 demonstrated a similar extent of food effect in terms of AUC, Cmax and Tmax as compared to Roxicodone. Therefore, it is reasonable that MNK-812 may be labeled to be taken without regard to food intake.

The intranasal (IN) abuse potential of MNK-812 tablets (30 mg) versus Roxicodone tablets (30 mg) was evaluated in nondependent recreational opioid users in Study MNK48121013.

The mean ± SD plasma concentration time profiles of oxycodone from tampered MNK-812 tablets versus tampered Roxicodone tablets after IN administration are shown in Figure 5A.
Based on the PK profiles of the two tampered products, the differences in concentration of oxycodone after IN administration does not appear to be clinically significant. The mean ± SD plasma concentration time profiles of oxycodone from tampered MNK-812 tablets after IN administration versus intact MNK-812 tablets after oral administration are shown in Figure 5B. Similarly, the differences in concentrations of oxycodone between the intact oral MNK-812 and IN MNK-812 treatment arms does not appears to be clinically significant.

**Figure 5:** The mean ± SD plasma concentration time profiles of oxycodone from tampered MNK-812 tablets versus tampered Roxicodone tablets after IN administration (5A) and tampered MNK-812 tablets after IN administration versus intact oral MNK-812 tablets (5B).

In summary, MNK-812 met bioequivalence criteria for both AUC and Cmax compared to Roxicodone under both fasted and fed conditions at the 15 mg strength. MNK-812 has a similar extent of food effect compared to Roxicodone and can be labeled to be taken without regard to food intake. A biowaiver is appropriate for the 5 mg, 10 mg, 20 mg, and 30 mg strengths of MNK-812. In the intranasal abuse potential study, the plasma concentrations of oxycodone do not appear to be significantly different between IN MNK-812 tablets and IN Roxicodone tablets.
Non-Clinical Summary

The Applicant is cross-referencing the nonclinical data in their original Roxicodone NDA to support this application. No new toxicology studies for oxycodone were required. As such, the drug product labeling will be virtually identical to that of Roxicodone with respect to pharmacology (mechanism of action), pregnancy, and nonclinical toxicology.

There are no safety concerns with the new drug product formulation when the drug product is used as labeled via the intended oral route of administration. The Applicant initiated studies during the review cycle to characterize the potential toxicological effects of the drug product if it were to be manipulated for intravenous abuse. However, final study reports for several key studies have not been submitted to the NDA in time to be included in this background document and are expected late in the review cycle. As such, the Agency has not made any definitive conclusions regarding the potential risks associated with manipulation and abuse of this product via the intravenous route of administration.
MEMORANDUM

DATE: October 5, 2018
FROM: Valerie Amspacher, Pharm.D.
       Julia Pinto, Ph.D.
TO: Chair, Members and Invited Guests
    Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC)
    Drug Safety and Risk Management Advisory Committee (DSaRM)
RE: Background Document: In Vitro Studies of Proposed Abuse-Deterrent Properties,
    NDA 209774 immediate release oxycodone hydrochloride tablet

The drug product is an immediate-release (IR) oxycodone hydrochloride tablet presented in 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg dosage strengths. The abuse-deterrent properties of the drug product are imparted by excipients that act as gelling agents and potential nasal irritants.

Summary of In Vitro Studies

Extensive in vitro abuse-deterrent studies were conducted to assess the relative difficulty and effectiveness of various potential manipulation methods to defeat the drug product’s abuse-deterrent properties. Only the methodologies that reflect the most probable abuse approaches and that pose the most challenges to the drug product under evaluation are summarized below. When used, the comparator is Roxicodone IR 15 or 30 mg.

A. Physical Manipulation (Particle Size Reduction)
Several simulated common techniques that are used to manipulate the drug product were studied. Selected readily-available physical manipulation tools representative of crushing and grinding mechanisms were employed to reduce the particle size of MNK-812 and Roxicodone tablets that had not been subjected to pre-treatment. Particle size distribution of powders was measured after physical manipulation. Generally, particle size reduction with manual tools resulted in a maximum of about 10% of particles <500 microns for MNK-812 (15 and 30 mg tablets) and a maximum of about 70% of particles <500 microns for Roxicodone (15 and 30 mg tablets). The
use of readily-available mechanical tools generated a larger quantity of small particles than the manual tools. MNK-812 (15 and 30 mg tablets) gave a maximum of approximately 90% of particles <500 microns with the use of readily-available mechanical tools. The measurement of 500 microns is specifically mentioned because this is roughly an insufflatable particle size.

B. Large Volume Extraction Studies
Large volume extraction studies evaluated the extraction potential of oxycodone hydrochloride from intact or ground tablets not subjected to pre-treatment in 30 mL of solvent with and without stirring. In general, large volume extractions in several but not all ingestible solvents led to comparable amounts of oxycodone recovery between MNK-812 and Roxicodone. With an extraction time of 2 hours or less in a variety of ingestible solvents of varying pH, approximately 80-90% of oxycodone hydrochloride will be released from intact or ground tablets at room temperature. When tested using complex extraction and isolation procedures, 87% of oxycodone free base can be recovered from MNK-812.

C. Small Volume Extractability and Syringeability Studies
Small volume extractions were conducted to assess the potential for syringeability and injectability of the manipulated product. Testing included both pre-treated and non-pre-treated, intact and manipulated tablets at room temperature and elevated temperature. Ingestible solvents of varying pH were tested. Conditions were confirmed in which 50-60% of oxycodone present in a tablet could be isolated and potentially injected. Other conditions of temperatures and ingestible solvents could not isolate more than 50% of the oxycodone present in a tablet. FDA labs repeated the abuse-deterrence testing for relevant conditions, and the results of this testing are in general agreement with those provided by the sponsor.

D. Smoking
Smokeability was assessed. Oxycodone free base could not be extracted from the tablet using simple extraction procedures. Testing of physically manipulated tablets yielded maximum volatized recoveries of 14.5% in smoking simulation studies.
MEMORANDUM
Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research

Date: October 1, 2018

To: Sharon Hertz, M.D., Director
Division of Anesthesia, Analgesia, and Addiction Products

Through: Dominic Chiapperino, Ph.D., Director
Silvia Calderon, Ph.D., Lead Pharmacologist
Controlled Substance Staff

From: James M. Tolliver, Ph.D., Pharmacologist
Controlled Substance Staff

Subject: BACKGROUND DOCUMENT on Intranasal Human Abuse Potential (HAP) Study MNK48121013 Submitted Under NDA 209774. Prepared for the FDA Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee Meeting, November 14, 2018.
Sponsor: SpecGx LLC (formerly Mallinckrodt Inc.)

Background Document

SpecGx LLC submitted an intranasal HAP study MNK48121013 under NDA 209774 in support of MNK-812 tablets (oxycodone hydrochloride (HCl) immediate release (IR) tablets). MNK-812 tablets were designed to have abuse-deterrent properties based in physical/chemical barriers as well as possible aversive effects. Intranasal HAP studies conducted as part of a pre-market abuse-deterrent assessment are generally thought to be predictive of the likelihood that proposed abuse-deterrent properties in a new drug product formulation will deter or reduce the abuse of the product when taken via the intranasal route of abuse.

A description of Study MNK48121013, along with relevant findings, are provided below. Statistical analyses of pharmacodynamic measures were conducted by the CDER Office of Biostatistics.
Description of Study MNK48121013

Study MNK48121013 is a single-center, randomized, double-blind, double-dummy, 4-period crossover study having a screening phase, drug discrimination phase, treatment phase, and follow-up period. To enter the drug discrimination phase, subjects were required to pass a Naloxone Challenge Test to ensure that the subject was not physically dependent on opioids.

The primary objective was to compare the relative abuse potential of tampered MNK-812 tablets vs. tampered commercially available oxycodone hydrochloride immediate-release tablets following intranasal administration.

The determination of relative abuse potential was assessed using subjective measures that are based on visual analogue scales (VAS), which are used in the Drug Discrimination Phase and Treatment Phase. Some of the key VAS measures used included the following:

- Bipolar 0-100 mm “at the moment” Drug Liking VAS anchored on the left by “Strong Disliking” (score of 0), in the center by “Neither Like Nor Dislike” (score of 50), and on the right by “Strong Liking” (score of 100). Subjects are asked to respond to the question "Do you like the drug effect you are feeling now?"
- Unipolar 0-100 mm "at the moment" High VAS anchored on the left by "None" (score of 0) and on the right by “Extremely” (score of 100). Subjects are asked to respond to the statement “I am feeling high…”
- Bipolar 0-100 mm Take Drug Again VAS required subjects to reflect back over their experience at 12 hours and 24 hours post-dosing for each treatment. The VAS was anchored on the left by “Definitely Would Not” (score of 0), in the center by "do not care" (score of 50) and on the right by “Definitely Would” (score of 100). Subjects are asked to respond to the question “Would you want to take the drug you just received again, if given the opportunity?”
- Bipolar 0-100 mm Overall Drug Liking VAS also required subjects to reflect back over their experience at 12 hours and 24 hours post-dosing for each treatment. The VAS was anchored on the left by “Strong Disliking” (score of 0), in the center by "Neither Like Nor Dislike" (score of 50) and on the right by “Strong Liking” (score of 100). Subjects responded to the statement “Overall, my liking for this drug is…”
- Unipolar 0-100 mm "at the moment" Bad Effects VAS which was anchored on the left by "None" (score of 0) and on the right by "Extremely" (score of 100). Subjects responded to the question "Does the drug have any bad effects?"
- The Ease of Snorting VAS is intended to assess the difficulty of snorting the study drugs. Subjects responded to the statement “Snorting the drug was…” The question was scored using a 0 to 100 point, unipolar VAS anchored on the left with “very easy” (score of 0) and anchored on the right with “very difficult” (score of 100).

The completer population consisted of 38 subjects consisting of recreational opioid users who had at least 5 occasions of recreational prescription opioid use over the last 12 months and who had a history of intranasal drug administration of at least 3 times within the last year prior to the screening phase.
During the Drug Discrimination Phase, subjects randomly received 1 of the 3 treatments, 1 treatment per day, over 3 consecutive days (Days 1 - 3), in a fasted state and double-blind fashion:

- Oxycodone HCl IR 20 mg (e.g., 4 × 5 mg) tablets crushed in solution, and
- Oxycodone HCl IR 40 mg (e.g., 2 × 5 mg + 1 × 30 mg) tablets crushed in solution, and
- Placebo solution.

To advance to the Treatment Phase, subjects were required to pass a Drug Discrimination Test by successfully discriminating between intranasal powdered Oxycodone IR 15 mg and placebo. Subjects were required to completely insufflate the entire volume of study drug during the Drug Discrimination Phase. The ability to discriminate was defined for bipolar Drug Liking VAS as follows:

- A minimum score of 65 points for Drug Liking in response to active treatment;
- A ≥ 15-point difference between active and placebo treatments during the first 2 hours following drug administration; and
- A placebo response ≥ 40 and ≤ 60 points for Drug Liking during the first 2 hours following drug administration.

During the treatment phase, the doses were administered in randomized, double-dummy, double-blind, crossover manner such that all subjects received each of the treatments (1 per treatment day). Each treatment day was separated by a 72 (± 2) hour washout. Each subject was randomly assigned to 1 of 4 treatment sequences based on a Williams design and received 1 of 4 treatments in each treatment period. Study drug was prepared for each subject based on the actual randomization scheme.

The following treatments were administered during the Treatment Phase.

- Intact oral 30 mg MNK-812 and manipulated intranasal Oxycodone HCl IR placebo.
- Intact oral MNK-812 placebo and manipulated intranasal 30 mg MNK-812.
- Intact oral MNK-812 placebo and manipulated intranasal 30 mg Oxycodone HCl IR.
- Intact oral MNK-812 placebo and manipulated intranasal Oxycodone HCl IR placebo.

Subjects were instructed to insufflate as much of the dose as possible within 10 minutes. If the study drug was not 100% insufflated, the amount (weight) not administered was recorded and the subject continued with all study procedures. Subjects were not allowed to blow their noses for 2 hours post-dose, and any episodes of sneezing within 1 hour post-dose were documented.

Oxycodone plasma pharmacokinetic parameters were determined from blood samples taken pre-dose and at hours 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, and 24 post-dosing. Oxycodone PK parameters that were evaluated included, but were not limited to, the following:

- Cmax = Maximum oxycodone plasma level achieved following treatment
- Tmax = Time to achieve Cmax
- AUC0-1hours = Area under the oxycodone plasma concentration curve over the first hours post-dosing, a measure of cumulative drug exposure over the first hour.

Drug Liking VAS was the primary measure while peak effect (Emax) of Drug Liking was the primary endpoint. High VAS, Take Drug Again VAS, and Overall Drug Liking VAS were
secondary measures. Drug Liking VAS, High VAS, and Bad Effects VAS were conducted at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 hours post-dosing. Take Drug Again VAS and Overall Drug Liking VAS were assessed at hour 12 and 24 after post-dosing. Ease of Snorting VAS was conducted once, just following insufflation of each treatment.

Pharmacodynamic parameters determined included but were not limited to:
- $E_{\text{max}} =$ maximum effect observed
- $T_{\text{max}} =$ time to maximum effect ($E_{\text{max}}$
- $A_{\text{UE0-1hr}} =$ area under the effect curve out to 1 hour post-dosing.

Subject assessment of nasal tolerability assessed the effect of each treatment on the following clinical features: nasal irritation, nasal burning, runny nose/nasal discharge, facial pain/pressure, nasal congestion, and need to blow nose. Each was quantitated using a 0 to 3 point scale with 0 = None, 1 = Mild, 2 = Moderate, and 3 = Severe.

Statistical analyses of pharmacodynamic endpoints were conducted by the CDER Office of Biostatistics. Statistical model used was a mixed-effects model with period, sequence, and treatment as fixed effects and subjects as a random effect. All tests were one-sided with $\alpha = 0.025$. Statistical analyses of pharmacodynamic endpoints were assessed using data from 38 completers. The primary treatment comparison was that of intranasal MNK-812 (30 mg) versus intranasal Oxycodone HCl IR (30 mg).

Findings Regarding Study MNK48121013

1. The mean $E_{\text{max}}$ of 84.13 mm on the 0-100 mm unipolar Ease of Snorting VAS suggests that subjects perceived difficulty in the insufflation of 30 mg MNK-812 powder. By contrast, with mean $E_{\text{max}}$ of less than 12, subjects appeared to have little problem in the insufflation of either 30 mg oxycodone HCl IR powder or placebo.

2. The mean percentage of dose insufflated was above 98% for the three intranasal treatments of MNK-812, oxycodone HCl IR and placebo. This indicates that overall subjects were able to insufflate most of the dose for each treatment.

3. Following oral and intranasal MNK-812, and intranasal Oxycodone HCl IR, the mean maximum plasma levels of oxycodone achieved were 57.7, 55.0, and 55.7 ng/mL, respectively. Time to achieve Cmax ($T_{\text{max}}$) following oral administration was 1.51 hours, compared to the $T_{\text{max}}$ values of 2.41 hours and 2.06 hours for intranasal MNK-812 and intranasal Oxycodone HCl IR. Overall oxycodone exposure over the first hour was highest for intranasal Oxycodone HCl IR ($A_{\text{UC0-1hour}} = 33.29 \text{ ng x h/mL}$) compared to either oral MNK-812 or intranasal MNK-812 with $A_{\text{UC0-1hour}}$ of 27.55 and 22.32 ng x h/mL, respectively.

4. With respect to Drug Liking VAS, High VAS, Take Drug Again VAS, and Overall Drug Liking VAS, the positive comparator, oxycodone HCl IR 30 mg, had a LSmean $E_{\text{max}}$ statistically significantly larger compared to placebo ($p < 0.001$), thereby validating the study with respect to these subjective measures.
5. Least square means (LSmean) for Emax of Drug Liking VAS following oral and intranasal MNK-812 tablets, intranasal Oxycodone HCl IR tablets and intranasal placebo were 83.9 mm, 77.4 mm, 82.7 mm, and 50.7 mm, respectively. When assessing for any statistically significant effect (δ* = 0), the 5.3 mm LSmean difference in the primary comparison of intranasal oxycodone HCl IR versus intranasal MNK-812 was statistically significant (p = 0.0039). However, no statistically significant difference in LSmean Emax was found (p = 0.1409) when looking for at least a 10% reduction in the Emax produced by intranasal MNK-812 versus intranasal oxycodone HCl IR. The median (range) times to achieve Emax (TEmax) of Drug Liking following treatments with intact oral MNK-812, intranasal MNK-812, and oxycodone HCl IR were 1.00 (0.48 – 3.98), 1.49 (0.23 – 12.00), and 1.00 (0.23 – 3.00) hours, respectively.

6. LSmeans of Emax for High VAS following oral and intranasal MNK-812, intranasal Oxycodone HCl IR, and placebo were 74.8, 68.0, 72.6, and 0.8, respectively. The LSmeans for Emax for High VAS following oral and intranasal MNK-812 were not statistically significantly different from Emax of High following intranasal Oxycodone HCl IR (p ≥ 0.0786). The median (range) time to achieve Emax (TEmax) of High following treatments with intact oral MNK-812, intranasal MNK-812, and oxycodone HCl IR were 1.00 (0.50 – 4.00), 1.50 (0.25 – 6.02), and 1.00 (0.25 – 3.00) hours, respectively.

7. LSmeans of Emax for Take Drug Again VAS following oral and intranasal MNK-812, intranasal Oxycodone HCl IR, and placebo were 74.7, 46.4, 77.0, and 50.1, respectively. There was a statistically significant reduction in Emax of Take Drug Again following intranasal MNK-812 compared to intranasal Oxycodone HCl IR (p < 0.001). The Emax of Take Drug Again following oral MNK-812 was not statistically significantly different from that produced by Oxycodone HCl IR (p = 0.3102).

8. LSmeans for Emax of Overall Drug Liking for oral MNK-812, intranasal MNK-812, oxycodone HCl IR, and placebo were 75.3, 49.8, 77.5, and 48.6, respectively. The 27.7 point LSmean reduction in Overall Drug Liking following intranasal MNK-812 compared to intranasal oxycodone HCl IR was statistically significant (p < 0.001). No statistically significant difference in Emax of Overall Drug Liking was observed between oral MNK-812 and intranasal Oxycodone HCl IR.

9. The LSmean Emax for Bad Drug Effects following intranasal MNK-812 (30 mg), intranasal Oxycodone HCl IR (30 mg), and intranasal placebo were 38.6 mm, 18.5 mm, and 1.0 mm, respectively. The LSmean of 38.6 out of a total 100 point scale suggest a limited bad effect produced my intranasal MNK-812. With respect to the primary treatment comparison of intranasal MNK-812 versus intranasal Oxycodone HCl IR, the LSmean difference was 20.1 mm and was statistically significant. At the same time this 20.1 points difference on the 100 point unipolar Bad VAS suggests a limited difference with respect to producing reduced nasal tolerability.
MEMORANDUM

DATE: October 15, 2018

FROM: Sharon Hertz, MD
Director
Division of Anesthesia, Analgesia, and Addiction Products
Office of Drug Evaluation II, CDER, FDA

TO: Chair, Members and Invited Guests
Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC)
Drug Safety and Risk Management Advisory Committee (DSaRM)

RE: Opioids with Abuse-Deterrent Labeling

Opioids with Abuse-Deterrent Labeling: Section 9.2 Drug Abuse
Based on feedback from previous advisory committee meetings where abuse-deterrent opioid analgesics were discussed, excerpts are included here from the labels of approved opioids analgesics with abuse-deterrent labeling, specifically Section 9.2, which describes the in vitro and in vivo studies conducted to support the abuse-deterrent properties. The products are listed in the order in which they were approved.

EMBEDA (morphine sulfate and naltrexone hydrochloride) extended-release capsules
[NDA 022321]

Approval Date: August 13, 2009
Abuse Deterrence Labeling Update: October 17, 2014

Abuse Deterrence Studies
EMBEDA is formulated with a sequestered opioid antagonist, naltrexone HCl, which is released with manipulation by crushing.

In Vitro Testing
In vitro laboratory tests were performed to evaluate the effect of different physical and chemical conditions intended to defeat the extended-release formulation. When EMBEDA is crushed and
mixed in a variety of solvents, both morphine sulfate and naltrexone hydrochloride are simultaneously extracted.

**Clinical Studies**

The abuse potential of EMBEDA when crushed was examined in three studies following administration by the oral (Studies 1 and 2) and intranasal (Study 3) routes. A fourth study was conducted with IV administration of simulated crushed EMBEDA (Study 4). These were randomized, double-blind, single-dose, placebo and active-controlled, crossover studies in non-dependent recreational opioid users. Drug Liking in Studies 1-3 was measured on a bipolar 100-point Visual Analog Scale (VAS) where 0 represents maximum disliking, 50 represents a neutral response (neither like nor dislike), and 100 represents maximum liking. Drug Liking in Study 4 and Drug High in all studies was measured on a unipolar 100-point VAS where 0 represents no response and 100 represents maximum response. Response to whether the subject would take the study drug again was also measured in two studies (Study 2, Study 3) on a bipolar 100-point VAS where 0 represents the strongest negative response (e.g., ‘definitely would not’), 50 represents a neutral response, and 100 represents the strongest positive response (e.g., ‘definitely would’). The pharmacokinetics of morphine sulfate and naltrexone hydrochloride were also determined in these abuse potential studies. When EMBEDA was crushed and administered by the oral and intranasal routes, morphine and naltrexone were absorbed with similar median time-to-peak concentration ($T_{\text{max}}$) values of 1 hour following oral administration and approximately 36 minutes following intranasal administration.

**Oral Studies**

Study 1 compared EMBEDA to IR morphine sulfate. In this study 32 subjects received four treatments: 120 mg/4.8 mg as intact EMBEDA capsules, 120 mg/4.8 mg as crushed EMBEDA in solution, 120 mg IR morphine in solution, and placebo. When EMBEDA was crushed and taken orally, the geometric mean ($\pm$SD) values for naltrexone $C_{\text{max}}$ and AUC$_{\text{inf}}$ were $1073 \pm 721$ pg/mL and $3649 \pm 1868$ pg·hr/mL, respectively. The oral administration of crushed EMBEDA was associated with statistically significantly lower mean and median Drug Liking and Drug High scores compared with crushed IR morphine (as summarized in Table 3).

Figure 1 (Study 1) demonstrates a comparison of Drug Liking for crushed EMBEDA compared to crushed IR morphine sulfate when given by the oral route in subjects who received both treatments. The Y-axis represents the percent of subjects attaining a percent reduction in Drug Liking with crushed EMBEDA vs. morphine greater than or equal to the value on the X-axis. Of the 32 subjects who completed the study, approximately 81% of subjects had some reduction in Drug Liking and Drug High with crushed EMBEDA compared to administration of IR morphine sulfate, while approximately 19% had no reduction in Drug Liking or in Drug High. At least a 30% and 50% reduction in Drug Liking with crushed EMBEDA compared to IR morphine was observed in 72% and 56% of subjects, respectively (summarized in Figure 1). At least a 30% and 50% reduction in Drug High with crushed EMBEDA was observed in 56% and 31% of subjects, respectively.
Study 2 compared EMBEDA to ER morphine sulfate. In this study 36 subjects were randomized to receive three treatments in solution: 120 mg/4.8 mg as crushed EMBEDA capsules, 120 mg crushed ER morphine, and placebo. When EMBEDA was crushed and taken orally, the geometric mean (±SD) values for naltrexone C_{max}, AUC_{0-2h}, and AUC_{inf} were 824 ± 469 pg/mL, 1121 ± 561 pg·hr/mL, and 2984 ± 1388 pg·hr/mL, respectively. The oral administration of crushed EMBEDA was associated with statistically significantly lower mean and median Drug Liking, Drug High, and Take Drug Again scores compared with crushed ER morphine (summarized in Table 3).

Figure 1 (Study 2) demonstrates a comparison of maximum Drug Liking for crushed EMBEDA compared to crushed ER morphine in subjects who received both treatments. Of the 33 subjects who completed the study, approximately 85% of subjects had some reduction in Drug Liking with crushed EMBEDA compared to administration of crushed ER morphine sulfate, while approximately 15% had no reduction in Drug Liking. Similarly, 100% of subjects showed some reduction in Drug High with crushed EMBEDA compared to crushed ER morphine. At least a 30% and 50% reduction in Drug Liking with crushed EMBEDA compared to crushed ER morphine was observed in 76% and 52% of subjects, respectively (summarized in Figure 1). At least a 30% and 50% reduction in Drug High with crushed EMBEDA was observed in 79% and 64% of subjects, respectively.

Table 3. Summary of Abuse Potential Maximal Responses (E_{max}) with Oral Administration of Crushed EMBEDA Compared to Crushed IR Morphine Sulfate (Study 1) or Crushed ER Morphine (Study 2)

<table>
<thead>
<tr>
<th>VAS Scale (100 point)</th>
<th>Crushed EMBEDA (120 mg/4.8 mg)</th>
<th>Crushed Morphine (120 mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>E_{max}</td>
<td>E_{max}</td>
</tr>
<tr>
<td></td>
<td>Immediate Release</td>
<td>Extended Release</td>
</tr>
<tr>
<td>Drug Liking*</td>
<td>Mean (SE) 68.1 (3.1)</td>
<td>89.5 (2.2)</td>
</tr>
<tr>
<td></td>
<td>Median (range) 62 (50-100)</td>
<td>93 (57-100)</td>
</tr>
<tr>
<td>Drug High**</td>
<td>Mean (SE) 54.7 (6.1)</td>
<td>90.2 (2.1)</td>
</tr>
<tr>
<td></td>
<td>Median (range) 64 (0-100)</td>
<td>97 (61-100)</td>
</tr>
<tr>
<td>Take Drug Again*</td>
<td>Mean (SE) 58.0 (3.8)</td>
<td>70.6 (4.3)</td>
</tr>
<tr>
<td></td>
<td>Median (range) 58 (9-100)</td>
<td>75 (12-100)</td>
</tr>
</tbody>
</table>

*Presented on bipolar 100-point Visual Analog Scales (VAS) (0=maximum negative response, 50=neutral response, 100=maximum positive response).
**Presented on a unipolar 100-point VAS scale (0=no response, 100=maximum response).

E_{max} = maximal response; ER = extended release; IR = immediate release; SE = standard error.
Figure 1: Percent Reduction Profiles for $E_{\text{max}}$ of Drug Liking VAS for EMBEDA vs. Morphine Following Oral Administration in Studies 1 and 2.

Intranasal Study
Study 3 compared intranasal administration of crushed EMBEDA to crushed ER morphine sulfate. In this study, 33 subjects were randomized to receive three treatments: 30 mg/1.2 mg as crushed EMBEDA, 30 mg crushed ER morphine, and crushed placebo. When EMBEDA was crushed and taken intranasally, the geometric mean ($\pm$SD) values for naltrexone $C_{\text{max}}$, $AUC_{0-2h}$, and $AUC_{\text{inf}}$ were $1441 \pm 411$ pg/mL, $1722 \pm 441$ pg·hr/mL and $3228 \pm 846$ pg·hr/mL, respectively. Intranasal administration of crushed EMBEDA was associated with statistically significantly lower mean and median Drug Liking, Drug High, and Take Drug Again scores compared with crushed ER morphine (summarized in Table 4).

Figure 2 demonstrates a comparison of maximum Drug Liking for intranasal administration of crushed EMBEDA compared to crushed ER morphine in subjects who received both treatments. Of the 27 subjects who completed the study, approximately 78% of subjects had some reduction in Drug Liking with crushed EMBEDA compared to administration of crushed ER morphine sulfate, while approximately 22% had no reduction in Drug Liking. Similarly, approximately 70% of subjects showed some reduction in Drug High with crushed EMBEDA compared to crushed ER morphine and approximately 30% of subjects had no reduction in Drug High. At least a 30% and 50% reduction in Drug Liking with crushed EMBEDA compared to crushed ER morphine was observed in 63% and 59% of subjects, respectively (summarized in Figure 2).
least a 30% and 50% reduction in Drug High with crushed EMBEDA was observed in 59% and 37% of subjects, respectively.

Table 4. Summary of Abuse Potential Maximal Responses ($E_{\text{max}}$) with Intranasal Administration of Crushed EMBEDA Compared to Crushed ER Morphine Sulfate (Study 3)

<table>
<thead>
<tr>
<th>VAS Scale (100 point)</th>
<th>$E_{\text{max}}$ Crushed EMBEDA (30 mg/1.2 mg)</th>
<th>$E_{\text{max}}$ Crushed ER Morphine (30 mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Liking*</td>
<td>Mean (SE) 69.0 (3.5)</td>
<td>88.4 (3.2)</td>
</tr>
<tr>
<td></td>
<td>Median (range) 66 (50-100)</td>
<td>100 (51-100)</td>
</tr>
<tr>
<td>Drug High**</td>
<td>Mean (SE) 48.6 (7.8)</td>
<td>84.4 (3.8)</td>
</tr>
<tr>
<td></td>
<td>Median (range) 51 (-39-100)</td>
<td>100 (42-100)</td>
</tr>
<tr>
<td>Take Drug Again*</td>
<td>Mean (SE) 59.1 (5.4)</td>
<td>87.0 (4.0)</td>
</tr>
<tr>
<td></td>
<td>Median (range) 56 (0-100)</td>
<td>100 (12-100)</td>
</tr>
</tbody>
</table>

* Presented on bipolar 100-point Visual Analog Scales (VAS) 0=maximum negative response, 50=neutral response, 100=maximum positive response.

**Presented on a unipolar 100-point VAS scale 0=no response, 100=maximum response).

Figure 2: Percent Reduction Profiles for $E_{\text{max}}$ of Drug Liking VAS for EMBEDA vs. Morphine Following Intranasal Administration in Study 3.

Simulated IV Study

Study 4, a randomized double-blind, placebo-controlled, three-way cross-over trial in 28 non-dependent recreational opioid users, was performed using 30 mg of intravenous (IV) morphine sulfate alone and 30 mg of IV morphine sulfate in combination with 1.2 mg of IV naltrexone to simulate parenteral use of crushed EMBEDA. These doses were based on the assumption of the complete release of both morphine sulfate and naltrexone hydrochloride upon crushing EMBEDA. Intravenous administration of the combination of morphine sulfate and naltrexone hydrochloride was associated with statistically significantly lower mean and median.
Drug Liking and Drug High scores (median scores 34 and 23, respectively) compared with morphine alone (median scores 86 and 89, respectively). Three of the 26 subjects who completed the study had no reduction in Drug Liking and all the subjects showed some reduction in Drug High. Intravenous injection of crushed EMBEDA may result in serious injury and death due to a morphine overdose and may precipitate a severe withdrawal syndrome in opioid-dependent patients.

**Summary**
The in vitro and pharmacokinetic data demonstrate that crushing EMBEDA pellets results in the simultaneous release and rapid absorption of morphine sulfate and naltrexone hydrochloride. These data along with results from the oral and intranasal human abuse potential studies indicate that EMBEDA has properties that are expected to reduce abuse via the oral and intranasal route. However, abuse of EMBEDA by these routes is still possible.

Additional data, including epidemiological data, when available, may provide further information on the impact of the current formulation of EMBEDA on the abuse liability of the drug. Accordingly, this section may be updated in the future as appropriate.

A human abuse potential study of intravenous morphine and naltrexone to simulate crushed EMBEDA demonstrated lower Drug Liking and Drug High compared with morphine alone. However, it is unknown whether these results with simulated crushed EMBEDA predict a reduction in abuse by the IV route until additional postmarketing data are available.

EMBEDA contains morphine sulfate, an opioid agonist and Schedule II controlled substance with an abuse liability similar to other opioid agonists, legal and illicit, including fentanyl, hydromorphone, methadone, oxycodone, and oxymorphone. EMBEDA can be abused and is subject to misuse, addiction, and criminal diversion

**OXYCONTIN (oxycodone hydrochloride) extended-release tablets [NDA 022272]**

Approval Date: April 5, 2010
Abuse Deterrence Labeling Update: April 16, 2013

**Abuse Deterrence Studies**
OXYCONTIN is formulated with inactive ingredients intended to make the tablet more difficult to manipulate for misuse and abuse. For the purposes of describing the results of studies of the abuse-deterrent characteristics of OXYCONTIN resulting from a change in formulation, in this section, the original formulation of OXYCONTIN, which is no longer marketed, will be referred to as “original OxyContin” and the reformulated, currently marketed product will be referred to as “OXYCONTIN”.

**In Vitro Testing**
In vitro physical and chemical tablet manipulation studies were performed to evaluate the success of different extraction methods in defeating the extended-release formulation. Results support that, relative to original OxyContin, there is an increase in the ability of OXYCONTIN to resist crushing, breaking, and dissolution using a variety of tools and solvents. The results of these studies also support this finding for OXYCONTIN relative to an immediate-release oxycodone. When subjected to an aqueous environment, OXYCONTIN gradually forms a viscous hydrogel (i.e., a gelatinous mass) that resists passage through a needle.

**Clinical Studies**

In a randomized, double-blind, placebo-controlled 5-period crossover pharmacodynamic study, 30 recreational opioid users with a history of intranasal drug abuse received intranasally administered active and placebo drug treatments. The five treatment arms were finely crushed OXYCONTIN 30 mg tablets, coarsely crushed OXYCONTIN 30 mg tablets, finely crushed original OxyContin 30 mg tablets, powdered oxycodone HCl 30 mg, and placebo. Data for finely crushed OXYCONTIN, finely crushed original OxyContin, and powdered oxycodone HCl are described below.

Drug liking was measured on a bipolar drug liking scale of 0 to 100 where 50 represents a neutral response of neither liking nor disliking, 0 represents maximum disliking and 100 represents maximum liking. Response to whether the subject would take the study drug again was also measured on a bipolar scale of 0 to 100 where 50 represents a neutral response, 0 represents the strongest negative response (“definitely would not take drug again”) and 100 represents the strongest positive response (“definitely would take drug again”).

Twenty-seven of the subjects completed the study. Incomplete dosing due to granules falling from the subjects’ nostrils occurred in 34% (n = 10) of subjects with finely crushed OXYCONTIN, compared with 7% (n = 2) of subjects with finely crushed original OxyContin and no subjects with powdered oxycodone HCl.

The intranasal administration of finely crushed OXYCONTIN was associated with a numerically lower mean and median drug liking score and a lower mean and median score for take drug again, compared to finely crushed original OxyContin or powdered oxycodone HCl as summarized in Table 4.
Table 4: Summary of Maximum Drug Liking ($E_{\text{max}}$) Data Following Intranasal Administration

<table>
<thead>
<tr>
<th>VAS Scale (100 mm)*</th>
<th>OXYCONTIN (finely crushed)</th>
<th>Original OxyContin (finely crushed)</th>
<th>Oxycodone HCl (powdered)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Liking</td>
<td>Mean (SE)</td>
<td>80.4 (3.9)</td>
<td>94.0 (2.7)</td>
</tr>
<tr>
<td></td>
<td>Median (Range)</td>
<td>88 (36-100)</td>
<td>100 (51-100)</td>
</tr>
<tr>
<td>Take Drug Again</td>
<td>Mean (SE)</td>
<td>64.0 (7.1)</td>
<td>89.6 (3.9)</td>
</tr>
<tr>
<td></td>
<td>Median (Range)</td>
<td>78 (0-100)</td>
<td>100 (20-100)</td>
</tr>
</tbody>
</table>

* Bipolar scales (0 = maximum negative response, 50 = neutral response, 100 = maximum positive response)

Figure 1 demonstrates a comparison of drug liking for finely crushed OXYCONTIN compared to powdered oxycodone HCl in subjects who received both treatments. The Y-axis represents the percent of subjects attaining a percent reduction in drug liking for OXYCONTIN vs. oxycodone HCl powder greater than or equal to the value on the X-axis. Approximately 44% (n = 12) had no reduction in liking with OXYCONTIN relative to oxycodone HCl. Approximately 56% (n = 15) of subjects had some reduction in drug liking with OXYCONTIN relative to oxycodone HCl. Thirty-three percent (n = 9) of subjects had a reduction of at least 30% in drug liking with OXYCONTIN compared to oxycodone HCl, and approximately 22% (n = 6) of subjects had a reduction of at least 50% in drug liking with OXYCONTIN compared to oxycodone HCl.
The results of a similar analysis of drug liking for finely crushed OXYCONTIN relative to finely crushed original OxyContin were comparable to the results of finely crushed OXYCONTIN relative to powdered oxycodone HCl. Approximately 43% (n = 12) of subjects had no reduction in liking with OXYCONTIN relative to original OxyContin. Approximately 57% (n = 16) of subjects had some reduction in drug liking, 36% (n = 10) of subjects had a reduction of at least 30% in drug liking, and approximately 29% (n = 8) of subjects had a reduction of at least 50% in drug liking with OXYCONTIN compared to original OxyContin.

Summary
The in vitro data demonstrate that OXYCONTIN has physicochemical properties expected to make abuse via injection difficult. The data from the clinical study, along with support from the in vitro data, also indicate that OXYCONTIN has physicochemical properties that are expected to reduce abuse via the intranasal route. However, abuse of OXYCONTIN by these routes, as well as by the oral route, is still possible.

Additional data, including epidemiological data, when available, may provide further information on the impact of the current formulation of OXYCONTIN on the abuse liability of the drug. Accordingly, this section may be updated in the future as appropriate.

OXYCONTIN contains oxycodone, an opioid agonist and Schedule II controlled substance with an abuse liability similar to other opioid agonists, legal or illicit, including fentanyl,
hydromorphone, methadone, morphine, and oxymorphone. OXYCONTIN can be abused and is subject to misuse, addiction, and criminal diversion.

**TARGINIQ ER (oxycodone hydrochloride and naloxone hydrochloride) extended-release tablets [NDA 205777]**

Approval Date: July 23, 2014

**Abuse Deterrence Studies**

**In Vitro Testing**

In vitro physical and chemical tablet manipulation studies were performed to evaluate the success of different extraction methods in defeating the controlled-release formulation of TARGINIQ ER and separating the oxycodone component from naloxone, a potent opioid antagonist. Laboratory test data demonstrate that TARGINIQ ER can be crushed and dissolved in solution. However, complete separation or complete inactivation of naloxone from oxycodone was not achieved despite using various techniques and conditions.

**Clinical Abuse Potential Studies**

In the clinical abuse potential studies described below, drug-liking was measured on a bipolar drug liking scale of 0 to 100 where 50 represents a neutral response of neither liking nor disliking, 0 represents maximum disliking and 100 represents maximum liking. Response to whether the subject would take the study drug again was measured on a unipolar scale of 0 to 100 where 0 represents the strongest negative response (“definitely would not take drug again”) and 100 represents the strongest positive response (“definitely would take drug again”). Response to subjective feeling of getting “high” was measured on a unipolar scale of 0 to 100, where 0 represents “definitely not” and 100 represents “definitely so”.

**Study in Non-Dependent, Opioid Abusers (Intranasal (IN) Administration)**

In a randomized, double-blind, placebo- and active-controlled, 3-period crossover pharmacodynamic study, 23 non-dependent, opioid abusers with moderate experience with opioids received IN administered TARGINIQ ER 40 mg/20 mg (finely crushed tablets), oxycodone HCl 40 mg powder (active control), and placebo treatments.

IN administration of finely crushed TARGINIQ ER was associated with statistically significant lower maximum drug liking scores \((p < 0.001)\) and statistically significant lower maximum scores for take drug again \((p < 0.001)\), compared to powdered oxycodone HCl, and was associated with similar mean and median maximum scores for drug liking and take drug again, compared to placebo treatment, as summarized in Table 5.
Table 5. Summary of Maximum Drug Liking (\(E_{\text{max}}\)) and Take Drug Again (\(E_{\text{max}}\)) Following Intranasal (IN) Administration of TARGINIQ ER, Oxycodone, and Placebo in Non-Dependent, Opioid Abusers (N=23)

<table>
<thead>
<tr>
<th>VAS</th>
<th>TARGINIQ ER 40 mg/20 mg (finely crushed)</th>
<th>Oxycodone HCl 40 mg (powdered)</th>
<th>Placebo (lactose powder)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Liking*</td>
<td>Mean (SE)</td>
<td>59.1 (2.8)</td>
<td>94.8 (2.2)</td>
</tr>
<tr>
<td></td>
<td>Median (Range)</td>
<td>51 (50-100)</td>
<td>100 (61-100)</td>
</tr>
<tr>
<td>Take Drug Again**</td>
<td>Mean (SE)</td>
<td>42.6 (6.4)</td>
<td>93.6 (2.3)</td>
</tr>
<tr>
<td></td>
<td>Median (Range)</td>
<td>50.0 (0-100)</td>
<td>100 (62-100)</td>
</tr>
</tbody>
</table>

VAS: visual analog scale  
SE: standard error  
* Drug Liking Question text: “At this moment, my liking for this drug is”; scale: 0 = maximum disliking, 50 = neither liking nor disliking (neutral response), 100 = maximum liking.  
**Take Drug Again Question text: “I would take this drug again”; scale: 0 = definitely not, 100 = definitely so.

Figure 1 demonstrates a comparison of maximum drug liking for finely crushed TARGINIQ ER compared to powdered oxycodone HCl in subjects who received both treatments. The Y-axis represents the percent of subjects attaining a percent reduction in maximum drug liking for TARGINIQ ER vs. oxycodone HCl powder greater than or equal to the value on the X-axis. Among non-dependent, opioid drug abusers, 78% (n = 18) of subjects had a reduction of at least 30% in maximum drug liking with TARGINIQ ER compared to oxycodone HCl, and approximately 74% (n = 17) of subjects had a reduction of at least 50% in maximum drug liking with TARGINIQ ER compared to oxycodone HCl.
Figure 1. Percent Reduction in Maximum Drug Liking for Finely Crushed TARGINIQ ER 40 mg/20 mg vs. Powdered Oxycodone HCl 40 mg Following Intranasal Administration in Non-Dependent Opioid Abusers

Study in Non-Dependent, Opioid Abusers (Intravenous (IV) Administration)
In a randomized, double-blind, placebo- and active-controlled, 3-period crossover pharmacodynamic study, 22 non-dependent, opioid abusers with moderate experience with opioids received intravenously administered 0.07 mg/kg oxycodone HCl and 0.035 mg/kg naloxone HCl solution (simulated version of TARGINIQ ER), oxycodone HCl (0.07 mg/kg solution; active control) and placebo (saline) treatments.

The intravenous administration of simulated TARGINIQ ER solution was associated with statistically significant lower maximum drug liking scores ($p < 0.001$) and statistically significant lower maximum scores for take drug again ($p < 0.001$), compared to oxycodone solution, and was associated with similar mean and median scores for drug liking and take drug again, compared to placebo treatment, as summarized in Table 6.
Table 6. Summary of Maximum Drug Liking ($E_{max}$) and Take Drug Again Following IV Administration of Oxycodone HCl + Naloxone HCl (Simulated TARGINIQ ER Solution), Oxycodone HCl, and Placebo in Non-Dependent, Opioid Abusers (N=22)

<table>
<thead>
<tr>
<th>VAS</th>
<th>Oxycodone HCl/ Naloxone HCl 0.07/0.35 mg/kg</th>
<th>Oxycodone HCl 0.07 mg/kg</th>
<th>Placebo saline (0.9% NaCl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Liking*</td>
<td>Mean (SE)</td>
<td>56.5 (2.8)</td>
<td>96.4 (2.3)</td>
</tr>
<tr>
<td></td>
<td>Median (Range)</td>
<td>51 (50-100)</td>
<td>100 (50-100)</td>
</tr>
<tr>
<td>Take Drug Again**</td>
<td>Mean (SE)</td>
<td>37.0 (6.2)</td>
<td>82.0 (6.0)</td>
</tr>
<tr>
<td></td>
<td>Median (Range)</td>
<td>50.0 (0-100)</td>
<td>99.0 (0-100)</td>
</tr>
</tbody>
</table>

VAS: visual analog scale  
SE: standard error  
* Drug Liking Question text: “At this moment, my liking for this drug is”; scale: 0 = maximum disliking, 50 = neither liking nor disliking (neutral response), 100 = maximum liking.  
**Take Drug Again Question text: “I would take this drug again”; scale: 0 = definitely not, 100 = definitely so; Values obtained at 8 hours post dose.

Figure 2 demonstrates a comparison of maximum drug liking for simulated TARGINIQ ER solution compared to oxycodone HCl solution in subjects who received both treatments. Among non-dependent, opioid drug abusers, approximately 91% (n = 20) of subjects had a reduction of at least 50% in maximum drug liking with TARGINIQ ER compared to oxycodone solution.

Figure 2. Percent Reduction in Maximum Drug Liking for Oxycodone 0.07 mg/kg + Naloxone 0.035 mg/kg (Simulated TARGINIQ ER) vs. Oxycodone HCl 0.07 mg/kg Following Intravenous Administration in Non-Dependent, Opioid Abusers
Study in Opioid-Dependent Subjects

In a randomized, double-blind, placebo- and positive-controlled, 4-period crossover pharmacodynamic study, 29 opioid-dependent, methadone-maintained subjects received orally administered TARGINIQ ER 60 mg/30 mg chewed and intact tablets, oxycodone HCl solution 60 mg (active control) and placebo (chewed and intact tablets and solution) treatments.

The oral administration of TARGINIQ ER, either chewed or intact, was associated with statistically significant lower maximum drug liking scores \( p < 0.001 \) and statistically significant lower scores for take drug again \( p < 0.001 \), compared to oxycodone solution, and was associated with similar mean and median maximum scores for drug liking and take drug again, compared to placebo treatment, as summarized in Table 7.

Table 7. Summary of High, Maximum Drug Liking (E_{max}), and Take Drug Again Following Oral Administration of TARGINIQ ER (Intact and Chewed), Oxycodone HCl solution, and Placebo in Opioid-Dependent Subjects (N=29)

<table>
<thead>
<tr>
<th>VAS</th>
<th>TARGINIQ ER 60 mg/30 mg intact</th>
<th>TARGINIQ ER 60 mg/30 mg chewed</th>
<th>Oxycodone HCl solution 60 mg</th>
<th>Placebo chewed and intact tablet, solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Liking*</td>
<td>Mean (SE) 54.7 (2.0)</td>
<td>54.6 (3.2)</td>
<td>77.9 (3.8)</td>
<td>54.4 (2.1)</td>
</tr>
<tr>
<td></td>
<td>Median (Range) 51.0 (50-99)</td>
<td>51.0 (0-100)</td>
<td>78.0 (50-100)</td>
<td>51.0 (50-100)</td>
</tr>
<tr>
<td>Take Drug Again**</td>
<td>Mean (SE) 38.5 (5.7)</td>
<td>32.6 (5.9)</td>
<td>61.4 (5.9)</td>
<td>41.5 (5.0)</td>
</tr>
<tr>
<td></td>
<td>Median (Range) 50.0 (0-100)</td>
<td>50.0 (0-100)</td>
<td>50.0 (0-100)</td>
<td>50.0 (0-100)</td>
</tr>
<tr>
<td>Getting High***</td>
<td>Mean (SE) 20.6 (5.1)</td>
<td>27.7 (6.5)</td>
<td>77.9 (5.0)</td>
<td>20.6 (5.0)</td>
</tr>
<tr>
<td></td>
<td>Median (Range) 1.0 (0-73)</td>
<td>1.0 (0-100)</td>
<td>86.0 (0-100)</td>
<td>1.0 (0-82)</td>
</tr>
</tbody>
</table>

VAS: visual analog scale  
SE: standard error  
* Drug Liking Question text: “At this moment, my liking for this drug is”; scale: 0 = maximum disliking, 50 = neither liking nor disliking (neutral response), 100 = maximum liking.  
**Take Drug Again Question text: “I would take this drug again”; scale: 0 = definitely not, 100 = definitely so; Values obtained at 12 hours post dose.  
***Getting High Question Text: “I am feeling high”; scale: 0 = definitely not, 100 = definitely so.

Figure 3 demonstrates a comparison of maximum drug liking \( (E_{max}) \) for TARGINIQ ER either chewed or intact compared to oxycodone solution in subjects who received both treatments. Among opioid-dependent subjects, 69.0% \( (n = 20) \) had a reduction of at least 30%, and 65.5% \( (n = 19) \) of subjects had a reduction of at least 50% in maximum drug liking with chewed TARGINIQ ER tablets compared to oxycodone solution; 79.3% \( (n = 23) \) of subjects had a
reduction at least 50% in maximum drug liking with intact TARGINIQ ER tablets compared to oxycodone solution.

**Figure 3. Percent Reduction in Maximum Drug Liking for TARGINIQ ER 60 mg/30 mg Chewed or Intact vs. Oxycodone HCl 60 mg Solution Following Oral Administration in Opioid-Dependent Subjects**

### Summary
Based on the *in vitro* study results, it is expected that abuse of oxycodone from physically and chemically manipulated TARGINIQ ER tablets will be deterred by the inability to separate the two active components.

The data from the clinical abuse potential studies indicate that TARGINIQ ER has pharmacologic properties that are expected to reduce abuse via the intranasal and intravenous routes of administration. However, abuse of TARGINIQ ER by these routes is still possible.

Additional data, including epidemiological data, when available, may provide further information on the impact of TARGINIQ ER on the abuse liability of the drug in the community. Accordingly, this section may be updated in the future as appropriate.
Targiniq ER contains oxycodone, an opioid agonist and Schedule II controlled substance with an abuse liability similar to other opioid agonists, legal or illicit, including fentanyl, hydromorphone, methadone, morphine, and oxymorphone. Targiniq ER can be abused and is subject to misuse, addiction, and criminal diversion.

**Hysingla ER (Hydrocodone Bitartrate) Extended-Release Tablets [NDA 206627]**

Approval Date: November 20, 2014

*Abuse Deterrence Studies*

Hysingla ER is formulated with physicochemical properties intended to make the tablet more difficult to manipulate for misuse and abuse, and maintains some extended release characteristics even if the tablet is physically compromised. To evaluate the ability of these physicochemical properties to reduce the potential for abuse of Hysingla ER, a series of in vitro laboratory studies, pharmacokinetic studies and clinical abuse potential studies was conducted. A summary is provided at the end of this section.

*In Vitro Testing*

In vitro physical and chemical tablet manipulation studies were performed to evaluate the success of different extraction methods in defeating the extended-release formulation. Results support that Hysingla ER resists crushing, breaking, and dissolution using a variety of tools and solvents and retains some extended-release properties despite manipulation. When subjected to an aqueous environment, Hysingla ER gradually forms a viscous hydrogel (i.e., a gelatinous mass) that resists passage through a hypodermic needle.

*Clinical Abuse Potential Studies*

**Studies in Non-dependent Opioid Abusers**

Two randomized, double-blind, placebo and active-comparator studies in non-dependent opioid abusers were conducted to characterize the abuse potential of Hysingla ER following physical manipulation and administration via the intranasal and oral routes. For both studies, drug liking was measured on a bipolar drug liking scale of 0 to 100 where 50 represents a neutral response of neither liking nor disliking, 0 represents maximum disliking, and 100 represents maximum liking. Response to whether the subject would take the study drug again was measured on a unipolar scale of 0 to 100 where 0 represents the strongest negative response (“definitely would not take drug again”) and 100 represents the strongest positive response (“definitely would take drug again”).

**Intranasal Abuse Potential Study**

In the intranasal abuse potential study, 31 subjects were dosed and 25 subjects completed the study. Treatments studied included intranasally administered tampered Hysingla ER 60 mg tablets, powdered hydrocodone bitartrate 60 mg, and placebo. Incomplete dosing due to granules...
falling from the subjects’ nostrils occurred in 82% (n = 23) of subjects receiving tampered HYSINGLA ER compared to no subjects with powdered hydrocodone or placebo.

The intranasal administration of tampered HYSINGLA ER was associated with statistically significantly lower mean and median scores for drug liking and take drug again (P<0.001 for both), compared with powdered hydrocodone as summarized in Table 3.

Table 3. Summary of Maximum Scores (E_{max}) on Drug Liking and Take Drug Again VAS Following intranasal Administration of HYSINGLA ER and Hydrocodone Powder in Non-depended Opioid Abusers

<table>
<thead>
<tr>
<th>VAS Scale (100 point)</th>
<th>HYSINGLA ER Manipulated</th>
<th>Hydrocodone Powder</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Liking*</td>
<td>65.4 (3.7)</td>
<td>90.4 (2.6)</td>
</tr>
<tr>
<td>Mean (SE)</td>
<td>65.4 (3.7)</td>
<td>90.4 (2.6)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>56 (50–100)</td>
<td>100 (51–100)</td>
</tr>
<tr>
<td>Take Drug Again**</td>
<td>36.4 (8.2)</td>
<td>85.2 (5.0)</td>
</tr>
<tr>
<td>Mean (SE)</td>
<td>36.4 (8.2)</td>
<td>85.2 (5.0)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>14 (0–100)</td>
<td>100 (1–100)</td>
</tr>
</tbody>
</table>

*Bipolar scale (0=maximum negative response, 50=neutral response, 100=maximum positive response)  ** Unipolar scale (0=maximum negative response, 100=maximum positive response)

Figure 1 demonstrates a comparison of peak drug liking scores for tampered HYSINGLA ER compared with powdered hydrocodone in subjects (n = 25) who received both treatments intranasally. The Y-axis represents the percent of subjects attaining a percent reduction in peak drug liking scores for tampered HYSINGLA ER vs. hydrocodone powder greater than or equal to the value on the X-axis.

Approximately 80% (n = 20) of subjects had some reduction in drug liking with tampered HYSINGLA ER relative to hydrocodone powder. Sixty-eight percent (n = 17) of subjects had a reduction of at least 30% in drug liking with tampered HYSINGLA ER compared with hydrocodone powder, and approximately 64% (n = 16) of subjects had a reduction of at least 50% in drug liking with tampered HYSINGLA ER compared with hydrocodone powder. Approximately 20% (n = 5) of subjects had no reduction in liking with tampered HYSINGLA ER relative to hydrocodone powder.
Oral Abuse Potential Study

In the oral abuse potential study, 40 subjects were dosed and 35 subjects completed the study. Treatments studied included oral administrations of chewed HYSINGLA ER 60 mg tablets, intact HYSINGLA ER 60 mg tablets, 60 mg aqueous hydrocodone bitartrate solution, and placebo.

The oral administration of chewed and intact HYSINGLA ER was associated with statistically lower mean and median scores on scales that measure drug liking and desire to take drug again (P<0.001), compared to hydrocodone solution as summarized in Table 4.

Table 4. Summary of Maximum Scores ($E_{\text{max}}$) on Drug Liking and Take Drug Again VAS Following Oral Administration of HYSINGLA ER and Hydrocodone Solution in Non-dependent Recreational Opioid Users

<table>
<thead>
<tr>
<th>VAS Scale (100 point)</th>
<th>HYSINGLA ER</th>
<th>Hydrocodone Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral (n=35)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Liking*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SE)</td>
<td>63.3 (2.7)</td>
<td>69.0 (3.0)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>58 (50–100)</td>
<td>66 (50–100)</td>
</tr>
<tr>
<td>Take Drug Again**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SE)</td>
<td>34.3 (6.1)</td>
<td>44.3 (6.9)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>24 (0–100)</td>
<td>55 (0–100)</td>
</tr>
</tbody>
</table>

*Bipolar scale (0=maximum negative response, 50=neutral response, 100=maximum positive response)

** Unipolar scale (0=maximum negative response, 100=maximum positive response)
Figure 2 demonstrates a comparison of peak drug liking scores for chewed HYSINGLA ER compared with hydrocodone solution in subjects who received both treatments orally. The Y-axis represents the percent of subjects attaining a percent reduction in peak drug liking scores for chewed HYSINGLA ER vs. hydrocodone solution greater than or equal to the value on the X-axis.

Approximately 80% (n = 28) of subjects had some reduction in drug liking with chewed HYSINGLA ER relative to hydrocodone solution. Approximately 69% (n = 24) of subjects had a reduction of at least 30% in drug liking with chewed HYSINGLA ER compared with hydrocodone solution, and approximately 60% (n = 21) of subjects had a reduction of at least 50% in drug liking with chewed HYSINGLA ER compared with hydrocodone solution. Approximately 20% (n = 7) of subjects had no reduction in drug liking with chewed HYSINGLA ER relative to hydrocodone solution.

The results of a similar analysis of drug liking for intact HYSINGLA ER relative to hydrocodone solution were comparable to the results of chewed HYSINGLA ER relative to hydrocodone solution. Approximately 83% (n = 29) of subjects had some reduction in drug liking with intact HYSINGLA ER relative to hydrocodone solution. Eighty-three percent (n = 29) of subjects had a reduction of at least 30% in peak drug liking scores with intact HYSINGLA ER compared to hydrocodone solution, and approximately 74% (n = 26) of subjects had a reduction of at least 50% in peak drug liking scores with intact HYSINGLA ER compared to hydrocodone solution.

Figure 2. Percent Reduction Profiles for \( E_{\text{max}} \) of Drug Liking VAS for Chewed HYSINGLA ER vs. Hydrocodone Solution, N = 35 Following Oral Administration

The results of a similar analysis of drug liking for intact HYSINGLA ER relative to hydrocodone solution were comparable to the results of chewed HYSINGLA ER relative to hydrocodone solution. Approximately 83% (n = 29) of subjects had some reduction in drug liking with intact HYSINGLA ER relative to hydrocodone solution. Eighty-three percent (n = 29) of subjects had a reduction of at least 30% in peak drug liking scores with intact HYSINGLA ER compared to hydrocodone solution, and approximately 74% (n = 26) of subjects had a reduction of at least 50% in peak drug liking scores with intact HYSINGLA ER compared to hydrocodone solution.
50% in peak drug liking scores with intact HYSINGLA ER compared with hydrocodone solution. Approximately 17% (n = 6) had no reduction in drug liking with intact HYSINGLA ER relative to hydrocodone solution.

**Summary**
The in vitro data demonstrate that HYSINGLA ER has physical and chemical properties that are expected to deter intranasal and intravenous abuse. The data from the clinical abuse potential studies, along with support from the in vitro data, also indicate that HYSINGLA ER has physicochemical properties that are expected to reduce intranasal abuse and oral abuse when chewed. However, abuse of HYSINGLA ER by the intravenous, intranasal, and oral routes is still possible.

Additional data, including epidemiological data, when available, may provide further information on the impact of HYSINGLA ER on the abuse liability of the drug. Accordingly, this section may be updated in the future as appropriate.

HYSINGLA ER contains hydrocodone, an opioid agonist and Schedule II controlled substance with an abuse liability similar to other opioid agonists, legal or illicit, including fentanyl, hydromorphone, methadone, morphine, oxycodone, and oxymorphone. HYSINGLA ER can be abused and is subject to misuse, addiction, and criminal diversion.

**MORPHABOND (morphine sulfate) extended-release tablets [NDA 206544]**

Approval Date: October 2, 2015

**Abuse Deterrence Studies**
MORPHABOND is formulated with inactive ingredients that make the tablet more difficult to adulterate for misuse and abuse while maintaining extended-release characteristics even if the tablet is subjected to physical manipulation, and/or chemical extraction. To evaluate the ability of the abuse-deterrent technology to reduce the potential for abuse of MORPHABOND, a series of in vitro laboratory manipulation, extraction, and syringeability, studies was conducted. An in vivo clinical abuse potential study was also conducted. The results of these studies are summarized below. Overall, the results indicate that MORPHABOND has properties that are expected to reduce abuse or misuse via injection or insufflation; however, abuse by these routes is still possible.

**In Vitro Testing**
MORPHABOND has been tested in vitro using methods of manipulation that drug abusers commonly use for preparation of extended-release opioids for administration by various routes, including oral consumption, intranasal insufflation, injection, and smoking.

Abusers may manipulate extended-release opioids in order to prepare the tablets for oral, intranasal, or intravenous administration. The laboratory test data demonstrated that, relative to
morphine sulfate extended-release tablet, MORPHABOND has increased resistance to cutting, crushing, or breaking using a variety of tools. When subjected to a liquid environment the manipulated MORPHABOND formulation forms a viscous material that resists passage through a needle.

**Clinical Studies**
A randomized, double-blind, double-dummy, placebo-controlled, single-dose four-way crossover study in 25 non-dependent recreational opioid users with a history of intranasal drug abuse was performed to determine the relative bioavailability and abuse potential of crushed intranasal MORPHABOND 60 mg tablets compared with crushed intranasal morphine sulfate extended-release tablet 60 mg tablets, and intact orally administered MORPHABOND 60 mg tablets. The intact oral tablets were included as a reference for evaluating abuse potential after manipulation and administration via an unintended route.

Drug liking was measured on a 100 mm bipolar visual analog scale (VAS) where 50 represents a neutral response of neither liking nor disliking, 0 represents maximum disliking, and 100 represents maximum liking. Response to whether the subject would take the study drug again was also measured on a bipolar scale of 0 to 100 where 50 represents a neutral response, 0 represents the strongest negative response (‘definitely would not take drug again’) and 100 represents the strongest positive response (‘definitely would take drug again’).

Intranasal administration of crushed MORPHABOND was associated with statistically significantly lower drug liking ($E_{\text{max}}$) scores ($P < 0.0001$), and significantly lower willingness to take the drug again ($E_{\text{max}}$) scores ($P = 0.034$), compared to crushed extended-release morphine (Table 2). Drug liking and take drug again scores for crushed intranasal MORPHABOND were not significantly different from those of MORPHABOND taken orally intact. These data are consistent with the similar relative bioavailability after crushed intranasal and intact oral administration of MORPHABOND that support retention of its extended release properties when manipulated compared to morphine sulfate extended-release tablets.
Figure 1 demonstrates a comparison of peak drug liking scores for crushed MORPHABOND compared to crushed extended-release morphine in subjects who received both treatments intranasally. Seventy-six percent of subjects (n = 19) experienced some reduction in $E_{\text{max}}$ of Drug Liking VAS with crushed MORPHABOND compared with crushed extended-release morphine, 48%; (n = 12) experienced at least a 30% reduction in $E_{\text{max}}$ and 32% (n = 8) experienced at least a 50% reduction in $E_{\text{max}}$ of drug liking.

**Figure 1. Percent Reduction Profiles for $E_{\text{max}}$ of Drug Liking for MORPHABOND vs. Morphine Sulfate ER Tablets (n=25), Following Intranasal Administration**

<table>
<thead>
<tr>
<th></th>
<th>Crushed Intranasal MORPHABOND 60 mg</th>
<th>Crushed Intranasal morphine sulfate extended-release tablet 60 mg</th>
<th>Placebo</th>
<th>Crushed Intranasal morphine sulfate extended-release tablet vs. Crushed Intranasal MORPHABOND Difference of LS Means (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Liking ($E_{\text{max}}$) Mean (SEM)</td>
<td>71.7 (2.87)</td>
<td>85.3 (2.42)</td>
<td>54.3 (1.63)</td>
<td>13.65 (7.80, 19.51)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>72 (50-100)</td>
<td>85 (56-100)</td>
<td>51 (50-80)</td>
<td></td>
</tr>
<tr>
<td>Take Drug Again ($E_{\text{max}}$) Mean (SEM)</td>
<td>66.4 (3.76)</td>
<td>76.4 (4.17)</td>
<td>49.1 (2.21)</td>
<td>9.96 (0.77, 19.14)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>64.0 (38-100)</td>
<td>75.0 (17-100)</td>
<td>50.0 (0-64)</td>
<td></td>
</tr>
</tbody>
</table>

**Summary**
The in vitro data demonstrate that MORPHABOND has physiochemical properties expected to make abuse via injection difficult. The data from the clinical study, along with support from in
vitro data, also indicate that MORPHABOND has physicochemical properties that are expected to reduce abuse by the intranasal route of administration. However, abuse by intranasal, intravenous, and oral routes is still possible. Additional data, including epidemiological data, when available, may provide further information on the impact of the current formulation of MORPHABOND on the abuse liability of the drug.

**XTAMPZA ER (oxycodone) extended-release capsules [NDA 208090]**

*Approval Date:  April 26, 2016*

**Abuse Deterrence Studies**

XTAMPZA ER capsules contain microspheres formulated with inactive ingredients intended to make the formulation more difficult to manipulate for misuse and abuse.

**In Vitro Testing**

In vitro physical and chemical manipulation studies were performed to evaluate the success of different methods of defeating the extended-release formulation.

Results support that, relative to immediate-release oxycodone tablets, XTAMPZA ER is less susceptible to the effects of grinding, crushing, and extraction using a variety of tools and solvents.

XTAMPZA ER resisted attempts to pass the melted capsule contents or the microspheres suspended in water through a hypodermic needle.

**Pharmacokinetic Studies**

The pharmacokinetic profile of manipulated XTAMPZA ER capsule contents (36 mg; equivalent to 40 mg oxycodone HCl) was characterized following oral (two studies) and intranasal (two studies) administration. The studies were conducted in a randomized, cross-over design. In studies assessing manipulation by crushing, the most effective crushing method identified in previous in vitro studies was applied to the product(s).

**Oral Pharmacokinetic Studies, Manipulated and Intact XTAMPZA ER**

The effect of two types of product manipulation (crushing and chewing) on XTAMPZA ER pharmacokinetics was measured in two studies.

In Oral Pharmacokinetic Study 1, XTAMPZA ER capsule contents were crushed or chewed prior to oral administration in healthy, naltrexone blocked volunteers. The two comparators in this study were intact XTAMPZA ER capsules and an immediate-release solution of oxycodone.

In Oral Pharmacokinetic Study 2, XTAMPZA ER capsule contents were crushed prior to oral administration in healthy, naltrexone-blocked volunteers. The comparators in this study included intact XTAMPZA ER capsules and crushed immediate-release oxycodone tablets.
The pharmacokinetic data displayed in Table 3 illustrate the findings from these two studies. Collectively, the data from the two studies demonstrated that crushing or chewing XTAMPZA ER prior to administration did not increase the maximum observed plasma concentration (C\text{max}) or total exposure (AUC\text{0-INF}) relative to dosing the intact product under fed conditions. Relative to immediate-release oxycodone, the C\text{max} for all XTAMPZA ER treatments was significantly lower and the T\text{max} significantly longer, consistent with an extended-release profile.

Table 3: Oxycodone Pharmacokinetic Parameters, Administration of Manipulated Capsule Contents and Intact Capsules (36 mg)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>C\text{max} (ng/mL)</th>
<th>T\text{max} (hr)</th>
<th>AUC\text{0-INF} (hr*ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral Pharmacokinetic Study 1</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intact XTAMPZA ER Capsules (fed)</td>
<td>62.3 (13.0)</td>
<td>4.0 (1.5-6)</td>
<td>561 (124)</td>
</tr>
<tr>
<td>Crushed XTAMPZA ER Capsule Contents (fed)</td>
<td>57.6 (12.6)</td>
<td>4.5 (2.5-6)</td>
<td>553 (134)</td>
</tr>
<tr>
<td>Chewed XTAMPZA ER Capsule Contents (fed)</td>
<td>55.6 (10.9)</td>
<td>4.5 (2.5-8)</td>
<td>559 (113)</td>
</tr>
<tr>
<td>Immediate-Release Oxycodone Solution (fasted)</td>
<td>115 (27.3)</td>
<td>0.75 (0.5-2)</td>
<td>489 (80.2)</td>
</tr>
<tr>
<td><strong>Oral Pharmacokinetic Study 2</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intact XTAMPZA ER Capsules (fed)</td>
<td>67.5 (17.6)</td>
<td>3.5 (1.25 – 6.0)</td>
<td>581 (138)</td>
</tr>
<tr>
<td>Crushed XTAMPZA ER Capsule Contents (fed)</td>
<td>62.9 (12.6)</td>
<td>4.0 (2.0 – 7.0)</td>
<td>597 (149)</td>
</tr>
<tr>
<td>Crushed Immediate-Release Oxycodone Tablets (fed)</td>
<td>79.4 (17.1)</td>
<td>1.75 (0.5-4.0)</td>
<td>561 (146)</td>
</tr>
</tbody>
</table>

Values shown for C\text{max} and AUC\text{0-INF} are mean (standard deviation); values shown for T\text{max} are median (minimum-maximum).

**Nasal Pharmacokinetic Studies**

The pharmacokinetic profile following intranasal administration of crushed XTAMPZA ER capsule contents was characterized in two clinical studies.

In Nasal Pharmacokinetic Study 1, XTAMPZA ER capsule contents were crushed and intranasally administered by non-dependent, naltrexone-blocked subjects with a history of nasal abuse of opioids. The two comparators in this study were intact XTAMPZA ER capsules (oral) and oxycodone HCl powder (intranasal) at an equivalent dose.

In Nasal Pharmacokinetic Study 2, XTAMPZA ER capsule contents were crushed and intranasally administered by non-dependent subjects with a history of nasal abuse of opioids.
The two comparators in this study were intact XTAMPZA ER capsules (oral) and crushed oxycodone immediate-release tablets (intranasal) at an equivalent dose.

The results of Nasal Pharmacokinetic Studies 1 and 2 are comparable and both studies demonstrated that intranasal administration of crushed XTAMPZA ER capsule contents did not result in higher peak plasma concentration (C_{max}) or shorter time to peak concentration (T_{max}) than taking XTAMPZA ER orally. The data from Nasal Pharmacokinetic Study 2 are displayed in Table 4 to represent these findings.

**Table 4: Pharmacokinetic Parameters, Nasal Pharmacokinetic Study 2:**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>C_{max} (ng/mL)</th>
<th>T_{max} (hr)</th>
<th>AUC_{0-INF} (hr•ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intact XTAMPZA ER Capsules (oral)</td>
<td>41.0 (10.0)</td>
<td>5.1 (1.6-8.1)</td>
<td>477 (89.6)</td>
</tr>
<tr>
<td>Crushed XTAMPZA ER Capsule Contents (nasal)</td>
<td>29.8 (6.6)</td>
<td>5.1 (1.6-12.1)</td>
<td>459 (106)</td>
</tr>
<tr>
<td>Crushed Immediate-Release Tablets (nasal)</td>
<td>60.9 (11.9)</td>
<td>2.6 (0.3-6.1)</td>
<td>577 (124)</td>
</tr>
</tbody>
</table>

Values shown for C_{max} and AUC_{0-INF} are mean (standard deviation); values shown for T_{max} are median (minimum-maximum).

**Clinical Studies**

**Oral Abuse Potential Study:**

In the Oral Abuse Potential Study, a randomized, double-blind, active- and placebo-controlled, single-dose, six-way crossover pharmacodynamic study, 61 recreational opioid users with a history of oral drug abuse received orally administered active and placebo treatment. The six treatment arms were intact XTAMPZA ER (36 mg, fed and fasted); chewed XTAMPZA ER (36 mg, fed and fasted); crushed immediate-release oxycodone HCl in water (40 mg, fasted, equivalent to 36 mg of XTAMPZA ER), and placebo. Data for chewed XTAMPZA ER and crushed IR oxycodone in the fasted state are described below.

Drug Liking was measured on a bipolar 100-point Visual Analog Scale (VAS) where 50 represents a neutral response, 0 represents maximum disliking, and 100 represents maximum liking. Response to whether the subject would take the study drug again was also measured on a bipolar 100-point VAS where 50 represents a neutral response, 0 represents the strongest negative response (e.g., ‘definitely would not take drug again’), and 100 represents the strongest positive response (e.g., ‘definitely would take drug again’).

Thirty-eight subjects completed the study. The results are summarized in Table 5. The oral administration of chewed and intact XTAMPZA ER in the fasted state was associated with statistically lower mean Drug Liking scores compared with crushed immediate-release oxycodone. However, the differences for XTAMPZA ER chewed and intact compared with
crushed immediate-release oxycodone for the Take Drug Again scores were small and not statistically significant.

**Table 5: Summary of Maximum Drug Liking and Take Drug Again (E_{max}) Following Oral Administration**

<table>
<thead>
<tr>
<th></th>
<th>XTAMPZA A ER Intact (Fasted)</th>
<th>XTAMPZA A ER Chewed (Fasted)</th>
<th>Crushed IR Oxycodone (Fasted)</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Liking* (E_{max})</td>
<td>Mean (SEM)</td>
<td>68.8 (2.11)</td>
<td>73.4 (2.26)</td>
<td>81.8 (1.86)</td>
</tr>
<tr>
<td></td>
<td>Median (Range)</td>
<td>72 (50-89)</td>
<td>76 (50-95)</td>
<td>83 (50-99)</td>
</tr>
<tr>
<td>Take Drug Again (E_{max})*</td>
<td>Mean (SEM)</td>
<td>70.2 (2.59)</td>
<td>73.7 (2.42)</td>
<td>75.4 (2.72)</td>
</tr>
<tr>
<td></td>
<td>Median (Range)</td>
<td>69 (50-98)</td>
<td>74 (50-98)</td>
<td>76 (37-100)</td>
</tr>
</tbody>
</table>

* Bipolar scale (0=maximum negative response, 50=neutral response, 100=maximum positive response)

E_{max} = maximum (peak) effect; ER = extended-release; IR = immediate-release; VAS = visual analogue scale; SEM= standard error of the mean.

**Nasal Abuse Potential Study:**

In a randomized, double-blind, active- and placebo-controlled, single-dose, four-way crossover pharmacodynamic study, 39 recreational opioid users with a history of intranasal drug abuse received nasally administered active and placebo drug treatment. The four treatment arms were crushed XTAMPZA ER 36 mg dosed intranasally; intact XTAMPZA ER 36 mg dosed orally; crushed immediate-release oxycodone HCl 40 mg (equivalent to 36 mg of XTAMPZA ER) dosed intranasally; and placebo. Data for intranasal XTAMPZA ER and crushed immediate-release oxycodone are described below.

Thirty-six subjects completed the study. Intranasal administration of crushed XTAMPZA ER was associated with statistically lower mean Drug Liking and Take Drug Again scores compared with crushed immediate-release oxycodone (summarized in Table 6).
Table 6: Summary of Maximum Drug Liking and Take Drug Again ($E_{\text{max}}$) Following Intranasal Administration

<table>
<thead>
<tr>
<th></th>
<th>XTAMPZA ER Intranasal</th>
<th>Crushed IR Oxycodone Intranasal</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Liking* ($E_{\text{max}}$) Mean (SEM)</td>
<td>61.8 (2.6)</td>
<td>82.7 (1.8)</td>
<td>54.5 (2.0)</td>
</tr>
<tr>
<td></td>
<td>Median (Range)</td>
<td>59.5 (16-94)</td>
<td>84 (60-100)</td>
</tr>
<tr>
<td>Take Drug Again* ($E_{\text{max}}$) Mean (SEM)</td>
<td>47.7 (4.6)</td>
<td>71.4 (3.9)</td>
<td>45.9 (2.9)</td>
</tr>
<tr>
<td></td>
<td>Median (Range)</td>
<td>50 (0-100)</td>
<td>78.5 (18-100)</td>
</tr>
</tbody>
</table>

* Bipolar scale (0=maximum negative response, 50=neutral response, 100=maximum positive response).

$E_{\text{max}}$ = maximum (peak) effect; ER = extended-release; IR = immediate-release; VAS = visual analogue scale; SEM = Standard error of the mean.

Figure 1 demonstrates a comparison of Drug Liking for intranasal administration of crushed XTAMPZA ER compared to crushed immediate-release oxycodone in subjects who received both treatments (N=36). The Y-axis represents the percent of subjects attaining a percent reduction in drug liking for XTAMPZA ER vs. immediate-release oxycodone greater than or equal to the value on the X-axis. Approximately 92% (n = 33) of subjects had some reduction in drug liking with XTAMPZA ER relative to crushed immediate-release oxycodone HCl. 78% (n = 28) of subjects had a reduction of at least 30% in drug liking with XTAMPZA ER compared to crushed immediate-release oxycodone HCl, and approximately 58% (n = 21) of subjects had a reduction of at least 50% in drug liking with XTAMPZA ER compared to crushed immediate-release oxycodone HCl.
Summary
The in vitro data demonstrate that XTAMPZA ER has physicochemical properties expected to make abuse by injection difficult. The data from pharmacokinetic and human abuse potential studies, along with support from the in vitro data, also indicate that XTAMPZA ER has physicochemical properties that are expected to reduce abuse via the intranasal route. The data from the oral pharmacokinetic studies of manipulated XTAMPZA ER demonstrated a lack of dose dumping with no increase in oxycodone levels compared to intact XTAMPZA ER. Although the results of the oral human abuse potential study showed a difference in the Drug Liking endpoint, there was no statistically significant reduction in the response to Take Drug Again. Therefore, it cannot be concluded that XTAMPZA ER has physicochemical properties that are expected to reduce abuse via the oral route.

However, abuse of XTAMPZA ER by injection and by the nasal route of administration, as well as by the oral route is still possible.

Additional data, including epidemiological data, when available, may provide further information on the impact of the current formulation of XTAMPZA ER on the abuse liability of the drug. Accordingly, this section may be updated in the future as appropriate.

XTAMPZA ER contains oxycodone, an opioid agonist and Schedule II controlled substance with an abuse liability similar to other opioid agonists, legal or illicit, including fentanyl, hydromorphone, methadone, morphine, and oxymorphone. XTAMPZA ER can be abused and is subject to misuse, addiction, and criminal diversion.
TROXYCA ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules [NDA 207621]

Approval Date:  August 19, 2016

Abuse Deterrence Studies
TROXYCA ER is formulated with a sequestered opioid antagonist, naltrexone HCl, which is released with manipulation by crushing.

In Vitro Testing
In vitro laboratory tests were performed to evaluate the effect of different physical and chemical conditions intended to defeat the extended-release formulation. When TROXYCA ER is crushed and mixed in a variety of solvents, both oxycodone HCl and naltrexone HCl are simultaneously extracted.

Clinical Abuse Potential Studies
Two randomized, double-blind active- and placebo-controlled studies were conducted in non-dependent opioid abusers to characterize the abuse potential of oral or intranasal administration of TROXYCA ER following physical manipulation. A third randomized, double-blind, single-dose, placebo and active-controlled study was conducted with IV administration of simulated crushed TROXYCA ER. For these studies, Drug Liking was measured on a bipolar 100-point Visual Analog Scale (VAS) where 0 represents maximum disliking, 50 represents a neutral response (neither like nor dislike), and 100 represents maximum liking. Response to whether the subject would Take Drug Again was measured on a bipolar 100-point VAS where 0 represents strongest negative response (e.g., ‘definitely would not take drug again’), 50 represents a neutral response, and 100 represents the strongest positive response (e.g., ‘definitely would take drug again’).

The pharmacokinetic profiles of oxycodone HCl and naltrexone HCl were also determined in these abuse potential studies. When TROXYCA ER was crushed and administered orally (40 mg/4.8 mg and 60 mg/7.2 mg doses) or intranasally (30 mg/3.6 mg doses), oxycodone HCl and naltrexone HCl were both absorbed rapidly with median time-to-peak concentration (T_{max}) values of approximately 0.6-1 hour and 0.6 hours, respectively, following oral administration and 1.6 hours and 0.3 hours, respectively, following intranasal administration.

Oral Abuse Potential Study
In this study, 31 non-dependent, recreational opioid abusers received all six treatments by the oral route: crushed 40 mg/4.8 mg TROXYCA ER in solution, crushed 40 mg immediate-release (IR) oxycodone HCl in solution, intact 60 mg/7.2 mg TROXYCA ER, crushed 60 mg/7.2 mg TROXYCA ER in solution, crushed 60 mg IR oxycodone HCl in solution, and placebo. When 40 mg/4.8 mg TROXYCA ER and 60 mg/7.2 mg TROXYCA ER were crushed and taken orally, the geometric mean (SD) values for naltrexone HCl C_{max} were 1074 (1463) pg/mL and
1810 (2450) pg/mL respectively; the AUC_{0-2h} values were 1217 (1471) and 2010 (1839) pg·h/mL, and the AUC_{inf} values were 2877 (2834) pg·h/mL and 4695 (3714) pg·h/mL, respectively.

Oral administration of crushed 40 mg/4.8 mg TROXYCA ER was associated with statistically significantly lower means and medians for Drug Liking and Take Drug Again E_{max} compared with crushed 40 mg IR oxycodone HCl. Oral administration of crushed 60 mg/7.2 mg TROXYCA ER was associated with statistically significantly lower means and medians for Drug Liking E_{max} compared to crushed 60 mg IR oxycodone HCl. The mean and median Take Drug Again E_{max} for crushed 60 mg/7.2 mg TROXYCA ER compared with crushed 60 mg IR oxycodone HCl was numerically lower; however, this finding did not reach statistical significance. The results from this study are summarized in Table 6.

Among the 31 subjects who received both TROXYCA ER and IR oxycodone by the oral route, 74% (23) and 77% (24) experienced some reduction in Drug Liking E_{max} with crushed 40 mg/4.8 mg TROXYCA ER and crushed 60 mg/7.2 mg TROXYCA ER, respectively, compared to crushed IR oxycodone, while 26% (8) and 23% (7) of subjects had no reduction in Drug Liking E_{max} for crushed 40 mg/4.8 mg TROXYCA ER and crushed 60 mg/7.2 mg TROXYCA ER, respectively, compared to crushed IR oxycodone. With crushed 40 mg/4.8 mg TROXYCA ER, 65% (20) of subjects had at least a 30% reduction and 55% (17) of subjects had at least a 50% reduction in Drug Liking E_{max} compared to crushed 40 mg IR oxycodone. With crushed 60 mg/7.2 mg TROXYCA ER, 61% (19) of subjects had at least a 30% reduction and 45% (14) of subjects had at least a 50% reduction in Drug Liking E_{max} compared to crushed 60 mg IR oxycodone.

### Intranasal Abuse Potential Study

In this study, 27 non-dependent, recreational opioid abusers with experience with intranasal administration of opioids received all four treatments by the intranasal route: crushed
30 mg/3.6 mg TROXYCA ER, crushed 30 mg IR oxycodone HCl, crushed placebo sugar spheres and crushed placebo lactose tablets. Placebo sugar spheres and placebo lactose tablets were weight matched to TROXYCA ER or IR oxycodone HCl. When TROXYCA ER was crushed and taken intranasally, the geometric mean (SD) values for naltrexone HCl $C_{\text{max}}$, $AUC_{0-2h}$, and $AUC_{\text{inf}}$ were 4372 (1409) pg/mL, 5481 (1472) pg·hr/mL, and 10710 (3213) pg·hr/mL, respectively.

Intranasal administration of crushed TROXYCA ER was associated with statistically significantly lower means and medians for Drug Liking and Take Drug Again $E_{\text{max}}$ compared with crushed IR oxycodone HCl (summary statistics for Drug Liking and Take Drug Again in Table 7).

<table>
<thead>
<tr>
<th>VAS Scale (100 point)</th>
<th>Placebo for TROXYCA ER</th>
<th>TROXYCA ER 30 mg/3.6 mg Crushed</th>
<th>Placebo for IR Oxycodone</th>
<th>IR Oxycodone 30 mg Crushed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Liking ($E_{\text{max}}$)*</td>
<td>Mean (SE)</td>
<td>Median (range)</td>
<td>Mean (SE)</td>
<td>Median (range)</td>
</tr>
<tr>
<td>51.0 (0.23)</td>
<td>60.3 (2.36)</td>
<td>51.3 (0.65)</td>
<td>93.7 (2.11)</td>
<td></td>
</tr>
<tr>
<td>51.0 (50.56)</td>
<td>55.0 (50.100)</td>
<td>51.0 (50.68)</td>
<td>100.0 (50.100)</td>
<td></td>
</tr>
<tr>
<td>Take Drug Again ($E_{\text{max}}$)*</td>
<td>Mean (SE)</td>
<td>Median (range)</td>
<td>Mean (SE)</td>
<td>Median (range)</td>
</tr>
<tr>
<td>47.9 (2.92)</td>
<td>58.1 (6.27)</td>
<td>46.5 (3.67)</td>
<td>88.5 (5.18)</td>
<td></td>
</tr>
<tr>
<td>50.0 (0.83)</td>
<td>51.0 (0.100)</td>
<td>50.0 (0.98)</td>
<td>100.0 (0.100)</td>
<td></td>
</tr>
</tbody>
</table>

* Presented on bipolar 100-point Visual Analog Scales (VAS) 0 = maximum negative response, 50 = neutral response, 100 = maximum positive response.

Among 27 subjects who received both TROXYCA ER and IR oxycodone by the intranasal route, 93% (25) experienced some reduction in Drug Liking $E_{\text{max}}$ with crushed TROXYCA ER compared to crushed IR oxycodone, while 7% (2) of subjects had no reduction in Drug Liking $E_{\text{max}}$ for crushed TROXYCA ER compared to crushed IR oxycodone. With crushed TROXYCA ER 93% (25) of subjects had at least a 30% reduction in Drug Liking $E_{\text{max}}$ and 85% (23) of subjects had at least a 50% reduction in Drug Liking $E_{\text{max}}$ compared to crushed IR oxycodone.

**Simulated IV Abuse Potential Study**

This study in non-dependent recreational opioid abusers compared 20 mg IV oxycodone HCl in combination with 2.4 mg IV naltrexone HCl (to simulate parenteral use of crushed TROXYCA ER) to 20 mg of IV oxycodone HCl and placebo; 29 subjects received all three treatments. These doses were based on the assumption of the complete release of both oxycodone HCl and naltrexone HCl upon crushing TROXYCA ER. Intravenous administration of the combination of oxycodone HCl and naltrexone HCl was associated with statistically significantly lower mean and median Drug Liking and Take Drug Again $E_{\text{max}}$ scores (median scores 51 and 50,
respectively) compared with oxycodone alone (median scores 97 and 81, respectively). Among 29 subjects, 90% (26) experienced some reduction in Emax of Drug Liking with simulated parenteral use of crushed TROXYCA ER compared to IV oxycodone HCl, while 10% (3) of subjects had no reduction in Drug Liking Emax for simulated parenteral use of crushed TROXYCA ER compared to IV oxycodone HCl.

**Summary**
The in vitro and pharmacokinetic data demonstrate that crushing TROXYCA ER pellets results in the simultaneous release and absorption of oxycodone HCl and naltrexone HCl. These data along with results from the oral and intranasal human abuse potential studies indicate that TROXYCA ER has properties that are expected to reduce abuse via the oral and intranasal routes. However, abuse of TROXYCA ER by these routes is still possible.

Additional data, including epidemiological data, when available, may provide further information on the impact of the current formulation of TROXYCA ER on the abuse liability of the drug. Accordingly, this section may be updated in the future as appropriate.

A human abuse potential study of intravenous oxycodone HCl and naltrexone HCl to simulate crushed TROXYCA ER demonstrated lower Drug Liking and Take Drug Again Emax compared with oxycodone HCl alone. However, it is unknown whether these results with simulated crushed TROXYCA ER predict a reduction in abuse by the IV route until additional postmarketing data are available.

TROXYCA ER contains oxycodone HCl, an opioid agonist and Schedule II controlled substance with an abuse liability similar to other opioid agonists, legal and illicit, including fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxymorphone, and tapentadol. TROXYCA ER can be abused and is subject to misuse, addiction, and criminal diversion.

**ARYMO ER (morphine sulfate) extended-release tablets [NDA 208603]**

Approval Date: January 9, 2017
Abuse Deterrence Labeling Update: October 12, 2018

**Abuse Deterrence Studies**
ARYMO ER is formulated with inactive ingredients that make the tablet more difficult to manipulate for misuse and abuse.

To evaluate the ability of ARYMO ER to reduce the potential for misuse and abuse, a series of abuse-deterrent in vitro laboratory physical manipulation, chemical extraction, and syringeability studies were conducted. One oral human abuse potential study and one intranasal human abuse
potential study were conducted. In each study both pharmacokinetic and pharmacodynamic (subjective measures) data were collected. These data are described below for both studies.

**In Vitro Testing**
In vitro physical and chemical manipulation studies were performed to evaluate the ability of different methods to defeat the extended-release properties. The results of this testing demonstrated that ARYMO ER tablets, in comparison to morphine sulfate extended-release tablets, have increased resistance to cutting, crushing, grinding or breaking using a variety of tools. When subjected to a liquid environment, the manipulated ARYMO ER tablets form a viscous hydrogel (i.e., a gelatinous mass) that resists passage through a hypodermic needle.

**Oral Human Abuse Potential Study**

**Pharmacokinetic Results**
The pharmacokinetic profile of manipulated ARYMO ER was characterized following oral administration. The study was conducted in a randomized cross-over design. The pharmacokinetic profile of manipulated and intact ARYMO ER compared to crushed morphine sulfate extended-release was evaluated in 38 subjects after oral administration. The results are summarized in Table 2 and demonstrate that oral ingestion of manipulated ARYMO ER resulted in a higher Cmax, but similar AUC, when compared to intact ARYMO ER. In addition, manipulated ARYMO ER had a lower Cmax and longer Tmax than crushed morphine sulfate extended-release tablets.

<table>
<thead>
<tr>
<th>Table 2: Results from Oral Pharmacokinetic Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>PK Parameter</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Cmax (ng/mL)</td>
</tr>
<tr>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Median (Range)</td>
</tr>
<tr>
<td>Tmax (h)</td>
</tr>
<tr>
<td>Median (Range)</td>
</tr>
<tr>
<td>AUC0→∞ (h*ng/mL)</td>
</tr>
<tr>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Median (Range)</td>
</tr>
</tbody>
</table>

Cmax = maximum observed plasma concentration; Tmax = time to achieve the maximum observed plasma concentration; AUC0→∞ = area under the curve, zero to infinity
Pharmacodynamic Results
An oral abuse potential study was conducted in 39 subjects who were non-dependent recreational opioid users; 38 subjects completed the study. Treatment arms included manipulated ARYMO ER 60 mg tablets (taken with juice), intact ARYMO ER 60 mg tablets (taken with juice), crushed 60 mg morphine sulfate extended-release tablets (mixed in juice), and placebo.

Drug liking was measured on a 100 mm bipolar visual analog scale (VAS) where 50 represents a neutral response of “neither like nor dislike”, 0 represents “strong disliking”, and 100 represents “strong liking.” Response to whether the subject would take the study drug again was also measured on a bipolar scale of 0 to 100 where 50 represents a neutral response (‘do not care’), 0 represents the strongest negative response (‘definitely would not’) and 100 represents the strongest positive response (‘definitely would’).

The study demonstrated that the oral administration of manipulated ARYMO ER resulted in a statistically lower mean drug liking score than the oral administration of crushed morphine sulfate extended-release tablets. However, the difference between manipulated ARYMO ER and crushed morphine sulfate extended-release tablets for Take Drug Again was not statistically significant, indicating that the difference in drug liking scores was not clinically meaningful.

These results are summarized in Table 3.

Table 3: Summary of Maximum Scores ($E_{max}$) for Drug Liking and Take Drug Again VAS1 Following Oral Administration of Manipulated and Intact ARYMO ER and Crushed Morphine Sulfate Extended-Release in Non-Dependent Recreational Opioid Users

<table>
<thead>
<tr>
<th>Parameter</th>
<th>ARYMO ER</th>
<th>Crushed Morphine Sulfate Extended-Release</th>
<th>Placebo (n = 38)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Manipulated (n = 38)</td>
<td>Intact (n = 38)</td>
<td></td>
</tr>
<tr>
<td>Maximum Drug Liking ($E_{max}$)</td>
<td>68.3 (12.3)</td>
<td>63.2 (10.1)</td>
<td>73.3 (9.8)</td>
</tr>
<tr>
<td>Median (Q1, Q3)</td>
<td>67.0 (61.0, 75.0)</td>
<td>62.0 (56.0, 68.0)</td>
<td>74.0 (68.0, 79.0)</td>
</tr>
<tr>
<td>Take Drug Again ($E_{max}$)</td>
<td>62.9 (19.6)</td>
<td>54.8 (20.8)</td>
<td>70.1 (17.5)</td>
</tr>
<tr>
<td>Median (Q1, Q3)</td>
<td>61.5 (51.0, 71.0)</td>
<td>56.0 (50.0, 65.0)</td>
<td>68.0 (56.0, 80.0)</td>
</tr>
</tbody>
</table>

1 100 point bipolar VAS (0=maximum negative response, 50=neutral response, 100=maximum positive response) Q1=1st Quartile; Q3=3rd Quartile
Intranasal Human Abuse Potential Study
Pharmacokinetic Results

The pharmacokinetic profile of manipulated ARYMO ER compared to crushed morphine sulfate extended-release was evaluated following intranasal administration in 46 subjects. The study was conducted in a randomized cross-over design. Subjects were non-dependent recreational opioid users with insufflation experience. The preparation of ARYMO ER in this study required a multi-step procedure (mechanical and electrical manipulations) compared to morphine sulfate extended-release tablets, which were crushed in a single-step (mechanical) procedure. Treatment arms included ARYMO ER 60 mg tablet manipulated, morphine sulfate extended-release 60 mg tablet crushed, oral intact ARYMO ER 60 mg tablet, and placebo.

The pharmacokinetic parameters that were measured include Cmax, Tmax and overall exposure (AUC0–∞). The results are summarized in Table 4 and demonstrate that snorting manipulated ARYMO ER had a lower Cmax, longer Tmax and lower overall exposure compared to snorting crushed morphine sulfate extended-release tablets. The pharmacokinetic profile of manipulated Arymo ER is consistent with an oral intact extended-release profile.

Table 4: Pharmacokinetic Results from Intranasal Study

<table>
<thead>
<tr>
<th>PK Parameter</th>
<th>Manipulated ARYMO ER (n = 45)</th>
<th>Intact ARYMO ER (Oral) (n = 46)</th>
<th>Crushed Morphine Sulfate Extended-Release (n = 46)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cmax (ng/mL)</td>
<td>19.0 (9.6)</td>
<td>17.2 (4.3)</td>
<td>36.3 (12.9)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (Range)</td>
<td>19.8 (4.2-40.1)</td>
<td>18.1 (9.3-24.8)</td>
<td>34.6 (6.5-62.3)</td>
</tr>
<tr>
<td>Tmax (h)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (Range)</td>
<td>2.2 (1.1-6.1)</td>
<td>3.7 (1.1-6.2)</td>
<td>1.1 (0.4-2.7)</td>
</tr>
<tr>
<td>AUC0–∞ (h*ng/mL)</td>
<td>125.2 (63.6)</td>
<td>149.0 (25.5)</td>
<td>181.6 (49.7)</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (Range)</td>
<td>137.7 (20.8-244.2)</td>
<td>153.4 (85.6-188.6)</td>
<td>177.6 (29.8-286.0)</td>
</tr>
</tbody>
</table>

Cmax = maximum observed plasma concentration; Tmax = time to achieve the maximum observed plasma concentration; AUC0–∞ = area under the curve, zero to infinity; SD = standard deviation

Pharmacodynamic Results
In the intranasal abuse potential study, drug liking was measured on a 100 mm bipolar visual analog scale (VAS) where 50 represents a neutral response of “neither like nor dislike”, 0 represents “strong disliking”, and 100 represents “strong liking.” Response to whether the subject would take the study drug again was also measured on a bipolar scale of 0 to 100 where 50 represents a neutral response (‘do not care’), 0 represents the strongest negative response
The study results demonstrated that subjects who snorted manipulated ARYMO ER reported statistically significantly lower maximum scores (Emax) for drug liking and take drug again compared to snorting crushed morphine sulfate extended-release tablets. These results are summarized in Table 5.

**Table 5: Summary of Maximum Scores (Emax) for Drug Liking and Take Drug Again following Intranasal Administration of Manipulated ARYMO ER and Crushed Morphine Sulfate Extended-Release Tablets in Non-Dependent Recreational Opioid Users**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Manipulated ARYMO ER (n = 46)</th>
<th>Crushed Morphine Sulfate Extended-Release (n = 46)</th>
<th>Placebo (n = 46)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Maximum Drug Liking (Emax)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>65.5 (14.3)</td>
<td>77.7 (11.7)</td>
<td>54.7 (10.6)</td>
</tr>
<tr>
<td>Median (Q1, Q3)</td>
<td>62.0 (52.0, 76.0)</td>
<td>77.5 (70.0, 85.0)</td>
<td>51.0 (50.0, 58.0)</td>
</tr>
<tr>
<td><strong>Take Drug Again (Emax)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>43.1 (29.6)</td>
<td>69.9 (27.4)</td>
<td>52.5 (12.7)</td>
</tr>
<tr>
<td>Median (Q1, Q3)</td>
<td>50.0 (19.0, 66.0)</td>
<td>73.0 (57.0, 90.0)</td>
<td>50.0 (50.0, 51.0)</td>
</tr>
</tbody>
</table>

1 100 point bipolar VAS (0=maximum negative response, 50=neutral response, 100=maximum positive response) Q1=1st Quartile; Q3=3rd Quartile

**Summary**

The in vitro data demonstrate that ARYMO ER has physical and chemical properties expected to make abuse by injection difficult. The data from the in vitro studies and the intranasal clinical abuse potential study indicate that ARYMO ER has physical and chemical properties that are expected to reduce abuse via the intranasal route.

Although the results of the oral human abuse potential study showed a difference in the Drug Liking endpoint, there was no statistically significant reduction in the response to Take Drug Again. Therefore, it cannot be concluded that ARYMO ER has physical and chemical properties that are expected to reduce abuse via the oral route.

Abuse of ARYMO ER by the intravenous and nasal routes, as well as by the oral route, is still possible.

Additional data, including epidemiological data, when available, may provide further information on the impact of the current formulation of ARYMO ER on the abuse liability of the drug. Accordingly, this section may be updated in the future as appropriate.
VANTRELA ER (hydrocodone bitartrate) extended-release tablets [NDA 207975]

Approval Date: January 17, 2017

Abuse Deterrence Studies
VANTRELA ER is formulated with physicochemical properties intended to make the tablet more difficult to manipulate for misuse and abuse.

In Vitro Testing
In vitro physical and chemical tablet manipulation studies were performed to evaluate the success of different extraction methods in defeating the extended-release formulation. Results support that VANTRELA ER resists crushing, breaking, and dissolution using a variety of tools and solvents and retains some extended-release properties despite manipulation. When VANTRELA ER was subjected to attempts at small volume extraction, the resulting material was viscous and resisted passage through a hypodermic needle.

Pharmacokinetics of Manipulated Tablets
The pharmacokinetic profile of manipulated VANTRELA ER tablet contents was characterized following oral and intranasal administration. The studies were conducted in a randomized, crossover design and are described in the section on Clinical Abuse Potential Studies. In the oral study assessing manipulation by crushing, the most effective crushing method identified in previous in vitro studies was applied to the product(s). For the intranasal study, VANTRELA ER tablets were manipulated to produce a powder suitable for nasal insufflation.

Oral Pharmacokinetic Data
The effect of product manipulation (crushing) on VANTRELA ER pharmacokinetics was measured in an oral clinical abuse potential study. VANTRELA ER tablets were crushed prior to oral administration in healthy, nondependent recreational opioid users. The two comparators in this study were intact VANTRELA ER tablets and an immediate-release hydrocodone powder.

The pharmacokinetic data displayed in Table 4 illustrate the findings from this study. The data demonstrated that crushing VANTRELA ER tablets prior to administration increased the maximum observed plasma concentration (Cmax) but not the total exposure (AUC0-inf) relative to dosing the intact product. Relative to immediate-release hydrocodone, the Cmax for all VANTRELA ER treatments was significantly lower and the Tmax significantly longer, consistent with an extended-release profile.
Nasal Pharmacokinetic Data
The pharmacokinetic profile following intranasal administration of manipulated VANTRELA ER tablet contents was characterized in a nasal clinical abuse potential study. VANTRELA ER tablets were finely milled and intranasally administered by non-dependent subjects with a history of nasal abuse of opioids. Two comparators in this study were intact VANTRELA ER tablets (oral) and immediate-release hydrocodone powder (intranasal) at an equivalent dose.

The results of the study demonstrated that intranasal administration of manipulated VANTRELA ER tablet contents resulted in higher peak plasma concentration (Cmax) and shorter time to peak concentration (Tmax) than taking VANTRELA ER orally and lower Cmax and longer Tmax then taking hydrocodone powder intranasally. The pharmacokinetic data from this nasal clinical abuse potential study are displayed in Table 5 to represent these findings.

Table 5: Hydrocodone Pharmacokinetic Parameters, Nasal and Oral Administration

<table>
<thead>
<tr>
<th>Treatment</th>
<th>C_{max} (ng/mL)</th>
<th>T_{max} (hr)</th>
<th>AUC_{0-inf} (hr*ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>45 mg intact Vantrela ER Tablets (oral)</td>
<td>25.05 (7.18)</td>
<td>9.11 (4.10 - 12.12)</td>
<td>568 (172)</td>
</tr>
<tr>
<td>45 mg Vantrela ER finely milled (nasal)</td>
<td>56.84 (15.1)</td>
<td>2.62 (1.33 - 7.02)</td>
<td>572 (150)</td>
</tr>
<tr>
<td>45 mg immediate-release hydrocodone powder (nasal)</td>
<td>71.28 (30.5)</td>
<td>1.38 (0.60 - 7.07)</td>
<td>579 (163)</td>
</tr>
</tbody>
</table>

Values shown for C_{max} and AUC_{0-inf} are mean (standard deviation); values shown for T_{max} are median (minimum-maximum).

Clinical Abuse Potential Studies
Two randomized, double-blind active- and placebo-controlled studies were conducted in nondependent opioid abusers to characterize the abuse potential of oral or intranasal administration of VANTRELA ER following physical manipulation. For both studies, Drug
Liking was measured on a bipolar drug-liking scale of 0 to 100 where 50 represents a neutral response of neither liking nor disliking, 0 represents maximum disliking and 100 represents maximum liking. Response to whether the subject would Take Drug Again was measured on a bipolar scale of 0 to 100 where 0 represents the strongest negative response (“definitely would not take drug again”), 50 represents a neutral response, and 100 represents the strongest positive response (“definitely would take drug again”).

**Oral Abuse Potential Study**

In a randomized, double-blind, placebo- and active-controlled, 4-period crossover study in nondependent opioid abusers, 35 of the 49 enrolled subjects completed all treatment conditions: 45 mg VANTRELA ER (intact), 45 mg VANTRELA ER (finely crushed), 45 mg hydrocodone bitartrate powder (immediate release (IR) condition), and placebo.

The oral administration of finely crushed VANTRELA ER was associated with statistically significantly lower mean scores for Drug Liking and Take Drug Again ($P<0.001$ for both), compared with powdered hydrocodone as summarized in Table 6.

<table>
<thead>
<tr>
<th>Measure</th>
<th>Statistic</th>
<th>Placebo (N=35)</th>
<th>Hydrocodone IR 45 mg (N=35)</th>
<th>VANTRELA ER 45 mg (finely crushed) (N=35)</th>
<th>VANTRELA ER 45 mg (intact) (N = 35)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Liking</td>
<td>Mean (SE)</td>
<td>53.4 (1.80)</td>
<td>85.0 (2.31)</td>
<td>65.6 (2.46)</td>
<td>54.5 (1.02)</td>
</tr>
<tr>
<td></td>
<td>Median (Range)</td>
<td>51.0 (50-100)</td>
<td>88.0 (50-100)</td>
<td>60.0 (50-98)</td>
<td>51.0 (50-70)</td>
</tr>
<tr>
<td>Take Drug Again</td>
<td>Mean (SE)</td>
<td>46.3 (2.88)</td>
<td>75.1 (3.04)</td>
<td>55.9 (3.53)</td>
<td>48.5 (2.77)</td>
</tr>
<tr>
<td></td>
<td>Median (Range)</td>
<td>50.0 (0-98)</td>
<td>74.0 (42-100)</td>
<td>56.0 (2-97)</td>
<td>50.0 (1-100)</td>
</tr>
</tbody>
</table>

**Intranasal Abuse Potential Study**

In a randomized, double-blind, placebo-and active-controlled, 5-period crossover study in nondependent opioid abusers, 34 of the 45 subjects enrolled completed all treatment conditions: intranasal administration of 45 mg VANTRELA ER (finely milled), intranasal administration of
45 mg hydrocodone bitartrate powder (immediate release condition), oral administration of 45 mg VANTRELA ER (intact), and intranasal administration of placebo.

The intranasal administration of finely milled VANTRELA ER was associated with statistically significantly lower mean and median scores for Drug Liking and Take Drug Again ($P<0.001$ for both), compared with powdered hydrocodone administered intranasally, as summarized in Table 7.

<table>
<thead>
<tr>
<th>Measure</th>
<th>Statistic</th>
<th>Placebo IN (N=34)</th>
<th>Hydrocodone IR 45 mg (N=34)</th>
<th>VANTRELA ER 45 mg Finely Milled (N=34)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Liking</td>
<td>Mean (SE)</td>
<td>58.6 (1.94)</td>
<td>80.2 (2.16)</td>
<td>72.8 (2.35)</td>
</tr>
<tr>
<td></td>
<td>Median (Range)</td>
<td>52.0 (50-90)</td>
<td>79.0 (57-100)</td>
<td>72.5 (50-100)</td>
</tr>
<tr>
<td>Take Drug Again</td>
<td>Mean (SE)</td>
<td>56.4 (2.13)</td>
<td>75.5 (2.57)</td>
<td>67.5 (3.45)</td>
</tr>
<tr>
<td></td>
<td>Median (Range)</td>
<td>50.0 (34-90)</td>
<td>76.5 (43-100)</td>
<td>67.0 (30-100)</td>
</tr>
</tbody>
</table>

The in vitro data demonstrate that VANTRELA ER has physical and chemical properties that are expected to make intravenous abuse difficult. The data from the in vitro studies and clinical abuse potential studies indicate that VANTRELA ER has physicochemical properties that are expected to reduce abuse via the oral route and the intranasal route. However, abuse of VANTRELA ER by the intravenous, nasal, and oral routes is still possible.

Additional data, including epidemiological data, when available, may provide further information on the impact of VANTRELA ER on the abuse liability of the drug. Accordingly, this section may be updated in the future as appropriate.

VANTRELA ER contains hydrocodone bitartrate, an opioid agonist and Schedule II controlled substance with an abuse liability similar to other opioid agonists, legal and illicit, including fentanyl, hydromorphone, methadone, oxycodone, and oxymorphone. VANTRELA ER can be abused and is subject to misuse, addiction, and criminal diversion.
ROXYBOND (oxycodone hydrochloride) immediate-release tablets [NDA 209777]

Approval Date: April 20, 2017

Abuse Deterrence Studies
ROXYBOND is formulated with inactive ingredients that make the tablet more difficult to manipulate for misuse and abuse even if the tablet is subjected to physical manipulation and/or chemical extraction. To evaluate the ability of the abuse-deterrent technology to reduce the potential for abuse of ROXYBOND, a series of in vitro laboratory manipulation, extraction, and syringeability studies were conducted. An in vivo intranasal clinical abuse potential study was also conducted.

In Vitro Testing
ROXYBOND has been tested in vitro using methods of manipulation that drug abusers commonly use for preparation of opioids for administration by various routes, including oral consumption, intranasal insufflation, and injection.

Abusers may manipulate prescription opioids in order to prepare the tablets for oral, intranasal, or intravenous administration. The laboratory test data demonstrated that, relative to oxycodone immediate-release tablets, ROXYBOND has increased resistance to cutting, crushing, grinding, or breaking using selected tools. In addition, the intact and manipulated tablets resisted extraction in selected household and laboratory solvents under various conditions, including selected pre-treatments. Relative to oxycodone immediate-release tablets, the formulation forms a viscous material that resists passage through a needle; it was also more difficult to prepare solutions suitable for intravenous injection.

Clinical Abuse Potential Studies
A randomized, double-blind, double-dummy, placebo-controlled, single-dose four-way crossover study in 29 non-dependent recreational opioid users with a history of intranasal drug abuse was performed to determine the relative bioavailability and abuse potential of crushed intranasal ROXYBOND 30 mg tablets compared with crushed intranasal 30 mg oxycodone immediate-release tablets and intact orally administered ROXYBOND 30 mg tablets. Intact oral ROXYBOND tablets were included as a reference for evaluating abuse potential after manipulation and administration via an unintended route.

Drug liking was measured on a 100-mm bipolar visual analog scale (VAS) where 50 represents a neutral response of neither liking nor disliking, 0 represents maximum disliking, and 100 represents maximum liking. Response to whether the subject would be willing to take the study drug again was also measured on a bipolar 0 to 100 VAS where 50 represents a neutral response, 0 represents the strongest negative response (“definitely would not take drug again”) and 100 represents the strongest positive response (“definitely would take drug again”).
The pharmacokinetic profiles of oxycodone were also determined in this study (Table 2). When crushed and insufflated, ROXYBOND showed a lower peak oxycodone plasma concentration ($C_{\text{max}} \sim 28\%$ reduction) and a 35% longer time to peak plasma concentration ($T_{\text{max}}$) relative to crushed and insufflated oxycodone immediate-release tablets. Similar results were demonstrated when crushed and insufflated ROXYBOND was compared to intact oral ROXYBOND with a reduction in $C_{\text{max}}$ and a longer time to $T_{\text{max}}$. Intact oral ROXYBOND resulted in a $C_{\text{max}}$ of oxycodone similar to that of crushed and insufflated oxycodone immediate-release tablets, with a similar $T_{\text{max}}$. 

<table>
<thead>
<tr>
<th>Treatment or Comparison</th>
<th>$C_{\text{max}}$ (ng/mL) LS Mean</th>
<th>$\text{AUC}_{0-t}$ (ng$\cdot$hr/mL) LS Mean</th>
<th>$T_{\text{max}}$ (hr) Median</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crushed, Insufflated oxycodone immediate-release tablets 30 mg</td>
<td>55.56</td>
<td>330.77</td>
<td>1.7</td>
</tr>
<tr>
<td>Crushed, Insufflated ROXYBOND 30 mg</td>
<td>40.04</td>
<td>309.21</td>
<td>2.3</td>
</tr>
<tr>
<td>Intact, oral ROXYBOND</td>
<td>56.97</td>
<td>265.38</td>
<td>1.3</td>
</tr>
</tbody>
</table>

$\text{AUC}_{0-t}$ = Area under the plasma concentration vs time curve from 0 to last measurable concentration.

Compared to crushed intranasal oxycodone immediate-release tablets, intranasal administration of crushed ROXYBOND was associated with statistically significantly lower drug liking ($E_{\text{max}}$) and take drug again ($E_{\text{max}}$) scores, as summarized in Table 3. Similar reductions in drug liking and willingness to take the drug again were reported for crushed intranasal ROXYBOND relative to intact oral ROXYBOND. These data are consistent with the slowing of the intended immediate-release properties of ROXYBOND when manipulated then insufflated compared to taking ROXYBOND orally intact. No statistically significant differences in $E_{\text{max}}$ of Drug Liking or Take Drug Again were observed between crushed intranasal oxycodone immediate-release tablets and intact oral ROXYBOND.
<table>
<thead>
<tr>
<th>VAS</th>
<th>Crushed Intranasal ROXYBOND 30 mg</th>
<th>Crushed Intranasal Oxycodone immediate-release tablets 30 mg</th>
<th>Intact Oral ROXYBOND 30 mg</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Drug Liking</strong> (E\textsubscript{max})</td>
<td><strong>Mean</strong></td>
<td>71.1</td>
<td>82.9</td>
<td>81.5</td>
</tr>
<tr>
<td></td>
<td><strong>(SD)</strong></td>
<td>(12.01)</td>
<td>(11.55)</td>
<td>(11.49)</td>
</tr>
<tr>
<td></td>
<td><strong>Median</strong></td>
<td>71</td>
<td>82</td>
<td>82.00</td>
</tr>
<tr>
<td></td>
<td><strong>(Range)</strong></td>
<td>(50 to 100)</td>
<td>(50 to 100)</td>
<td>(56 to 100)</td>
</tr>
<tr>
<td><strong>Take Drug Again</strong> (E\textsubscript{max})</td>
<td><strong>Mean</strong></td>
<td>62.2</td>
<td>82.1</td>
<td>77.3</td>
</tr>
<tr>
<td></td>
<td><strong>(SD)</strong></td>
<td>(24.51)</td>
<td>(16.44)</td>
<td>(18.11)</td>
</tr>
<tr>
<td></td>
<td><strong>Median</strong></td>
<td>62.0</td>
<td>86.0</td>
<td>81.0</td>
</tr>
<tr>
<td></td>
<td><strong>(Range)</strong></td>
<td>(3 to 99)</td>
<td>(37 to 100)</td>
<td>(13 to 100)</td>
</tr>
</tbody>
</table>
The majority of subjects (86%; n=25) experienced some reduction in \( E_{\text{max}} \) of Drug Liking VAS with crushed intranasal ROXYBOND compared with crushed intranasal oxycodone immediate-release tablets, whereas 59% (n=17) experienced at least a 30% reduction in \( E_{\text{max}} \) of drug liking and 21% (n=6) experienced at least a 50% reduction in \( E_{\text{max}} \) of drug liking.

**Summary**

The in vitro data demonstrate that ROXYBOND has physicochemical properties expected to make abuse via injection difficult. The data from the clinical study, along with support from in vitro data, also indicate that ROXYBOND has physicochemical properties that are expected to reduce abuse by the intranasal route of administration. However, abuse by the intranasal, oral, and intravenous route is still possible.

Additional data, including epidemiological data, when available, may provide further information on the impact of the current formulation of ROXYBOND on the abuse liability of the drug. Accordingly, this section may be updated in the future as appropriate.

**APADAZ (benzhydrocodone and acetaminophen) immediate-release tablets [NDA 208653]**

Approval Date: February 23, 2018
Based on the guidance, “Abuse-Deterrent Opioids – Evaluation and Labeling Guidance for Industry”, the primary pharmacodynamic endpoint of interest, Emax for drug liking VAS, and the secondary PD endpoints of interest, Emax for drug high VAS and take drug again VAS, Apadaz did not demonstrate abuse-deterrent properties. Section 9.2 of the label describes negative study results from in vitro testing and human abuse potential studies that do not support abuse-deterrent properties of Apadaz.

**Abuse Deterrent Studies**

In vitro and human abuse potential studies comparing APADAZ to an immediate-release hydrocodone/acetaminophen tablet control were conducted to assess the potential abuse deterrent properties of APADAZ.

**In Vitro Testing**

In vitro physical and chemical manipulation studies were performed to evaluate the ability of different methods to extract and convert benzyhydrocodone to hydrocodone for the purpose of preparing APADAZ for abuse by the intravenous route or by smoking. The efficiency of extracting benzhydrocodone from APADAZ was similar compared to the efficiency of extracting hydrocodone from the non-abuse-deterrent hydrocodone/acetaminophen control. Further conversion (hydrolysis) of benzhydrocodone to hydrocodone in vitro is a difficult process. Overall, these studies showed no advantage for APADAZ over the hydrocodone/acetaminophen control.

**Oral Clinical Abuse Potential Study**

In an oral, single-center, randomized, double-blind, active-and placebo-controlled, 7-period, crossover, human abuse potential study, 71 recreational opioid users were randomized into the Treatment Phase; 62 subjects completed the study. Treatment arms included APADAZ (4, 8, and 12 tablets, each containing 6.12 mg benzhydrocodone and 325 mg acetaminophen), hydrocodone/acetaminophen (4, 8 and 12 tablets, each containing 4.54 mg hydrocodone and 325 mg acetaminophen), and placebo. The respective dosage strengths for APADAZ and hydrocodone/acetaminophen contained equimolar amounts of hydrocodone. The rate (Cmax) and extent (AUClast, AUCinf) of hydrocodone exposure following APADAZ administration was comparable to that for hydrocodone/acetaminophen across all 3 dosage strengths. There were no statistically significant differences nor any clinically meaningful differences between APADAZ and the hydrocodone/acetaminophen control for the pre-specified primary endpoint of maximal score (Emax) for Drug Liking VAS or secondary endpoints of Emax for High VAS and Take Drug Again VAS. The results do not support a finding that APADAZ can be expected to deter abuse by the oral route of administration.

**Intranasal Clinical Abuse Potential Study**

In an intranasal single-center, randomized, double-blind, double-dummy, two-part human abuse potential study, 46 recreational opioid users were randomized into the Treatment Phase; 42
Subjects completed the study. Five treatment arms included intranasal crushed and oral APADAZ (2 tablets, each containing 6.12 mg benzhydrocodone and 325 mg acetaminophen), intranasal crushed and oral hydrocodone/acetaminophen (2 tablets, each containing 4.54 mg hydrocodone and 325 mg acetaminophen), and intranasal placebo powder. The respective dosage strengths for APADAZ and hydrocodone/acetaminophen contained equimolar amounts of hydrocodone.

The pharmacokinetic data showed that overall (AUClast, AUCinf, and Cmax) hydrocodone exposure was comparable between intranasal crushed APADAZ and intranasal crushed hydrocodone/acetaminophen. These treatments were also comparable with cumulative hydrocodone exposure at the timepoints of 4, 8, and 24 hours (AUC0-4, AUC0-8, AUC0-24). Over the first 2 hours post-dosing (AUC0-0.5, AUC0-1, and AUC0-2), the cumulative hydrocodone exposure was lower following intranasal APADAZ compared to intranasal hydrocodone/acetaminophen.

There were numerically small but not statistically significant differences between APADAZ and the hydrocodone-acetaminophen control observed for the pre-specified primary endpoint, maximum effect on Drug Liking VAS (Emax), and the secondary endpoints of Emax for High VAS and Take Drug Again VAS.

### Table 2: Summary Statistics of Maximum Scores (Emax) on Drug Liking, High and Take Drug Again, Following Intranasal Administration of Apadaz, Hydrocodone/APAP, and Placebo

<table>
<thead>
<tr>
<th>VAS Scale (100 point) intranasal (n=42)</th>
<th>Apadaz Crushed</th>
<th>Hydrocodone/APAP Crushed</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug Liking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SE)</td>
<td>75.9 (2.3)</td>
<td>79.0 (2.7)</td>
<td>53.0 (1.2)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>74.0 (50-100)</td>
<td>80.0 (50-100)</td>
<td>51.0 (50-85)</td>
</tr>
<tr>
<td>High**</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SE)</td>
<td>61.8 (4.6)</td>
<td>59.1 (5.1)</td>
<td>8.8 (3.8)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>68.5 (0-100)</td>
<td>67.5 (0-100)</td>
<td>0.0 (0-100)</td>
</tr>
<tr>
<td>Take Drug Again*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (SE)</td>
<td>69.5 (3.9)</td>
<td>74.5 (3.9)</td>
<td>48.2 (2.2)</td>
</tr>
<tr>
<td>Median (Range)</td>
<td>68.0 (0-100)</td>
<td>81.5 (0-100)</td>
<td>50.0 (0-100)</td>
</tr>
</tbody>
</table>

*Bipolar scale (0=maximum negative response, 50=neutral response, 100=maximum positive response)

**Unipolar scale (0=maximum negative response, 100=maximum positive response)

Additional secondary analyses of Drug Liking based on area under the effect curve analyses (AUE) for the first half hour, hour, and 2 hours post-dosing, demonstrated numerically small differences between intranasal APADAZ and intranasal hydrocodone/acetaminophen. However, there were no differences between these two treatments with respect to the cumulative High
experienced over the first 2 hours post-dosing using similar AUE analyses. There are no data to support that small differences in the early Drug Liking experience over the first 2 hours are clinically relevant findings consistent with possible abuse-deterrent effects, particularly in the setting of the Emax analyses for Drug Liking, Take Drug Again, and High that do not support a deterrent effect. Based on the overall results, APADAZ cannot be expected to deter abuse by the intranasal route of administration.

**Summary**

The in vitro studies that evaluated physical manipulation and extraction for the purpose of preparing APADAZ for abuse by the intravenous route or by smoking did not find an advantage for APADAZ over the hydrocodone/acetaminophen control.

The results of the oral and intranasal human abuse potential studies do not support a finding that APADAZ can be expected to deter abuse by the oral or nasal routes of administration.
Date: November 14, 2018

To: Members of the Joint Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management (DSaRM) Advisory Committee

From: Division of Risk Management (DRISK)
Office of Medication Error Prevention and Risk Management (OMEPRM)
Office of Surveillance and Epidemiology (OSE)

Drug Name: Oxycodone Hydrochloride

Application Number: NDA 209774

Subject: Risk Evaluation and Mitigation Strategy (REMS)

The Agency continues to monitor use, misuse, and abuse of prescription opioid analgesics. Of the approximately 196 million prescriptions for opioid analgesics dispensed from U.S. outpatient retail pharmacies in 2017, approximately 91% were for immediate-release (IR) formulations.\(^1\) Consistent with this wide availability, recent data indicate that IR opioid analgesics continue to be associated with large numbers of intentional abuse exposure calls to poison control centers and reports of recent abuse among individuals entering treatment for substance use disorders.\(^2\)

If approved, MNK-812, an oxycodone hydrochloride (HCl) immediate-release (IR) tablet (NDA 209774) will be required to become a member of the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) to ensure the benefits of the drug outweigh the risks of adverse outcomes (addiction, unintentional overdose, and death) resulting from inappropriate prescribing, abuse, and misuse. The Opioid Analgesic REMS is a shared system REMS that was initially approved as the Extended-Release (ER) and Long-Acting (LA) (ER/LA) REMS in July 2012 and expanded in September 2018 to include all application holders of IR opioid analgesics that are expected to be used in the outpatient setting and that are not already covered by another REMS program.

---

1. IQVIA National Prescription Audit (NPA) Year 2017 Extracted February 2018
The Opioid Analgesic REMS is part of a multi-agency federal effort to address the growing problem of prescription drug abuse and misuse. The Opioid Analgesic REMS is intended to reduce risks and improve safe use of opioid analgesics while continuing to provide access to these medications for patients in pain. The central component of the Opioid Analgesics REMS is an education program for healthcare providers (HCPs), including prescribers, nurses, and pharmacists, involved in the treatment and monitoring of patients with pain. Under the Opioid Analgesic REMS, application holders are required to make education programs available to HCPs. The application holders are meeting this requirement by providing educational grants to accredited continuing education (CE) providers who offer training to HCPs at no or nominal cost. The training must include successful completion of a knowledge assessment and proof of successful program completion.

To be considered compliant with the Opioid Analgesic REMS, the CE courses are required to include the content and messages of a “blueprint” developed by FDA for this purpose. The currently approved FDA Blueprint, *FDA’s Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain*, focuses on the fundamentals of acute and chronic pain management and provides a contextual framework for the safe prescribing of opioid analgesics. This includes principles related to the acute and chronic pain management; non-pharmacologic treatments for pain; and pharmacologic treatments for pain (both non-opioid analgesic and opioid analgesic). The FDA Blueprint covers basic information about addiction medicine and opioid use disorder. The core messages are directed to prescribers, pharmacists, and nurses, but are also relevant for other HCPs who participate in the management of pain.

The Opioid Analgesics REMS also includes a patient counseling guide for HCPs to assist in properly counseling patients on their responsibilities for using these medicines safely and to provide patients with additional written instructions as needed. The approved labeling for opioid analgesics includes a product-specific one-page Medication Guide to be given to patients each time they receive a prescription of their opioid analgesic medicine. The Medication Guide contains consumer-friendly information on the safe use and disposal of opioid analgesics and instructions for patients to consult their HCP before changing doses, signs of potential overdose and emergency contact instructions, and advice on safe storage to prevent accidental exposure to family members.

Appendix A: FDA’s Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain

---

3 Application holders refers to all the manufacturers of the new drug applications (NDAs) and abbreviated new drug applications (ANDAs) for opioid analgesics that are subject to the REMS requirements. ANDAs refer to generic drugs. The applicant holders have come together as a consortium and formed the REMS Program Companies (RPC). Throughout this background document, the manufacturers may be referred to as application holders or RPC.

4 Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain. The FDA Blueprint contains core messages intended for use by CE providers to develop educational materials to train HCPs under the REMS.
Introduction

FDA’s Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain

Background

In July 2012, FDA approved the Extended-Release and Long-Acting (ER/LA) Opioid Analgesic Risk Evaluation and Mitigation Strategy (ER/LA REMS) to ensure that the benefits of ER and LA opioid analgesics used in the outpatient setting outweigh the risks. That REMS was modified and the new Opioid Analgesic REMS includes, in addition to ER/LA opioid analgesics, all immediate-release (IR) opioids used in the outpatient setting that are not already covered by another REMS program. The Opioid Analgesic REMS is intended to support other national efforts underway to address the misuse and abuse of prescription opioid analgesics.

As part of the Opioid Analgesic REMS, all opioid analgesic companies must provide the following:

- Education for health care providers (HCPs) who participate in the treatment and monitoring of pain. For the purpose of the Opioid Analgesic REMS, HCPs will include not only prescribers, but also HCPs who participate in the treatment and monitoring of patients who receive opioid analgesics, including pharmacists and nurses.
  - Education will be offered through accredited continuing education (CE) activities. These activities will be supported by unrestricted educational grants from opioid analgesic companies.

- Information for HCPs to use when counseling patients about the risks of ER, LA, and IR opioid analgesic use.

To facilitate the development of CE educational materials and activities as part of the Opioid Analgesic REMS, FDA has also revised the education blueprint — originally designed to facilitate development of CE educational materials under the ER/LA REMS. FDA has completed the revisions to the FDA Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain (FDA Blueprint), following publication of a draft version and consideration of received public comments.

The FDA Blueprint contains a high-level outline of the core educational messages that will be included in the educational programs developed under the Opioid Analgesic REMS. The FDA Blueprint focuses on the fundamentals of acute and chronic pain management and provides a contextual framework for the safe prescribing of opioid analgesics. The core messages are directed to prescribers, pharmacists, and nurses, but are also relevant for other HCPs who participate in the management of pain. The course work is not intended to be exhaustive nor a substitute for a more comprehensive pain management course.
Accrediting bodies and CE providers will ensure that the CE activities developed comply with the standards for CE of the Accreditation Council for Continuing Medical Education,\(^1\)\(^2\) or another CE accrediting body, depending on the target audience’s medical specialty or health care profession.

FDA is making the FDA Blueprint, approved as part of the Opioid Analgesic REMS, available on the REMS@FDA Website (www.fda.gov/REMS), where it will remain posted for use by CE providers as they develop the CE materials and activities. A list of the REMS-compliant CE activities supported by unrestricted educational grants from the opioid analgesic companies to accredited CE providers will be posted at www.opioidanalgesicREMS.com as that information becomes available.

**Reasons Why HCP Education Is So Important**

Adverse outcomes of addiction, unintentional overdose, and death resulting from inappropriate prescribing, abuse, and misuse of opioids have emerged as major public health problems. It is critical that HCPs are knowledgeable about the risks associated with opioid analgesics as they pertain to their patients as well as from a public health perspective. The data continue to show problems associated with prescription opioid analgesics.

- In 2015, over 52,404 Americans died from drug poisonings, and of these, 24% or approximately 12,570 deaths involved opioid analgesics.\(^3\)

- Based on the 2016 National Survey on Drug Use and Health (NSDUH), an estimated 11.5 million Americans aged 12 or older misused a prescription pain reliever in the past year — with hydrocodone, oxycodone, and codeine products being the most commonly reported.\(^4\)

- The most common source of pain relievers in the 2016 NSDUH was “a friend or relative” (53%). “A physician’s prescription” was the second most common source, reported by approximately 35% of respondents.\(^5\)

The nation is facing competing public health problems: the need to adequately treat a large number of Americans with acute and chronic pain and an epidemic of prescription opioid abuse.

---


\(^5\) Ibid.
Described in the 2011 report by the National Academies of Science, Engineering, and Medicine (NASEM), *Relieving PAIN in America, A Blueprint for Transforming Prevention, Care, Education, and Research,⁶* 100 million Americans suffer from common chronic pain conditions; fewer than half of Americans undergoing surgery report adequate pain relief; and 60% of Americans visiting the emergency department with acute painful conditions receive analgesics.

The increasing availability of prescription opioids since the 1990’s has been accompanied by an epidemic of opioid addiction. The Substance Abuse and Mental Health Services Administration’s *National Survey of Drug Use and Health* has shown that most people who use prescription analgesics “nonmedically” obtain them from friends or family, who it is believed obtained the drugs from a doctor’s prescription.⁷

Some of the immediate consequences of untreated or undertreated pain include reduced quality of life, impaired physical function, and high economic costs. Chronic pain is associated with physical disability, fear, anger, depression, anxiety, and reduced ability to carry out the roles of family member, friend, and employee. It is critically important that HCPs have all the information they need to properly treat their patients and safely manage their pain. It is also critical for HCPs to understand when opioid analgesics are the appropriate treatment and how to implement best practices to ensure their patients’ safety. A 2017 report by NASEM, *Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use,* describes the challenges of providing adequate pain management and calls for the establishment of “comprehensive pain education materials and curricula” for HCPs.⁸

Having broad knowledge about how to manage patients with pain can create the opportunity for HCPs to consider *all* options for pain management, including nonpharmacologic and non-opioid pharmacologic options, and to reserve opioids for when non-opioid options are inadequate and when the benefits of the opioids are expected to outweigh the risks. This information can also aid HCPs in identifying and intervening when encountering obstacles that may reduce access to nonpharmacological and non-opioid medication options. Fully informed HCPs can help contribute to national efforts to address opioid addiction and reduce opioid misuse and abuse.


Purpose of the Opioid Analgesic REMS HCP Educational Effort

Following completion of educational activities under the Opioid Analgesic REMS, HCPs should be knowledgeable about the following.

- The fundamental concepts of pain management, including definitions and mechanisms of pain
- How to assess patients in pain, identifying risk factors for abuse and addiction
- The range of therapeutic options for managing pain, including nonpharmacologic approaches and pharmacologic (non-opioid and opioid analgesics) therapies
- How to integrate opioid analgesics into a pain treatment plan individualized to the needs of the patient
- How to safely and effectively manage patients on opioid analgesics in the acute and chronic pain settings, including initiating therapy, titrating, and discontinuing use of opioid analgesics
- How to counsel patients and caregivers about the safe use of opioid analgesics, including proper storage and disposal
- How to counsel patients and caregivers about the use of naloxone for opioid overdose
- When referral to a pain specialist is appropriate
- The fundamental elements of addiction medicine
- How to identify and manage patients with opioid use disorder

In addition, HCPs will gain an understanding of current information about safe opioid practices and about current Federal\(^9\) and State regulations, national guidelines,\(^10\) and professional organization\(^11\) and medical specialty guidelines on treating pain and prescribing opioids. HCPs will also become familiar with the use of naloxone and with the importance of its availability for use by patients and caregivers both in the community and in the home.

---


\(^11\) For example, see Federation of State Medical Boards’ Guidelines for the Chronic Use of Opioid Analgesics. Accessed July 2018.
Section 1: The Basics of Pain Management

I. THE NEED FOR COMPREHENSIVE PAIN EDUCATION

The FDA Blueprint was developed with two, competing, U.S. public health concerns in mind, (1) the large number of Americans with acute and chronic pain and (2) the epidemic of prescription opioid abuse.

1. Providing health care providers (HCPs) with a thorough understanding of the risks associated with opioids can give HCPs the opportunity to consider all pain management options, including nonpharmacologic and pharmacologic options, prescribing opioids only when non-opioid options are inadequate and when the benefits of using an opioid are expected to outweigh the risks.

2. When HCPs have information about the risks of opioid misuse and abuse, they will be better able to create opportunities for patient counseling and other strategies to reduce these risks.

II. DEFINITIONS AND MECHANISMS OF PAIN

Pain can be categorized according to its duration, underlying pathophysiology of the original insult, and whether a central sensitization component has developed. An understanding of these different categorizations can help direct therapeutic decisions.

When defining, and classifying pain, the following should be taken into consideration:

1. Biological significance of pain (survival value)
2. Relationship between acute and chronic pain
3. Distinction between nociceptive and neuropathic pain

III. ASSESSING PATIENTS IN PAIN

HCPs should be knowledgeable about how to assess each patient when initiating a pain management program. When appropriate, evidence-based, standardized scales and tools can be used to document pain characteristics and guide management decisions throughout treatment, noting the strengths and weaknesses regarding specificity and sensitivity of these scales.

Important elements of an initial assessment should include the following:

1. Patient history
2. Screening tools to evaluate the known risk factors for development of chronic pain after an acute injury or disease
3. Screening tools to evaluate the known risk factors for opioid use disorder (OUD) or abuse
4. Queries of state prescription drug monitoring programs (PDMPs)
5. Pain assessment scales/tools
6. Functional assessment scales
7. Physical examination
8. Family planning, including information about use of contraceptives, pregnancy intent/status and plans to breastfeed
9. Psychological and social evaluation
10. Diagnostic studies when indicated

**Section 2: Creating the Pain Treatment Plan**

A comprehensive pain treatment plan should be developed and customized to the needs of the individual patient. The treatment plan should include the types of therapies planned, the goals of treatment, and an explanation of the patient and prescriber roles and responsibilities. The goals of treatment should be based on (1) expected outcomes of pain reduction; (2) improvement in functional outcomes impaired by pain (e.g., activities of daily living); and (3) quality of life.

If HCPs encounter potential barriers to managing patients with pharmacologic and/or nonpharmacologic treatment options, such as lack of insurance coverage or inadequate availability of certain HCPs who treat patients with pain, attempts should be made to address these barriers. The overall treatment approach and plan should be well documented in the patient record, including written agreements and informed consent/patient provider agreements (PPAs) that reinforce patient-provider responsibilities and avoid punitive tones.

**I. COMPONENTS OF AN EFFECTIVE TREATMENT PLAN**

1. The goals of treatment, including the degree of improvement in pain and function when function has been impaired by pain
2. Possible constituents of the treatment plan, including nonpharmacologic approaches and pharmacologic therapies
3. Patient/prescriber/health care team interactions, including
• Patient responsibilities/compliance with the plan
• Responsibilities of the prescriber and health care team, including patient monitoring
• Plans for reviewing functional goals
• Use of supplemental medication for intermittent increases in pain
• Use of PPAs

II. GENERAL PRINCIPLES OF NONPHARMACOLOGIC APPROACHES

Pain can arise from a wide variety of causes. There are a number of nonpharmacologic and self-management treatment options that have been found to be effective alone or as part of a comprehensive pain management plan, particularly for musculoskeletal pain and chronic pain. Examples include, but are not limited to, psychological, physical rehabilitative, and surgical approaches, complementary therapies, and use of approved/cleared medical devices for pain management. HCPs should be knowledgeable about the range of treatment options available, the types of pain that may be responsive to those options, and when they should be used as part of a multidisciplinary approach to pain management. HCPs should also be aware that not all nonpharmacologic options have the same strength of evidence to support their utility in the management of pain, and some may be more applicable for some conditions than others.

III. GENERAL PRINCIPLES OF PHARMACOLOGIC ANALGESIC THERAPY

A variety of analgesics, including non-opioid and opioid medications, are available for use to manage pain symptoms. HCPs should be well informed about the range of analgesics available and the types of pain that may be responsive to those analgesics.

A. Non-opioid medications

When using non-opioid medications in pain management, HCPs should be knowledgeable about the following:
1. Mechanism of action of analgesic effect
2. Indications and uses for pain management
3. Routes of administration and formulations used in pain management
4. Initial dosing, dose titration, dose tapering (when appropriate) for analgesia
5. Contraindications
6. Adverse events, with emphasis on labeled warnings
7. Drug interactions — both pharmacodynamic and pharmacokinetic

B. Opioid analgesic medications

Opioid analgesic medications can be used successfully as a component of pain management. However, opioids carry risks not present with most non-opioid analgesics, specifically the risks

of addiction, abuse and misuse, which can lead to respiratory depression, overdose and death. Therefore, it is the responsibility of HCPs to be knowledgeable, not just about the presence of such risks, but about how to weigh these risks before prescribing an opioid and about how to properly manage patients who are prescribed opioids, both for short-term and long-term use. When using opioid analgesics as part of pain management, HCPs should be knowledgeable about the following:

1. General precautions
   a. Even at prescribed doses, opioid analgesics carry the risk of misuse, abuse, opioid use disorder, overdose, and death
   b. Importance of the appropriate use of PDMPs\textsuperscript{13} and their use as a clinical decision support tool
   c. DSM-5 (R) criteria (or the most recent version) for OUD and the concepts of abuse (taking an opioid to get high) vs. misuse (taking more than prescribed for pain or giving to someone else in pain)\textsuperscript{14}
   d. The concepts of tolerance and physiological dependence and how they differ from OUD (addiction)
   e. Recognition that some opioid analgesics (e.g., Transmucosal Immediate Release Fentanyl products, some ER/LA products) are safe only for opioid-tolerant patients

2. Mechanism of action and analgesic effect

3. Types of opioids (full agonists, partial agonists)

4. Indications and uses for pain management

5. Range of opioid analgesic products available for pain management and their related safety concerns
   a. Routes of administration including oral, transmucosal, transdermal
   b. Release characteristics of immediate release (IR), extended-release (ER), long-acting (LA)
   c. Abuse-deterrent formulations (ADFs)
      • Definition of ADF based on the FDA guidance for industry, Abuse-Deterrent Opioids – Evaluation and Labeling\textsuperscript{15}
      • Recognition that all ADFs have the same potential for addiction and overdose death as non-abuse-deterrent opioids
      • How to understand FDA-approved ADF product labeling

6. Initial dosing, dose titration, dose tapering (when appropriate) for analgesia
   a. Concepts and limitations of the conversion charts in labeling and the limitations of relative potency or equianalgesic dosing tables in literature

b. Interindividual variability of response
c. Special populations
   • Pregnant, postpartum, breastfeeding, and neonatal opioid withdrawal syndrome
   • Renal and hepatic impairment
   • Children and adolescents
   • Genetic and phenotypic variations
   • Older adults
   • Sleep disorders
   • Common and uncommon psychiatric disorders

7. Contraindications

8. Adverse Events
   a. Medication errors
   b. Periods of greater risk for significant respiratory depression, including at treatment initiation and with dose increases
   c. Serious adverse drug reactions (including overdose and death)
   d. Labeled warnings
   e. Common adverse drug reactions

9. Drug interactions
   a. Pharmacokinetic interactions based on metabolic pathway
   b. Pharmacokinetic and pharmacodynamic interactions with alcohol
   c. Concerns with particular drug–drug interactions, including, but not limited to:
      • Benzodiazepines and other central nervous system depressants, including alcohol
      • Monoamine oxidase inhibitors
      • Antidiuretic hormone drugs

10. Key safety strategies for use with opioid medications
    a. Dosing instructions including daily maximum
    b. Safe storage to reduce risk of accidental exposure/ingestion by household contacts, especially children/teens and to reduce risk of theft
    c. Naloxone products for use in the home to reduce risk of overdose deaths in patients and household contacts
    d. Proper disposal of used (e.g., transdermal systems) and unused opioids
    e. Pain management after an opioid overdose
    f. Driving and work safety
IV. MANAGING PATIENTS ON OPIOID ANALGESICS

HCPs should be knowledgeable about the appropriate use of opioids in patients with acute and chronic pain, including the importance of balancing potential benefits with the risks of serious adverse outcomes such as overdose and death.

A. Initiating treatment with opioids — acute pain

1. Patient selection — consider when an opioid is an appropriate option and consult the PDMP

2. Dosing — as needed vs. around-the clock dosing, prescribing an appropriate quantity based on the expected duration of pain, i.e., the least amount of medication necessary to treat pain and for the shortest amount of time

3. Naloxone for home use — prescribe and discuss the use of naloxone products and the various means of administration

4. Screening tools for risk of abuse

B. Initiating treatment with opioids — chronic pain

1. Patient selection
   a. Differences in benefit and risk and expected outcomes for patients with chronic pain, palliative care, or end-of-life care
   b. Differences in initiating treatment in opioid nontolerant vs. opioid-tolerant patients

2. Dosing
   a. As needed vs. around-the-clock
   b. How to determine a safe initial dose
   c. Safe conversion from other opioids

3. Considerations in opioid selection
   a. IR or ER/LA
   b. Special precautions with methadone
   c. Products restricted to opioid-tolerant patients

4. When and how to use an opioid or non-opioid analgesic to supplement pain management

C. Ongoing management of patients on opioid analgesics

1. Periodic review of pain and functional goals

2. Review adverse events at each visit
   - Eliciting signs or symptoms of opioid abuse
   - Screening for endocrine function may be recommended
• Importance of adverse event reporting and mechanisms to report

3. Review refill history/review PDMP

4. How to determine when an opioid analgesic is no longer necessary/beneficial

D. Long-term management

1. Evaluation of the patient with worsening pain for changes in underlying condition and for signs of OUD before increasing opioid dosage

2. Changing opioid medications
   • Concept of incomplete cross-tolerance when converting patients from one opioid to another
   • Concepts and limitations of the conversion charts in labeling and the limitations of relative potency or equianalgesic dosing tables in literature

3. Monitoring of patient adherence to the treatment plan, especially regarding misuse and abuse:
   • Perform medication reconciliation — recognize, document, and address aberrant drug-related behavior
   • Determine if nonadherence is due to inadequate pain management
   • Understand the utility and interpretation of urine drug testing (e.g., screening and confirmatory tests) and use as indicated
   • Screen and refer for substance use disorder treatment when concerns arise

E. How to recognize and intervene upon suspicion or identification of an OUD

HCPs should understand how to monitor patients taking opioid analgesics and identify the signs and symptoms of opioid misuse, abuse, and OUD and be knowledgeable about how to begin the process of intervention upon suspicion of an OUD.

F. When to consult with a pain specialist

HCPs should be knowledgeable about when referral to a pain management specialist is indicated, including identifying patients at high risk for OUD and patients unable to achieve adequate pain management.

G. Medically directed opioid tapering

HCPs should be knowledgeable about how to safely taper opioid analgesics, including how to recognize and manage signs and symptoms of opioid withdrawal. HCPs should be knowledgeable about the particular risks associated with tapering during pregnancy.
H. Importance of patient education

HCPs should recognize their role in reducing the risks associated with opioid analgesics through patient education at initiation of an opioid and throughout long-term management.

1. Inform patients about pain management expectations and managing pain through different pharmacologic and nonpharmacologic modalities.

2. Use the Patient Counseling Guide: What You Need to Know About Opioid Pain Medicines as part of discussion with patients and caregivers when prescribing opioid analgesics.

3. Counsel the patient about the following:
   a. Importance of adherence to prescribed dosing regimen
   b. Patients should use the least amount of medication necessary to treat pain and for the shortest amount of time
   c. The risk of serious adverse events that can lead to death
   d. The risk of addiction that can occur even when product is used as recommended
   e. Known risk factors for serious adverse events, including signs and symptoms of overdose and opioid-induced respiratory depression, GI obstruction, and allergic reactions, among others
   f. The most common side effects, along with the risk of falls, working with heavy machinery, and driving
   g. When to call the prescriber (e.g., managing adverse events, ongoing pain)
   h. How to handle missed doses
   i. The importance of full disclosure of all medications and supplements to all HCPs and the risks associated with the use of alcohol and other opioids/benzodiazepines
   j. Product-specific concerns, such as not to crush or chew ER products; transdermal systems and buccal films should not be cut, torn, or damaged before use, etc.
   k. How to safely taper dose to avoid withdrawal symptoms
   l. Safe storage and disposal, risks of theft by family members and household visitors
   m. Never share any opioid analgesic with another person
   n. How and when to use naloxone products and their various means of administration
   o. Seeking emergency medical treatment if an opioid overdose occurs
   p. How to report adverse events and medication errors to FDA (1-800-fda-1088 or via http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM163919.pdf)

V. ADDICTION MEDICINE PRIMER

HCPs should be knowledgeable about the basic elements of addiction medicine and be familiar with the definition, neurobiology, and pharmacotherapy of OUDs. In particular, stigmatizing or blaming language should be replaced with language that acknowledges that addiction,
reclassified as *substance use disorder*\textsuperscript{16} in the revised Diagnostic Statistical Manual–V, is a disease. The term *opioid use disorder* \textsuperscript{17} should be used when referring to the use of opioids, rather than other substances.

It should also be noted that there may be a different approach with a patient who misuses an opioid analgesic by taking the product differently than prescribed for the purpose of managing pain, in contrast to the patient who abuses an opioid analgesic with the intent of getting high. HCPs should be familiar with the following:

1. The neurobiology of OUD (addictive cycle)

2. Use of screening tools to identify patients at risk, based on known risk factors, and to identify patients developing signs of opioid dependence or addiction as early as possible.

3. Management of OUD, including the types of pharmacologic and nonpharmacologic treatments available and when to refer to an addiction medicine specialist.


\textsuperscript{17} Id.
MEMORANDUM

DATE: October 15, 2018
FROM: Sharon Hertz, MD
       Director
       Division of Anesthesia, Analgesia, and Addiction Products
       Office of Drug Evaluation II, CDER, FDA

TO: Chair, Members and Invited Guests
    Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC)
    Drug Safety and Risk Management Advisory Committee (DSaRM)

RE: Postmarketing Requirements (PMRs) for Opioid Analgesics Labeled with Abuse-Deterrent Properties

Postmarketing Requirements (PMRs) for Opioid Analgesics Labeled with Abuse-Deterrent Properties

The following PMRs are currently required for all approved opioid analgesics labeled with abuse-deterrent properties, in order to assess the known serious risks of misuse and abuse by determining whether the properties intended to deter misuse and abuse of the product actually result in a meaningful decrease in misuse and abuse, and their consequences of addiction, overdose, and death, in the community. The following studies are conducted according to a schedule agreed upon with the Agency.

1. In order to provide the baseline data to support the hypothesis-testing studies required under PMR 2 (below), conduct a descriptive study that analyzes data on the following:

   1) Utilization of [TRADENAME] and selected comparators. Reports should include nationally-projected quarterly retail dispensing, overall and by age group and census region; AND

   2) Abuse of [TRADENAME] and related clinical outcomes. These studies should utilize multiple data sources in different populations to establish the scope and
patterns of abuse for [TRADENAME] as well as mutually agreed-upon, selected comparators to provide context.

- Data should include route-specific abuse outcomes, be nationally-representative or from multiple large geographic areas, and use meaningful measures of abuse.

- Additional information, either qualitative or quantitative, from sources such as internet forums, spontaneous adverse event reporting, or small cohort studies may also be included to help better understand abuse of this drug, including routes and patterns of abuse in various populations.

- Formal hypothesis testing is not necessary during this phase, but provide information on the precision of abuse-related outcome estimates (e.g. 95% confidence intervals for quarterly estimates) and calculate utilization-adjusted outcome estimates where possible.

2. Conduct formal observational studies to assess whether the properties intended to deter misuse and abuse of [TRADENAME] actually result in a meaningful decrease in misuse and abuse, and their consequences, addiction overdose, and death, in post-approval settings. The studies should allow FDA to assess the impact, if any, attributable to the abuse-deterrent properties of [TRADENAME] and should incorporate recommendations contained in Abuse-Deterrent Opioids—Evaluation and Labeling: Guidance for Industry (April 2015). Assessing the impact of the abuse-deterrent formulation on the incidence of clinical outcomes, including overdose and death, is critical to fulfilling this PMR. Any studies using electronic healthcare data should use validated outcomes and adhere to guidelines outlined in FDA’s Guidance for Industry and FDA Staff: Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data.